

The Physiology of Glucagon-like Peptide 1

Physiological Reviews

87, 1409-1439

DOI: [10.1152/physrev.00034.2006](https://doi.org/10.1152/physrev.00034.2006)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The WNT signalling pathway and diabetes mellitus. <i>Diabetologia</i> , 2008, 51, 1771-1780.	6.3	167
2	Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2409-2413.	2.2	95
3	Watch Out for the Little Guy. <i>Obesity</i> , 2008, 16, 219-220.	3.0	0
4	Targeting bile-acid signalling for metabolic diseases. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 678-693.	46.4	1,084
5	The physiology and pharmacology of incretins in type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 14-21.	4.4	23
6	RD Lawrence Lecture 2008 Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. <i>Diabetic Medicine</i> , 2008, 25, 889-894.	2.3	30
7	Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic β -cell responsiveness to a meal in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2008, 25, 1268-1275.	2.3	45
8	The future of diabetes treatment. <i>Annales D'Endocrinologie</i> , 2008, 69, 166-167.	1.4	1
9	Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing. <i>Diabetes</i> , 2008, 57, 2603-2612.	0.6	116
10	Role of Gut Hormones in Obesity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 769-787.	3.2	26
11	Glucagon-like peptide-1, glucose homeostasis and diabetes. <i>Trends in Molecular Medicine</i> , 2008, 14, 161-168.	6.7	152
12	Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 639-645.	2.6	48
13	Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans. <i>Regulatory Peptides</i> , 2008, 149, 70-78.	1.9	199
14	A new endogenous form of PYY isolated from canine ileum: Gly-extended PYY(1-36). <i>Regulatory Peptides</i> , 2008, 151, 61-70.	1.9	6
15	Preservation of β -cell function by targeting β -cell mass. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 218-227.	8.7	64
16	Glucose Sensing in L Cells: A Primary Cell Study. <i>Cell Metabolism</i> , 2008, 8, 532-539.	16.2	624
17	The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions. <i>Diabetes and Metabolism</i> , 2008, 34, 550-559.	2.9	65
18	Incretin-based therapies in type 2 diabetes: A review of clinical results. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, S102-S107.	2.8	22

#	ARTICLE	IF	CITATIONS
19	Insuline et fonction pancréatique. Medecine Des Maladies Metaboliques, 2008, 2, S130-S136.	0.1	0
20	Association gliptines et sulfamides hypoglycémisants. Medecine Des Maladies Metaboliques, 2008, 2, 620-625.	0.1	0
21	GLP-1 et système nerveux: un mécanisme de son action antidiabétique. Medecine Des Maladies Metaboliques, 2008, 2, 502-508.	0.1	0
22	Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus. BioDrugs, 2008, 22, 251-257.	4.6	19
23	DUROS® Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months. Journal of Diabetes Science and Technology, 2008, 2, 461-467.	2.2	37
24	Plasma glucagon-like peptide 1 and peptide YY levels are not altered in symptomatic fructose-sorbitol malabsorption. Scandinavian Journal of Gastroenterology, 2008, 43, 1212-1218.	1.5	4
25	The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. Pharmacological Reviews, 2008, 60, 470-512.	16.0	681
26	Incretine e funzione insulare: fisiopatologia. L Endocrinologo, 2008, 9, 155-162.	0.0	0
27	GLP-1 Therapy. Circulation: Heart Failure, 2008, 1, 147-149.	3.9	33
28	Dissecting the Nutrigenomics, Diabetes, and Gastrointestinal Disease Interface: From Risk Assessment to Health Intervention. OMICS A Journal of Integrative Biology, 2008, 12, 237-244.	2.0	15
29	Cloning, Tissue Distribution, and Functional Characterization of Chicken Glucagon Receptor. Poultry Science, 2008, 87, 2678-2688.	3.4	17
30	Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas. Journal of Histochemistry and Cytochemistry, 2008, 56, 841-851.	2.5	205
31	Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model. Molecular Therapy, 2008, 16, 1805-1812.	8.2	49
32	Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E939-E951.	3.5	38
33	Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity. Diabetes, 2008, 57, 2577-2587.	0.6	107
34	Pharmacology of GLP-1-based therapies. British Journal of Diabetes and Vascular Disease, 2008, 8, S10-S18.	0.6	6
35	Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2479-2485.	3.6	615
36	Low, but Physiological, Concentration of GLP-1 Stimulates Insulin Secretion Independent of the cAMP-Dependent Protein Kinase Pathway. Journal of Pharmacological Sciences, 2008, 108, 274-279.	2.5	25

#	ARTICLE	IF	CITATIONS
37	Gut-brain axis. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 518-521.	2.5	91
38	Gastric secretion. Current Opinion in Gastroenterology, 2008, 24, 659-664.	2.3	26
40	Incretin-Based Therapy of Type 2 Diabetes Mellitus. Current Protein and Peptide Science, 2009, 10, 46-55.	1.4	40
41	Potential of liraglutide in the treatment of patients with type 2 diabetes. Vascular Health and Risk Management, 2009, 5, 199.	2.3	64
42	Ileal Interposition with Sleeve Gastrectomy for Control of Type 2 Diabetes. Diabetes Technology and Therapeutics, 2009, 11, 785-789.	4.4	47
43	Functional Ryanodine Receptors in the Plasma Membrane of RINm5F Pancreatic β -Cells. Journal of Biological Chemistry, 2009, 284, 5186-5194.	3.4	18
44	Agonizing obesity. Science-Business EXchange, 2009, 2, 1200-1200.	0.0	0
45	Unifying concepts in stimulus-secretion coupling in endocrine cells and some implications for therapeutics. American Journal of Physiology - Advances in Physiology Education, 2009, 33, 175-186.	1.6	5
46	β -Cell-Mediated Signaling Predominates Over Direct α -Cell Signaling in the Regulation of Glucagon Secretion in Humans. Diabetes Care, 2009, 32, 2275-2280.	8.6	43
47	Ion channels underlying stimulus-exocytosis coupling and its cell-to-cell heterogeneity in β -cells of transplantable porcine islets of Langerhans. Channels, 2009, 3, 91-100.	2.8	7
48	Electrical activity and exocytotic correlates of biphasic insulin secretion from β -cells of canine islets of Langerhans: Contribution of tuning two modes of Ca^{2+} -entry-dependent exocytosis to two modes of glucose-induced electrical activity. Channels, 2009, 3, 181-193.	2.8	16
49	New Therapeutic Agents for Diabetes Mellitus: Implications for Anesthetic Management. Anesthesia and Analgesia, 2009, 108, 1803-1810.	2.2	12
50	Changes in gut hormone levels and negative energy balance during aerobic exercise in obese young males. Journal of Endocrinology, 2009, 201, 151-159.	2.6	151
51	Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms. Endocrinology, 2009, 150, 1174-1181.	2.8	231
52	Insulin-Regulated Glucagon-Like Peptide-1 Release from L Cells: Actin Out. Endocrinology, 2009, 150, 5202-5204.	2.8	6
53	Long-Term Effects of Roux-en-Y Gastric Bypass Surgery on Plasma Glucagon-Like Peptide-1 and Islet Function in Morbidly Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 884-891.	3.6	90
54	Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1379-1385.	3.6	51
55	Peptide hormones and their prohormones as biomarkers. Biomarkers in Medicine, 2009, 3, 335-338.	1.4	10

#	ARTICLE	IF	CITATIONS
56	Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4398-4405.	3.6	238
57	Minireview: Finding the Sweet Spot: Peripheral Versus Central Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis. <i>Endocrinology</i> , 2009, 150, 2997-3001.	2.8	90
58	Impact of Different Bariatric Surgical Procedures on Insulin Action and β -Cell Function in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 514-520.	8.6	160
59	BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca^{2+} , and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 296, C346-C354.	4.6	21
60	Regulation of Na^{+}/H^{+} exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1647-F1655.	2.7	121
61	Loss of cholecystokinin and glucagon-like peptide-1-induced satiation in mice lacking serotonin 2C receptors. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 296, R51-R56.	1.8	33
62	Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E1358-E1365.	3.5	136
63	The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1843-1852.	3.6	176
64	Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 379-386.	3.4	15
65	The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2009, 29, 55S-67S.	2.6	17
66	The avian proglucagon system. <i>General and Comparative Endocrinology</i> , 2009, 163, 39-46.	1.8	31
67	A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2009, 31, 2472-2488.	2.5	96
68	Effect of dietary fibre type on physical activity and behaviour in kennelled dogs. <i>Applied Animal Behaviour Science</i> , 2009, 121, 32-41.	1.9	8
69	Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect. <i>International Journal of Pharmaceutics</i> , 2009, 382, 111-116.	5.2	35
70	The Correlation Between Intestinal Gonadotropin-Releasing Hormone (GnRH) and Proglucagon in Hyperlipidemic Rats and Goto-Kakizaki (GK) Rats. <i>Endocrine Pathology</i> , 2009, 20, 227-234.	9.0	7
71	Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence?. <i>Obesity Surgery</i> , 2009, 19, 217-229.	2.1	116
72	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. <i>Advances in Therapy</i> , 2009, 26, 488-499.	2.9	66
73	Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. <i>Diabetologia</i> , 2009, 52, 2046-2055.	6.3	747

#	ARTICLE	IF	CITATIONS
74	Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?. <i>Diabetologia</i> , 2009, 52, 2270-2276.	6.3	77
75	Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. <i>Neurogastroenterology and Motility</i> , 2009, 21, 978.	3.0	106
76	No increased risk of hypoglycaemic episodes during 48h of subcutaneous glucagon-like peptide-1 administration in fasting healthy subjects. <i>Clinical Endocrinology</i> , 2009, 71, 500-506.	2.4	26
77	Nutritional regulation of glucagon-like peptide-1 secretion. <i>Journal of Physiology</i> , 2009, 587, 27-32.	2.9	177
78	Vagally mediated effects of glucagon-like peptide 1: <i>in vitro</i> and <i>in vivo</i> gastric actions. <i>Journal of Physiology</i> , 2009, 587, 4749-4759.	2.9	69
79	Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 644-650.	4.7	41
80	Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>International Journal of Obesity</i> , 2009, 33, 786-795.	3.4	292
81	Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 159-165.	6.1	134
82	Metabolomics cuts to the chase to chase the cuts. <i>Nature Chemical Biology</i> , 2009, 5, 5-6.	8.0	7
83	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 369-385.	46.4	370
84	Gastric bypass and glucose metabolism. <i>Internal Medicine Journal</i> , 2009, 39, 502-505.	0.8	4
85	Growth factor control of pancreatic islet regeneration and function. <i>Pediatric Diabetes</i> , 2009, 10, 14-32.	2.9	63
86	Poly-GLP-1, a novel long-acting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 953-965.	4.4	16
87	The effects of glucagon-like peptide-1 on the beta cell. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 11-18.	4.4	98
88	Impact of glucagon-like peptide-1 on endothelial function. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 19-25.	4.4	21
89	Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). <i>Diabetic Medicine</i> , 2009, 26, 268-278.	2.3	731
90	7TM RECEPTORS. <i>British Journal of Pharmacology</i> , 2009, 158, S5.	5.4	2
91	Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4097-4101.	2.2	37

#	ARTICLE	IF	CITATIONS
92	Saxagliptin: a new option for the management of type 2 diabetes. <i>Future Prescriber</i> , 2009, 10, 13-17.	0.1	0
93	Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 84-90.	8.6	991
94	A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism. <i>Current Opinion in Pharmacology</i> , 2009, 9, 744-752.	3.5	47
95	CNS-targets in control of energy and glucose homeostasis. <i>Current Opinion in Pharmacology</i> , 2009, 9, 794-804.	3.5	49
96	Functional pancreatic beta-cell mass: Involvement in type 2 diabetes and therapeutic intervention. <i>Diabetes and Metabolism</i> , 2009, 35, 77-84.	2.9	88
97	Intestinal microflora and metabolic diseases. <i>Diabetes and Metabolism</i> , 2009, 35, 262-272.	2.9	67
98	GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 85, 1-3.	2.8	26
99	Incretin Therapies: Effects Beyond Glycemic Control. <i>European Journal of Internal Medicine</i> , 2009, 20, S319-S328.	2.2	17
100	Intestinal Cholecystokinin Controls Glucose Production through a Neuronal Network. <i>Cell Metabolism</i> , 2009, 10, 99-109.	16.2	155
101	Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 384, 401-404.	2.1	51
102	GLP-1 receptor antagonist as a potential probe for pancreatic β^2 -cell imaging. <i>Biochemical and Biophysical Research Communications</i> , 2009, 389, 523-526.	2.1	64
103	Imaging exocytosis of single glucagon-like peptide-1 containing granules in a murine enteroendocrine cell line with total internal reflection fluorescent microscopy. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 16-20.	2.1	15
104	Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 809-814.	2.1	52
105	Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 713-719.	2.6	53
106	The incretin system and its role in type 2 diabetes mellitus. <i>Molecular and Cellular Endocrinology</i> , 2009, 297, 127-136.	3.2	447
107	Identification of cAMP-Dependent Kinase as a Third in Vivo Ribosomal Protein S6 Kinase in Pancreatic β^2 -Cells. <i>Journal of Molecular Biology</i> , 2009, 389, 480-494.	4.2	47
108	Incretin Therapies: Effects Beyond Glycemic Control. <i>American Journal of Medicine</i> , 2009, 122, S25-S36.	1.5	30
110	Lizard Spit and Reperfusion Injury—Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2009, 53, 511-513.	2.8	6

#	ARTICLE	IF	CITATIONS
111	Immunoassays for the incretin hormones GIP and GLP-1. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 425-432.	4.7	55
112	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 453-462.	4.7	21
113	Low-carbohydrate diet disrupts the association between insulin resistance and weight gain. Metabolism: Clinical and Experimental, 2009, 58, 1116-1122.	3.4	15
115	Subject Standardization, Acclimatization, and Sample Processing Affect Gut Hormone Levels and Appetite in Humans. Gastroenterology, 2009, 136, 2115-2126.	1.3	75
116	Foxa1 and Foxa2 Control the Differentiation of Goblet and Enteroendocrine L- and D-Cells in Mice. Gastroenterology, 2009, 137, 2052-2062.	1.3	131
117	THE FOOD-ENTRAINABLE OSCILLATOR: A NETWORK OF INTERCONNECTED BRAIN STRUCTURES ENTRAINED BY HUMORAL SIGNALS?. Chronobiology International, 2009, 26, 1273-1289.	2.0	67
118	Chapter 16 Insulin Granule Biogenesis, Trafficking and Exocytosis. Vitamins and Hormones, 2009, 80, 473-506.	1.7	184
119	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). Diabetes Care, 2009, 32, 1224-1230.	8.6	768
120	Increasing intravenous infusions of glucose improve body condition but not lactation performance in midlactation dairy cows. Journal of Dairy Science, 2009, 92, 5645-5658.	3.4	34
121	Mechanisms of early improvement / resolution of type 2 diabetes after bariatric surgery. Diabetes and Metabolism, 2009, 35, 518-523.	2.9	151
122	Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Research and Clinical Practice, 2009, 86, S26-S34.	2.8	22
123	Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, The, 2009, 373, 473-481.	13.7	935
124	Treatment of type 2 diabetes with incretin-based therapies. Lancet, The, 2009, 373, 438-439.	13.7	31
125	Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy. Annals of Surgery, 2009, 250, 234-241.	4.2	498
126	Liraglutide: A new treatment for type 2 diabetes. Drugs of Today, 2009, 45, 101.	1.1	42
127	Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2009, 150, 94.	3.9	160
128	The effects of dietary fibre type on satiety-related hormones and voluntary food intake in dogs. British Journal of Nutrition, 2009, 102, 318-325.	2.3	72
129	Control of Eating. , 0, , 127-163.		2

#	ARTICLE	IF	CITATIONS
130	Endocrine and metabolic response to gastric bypass. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 515-521.	2.5	33
133	Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. American Journal of Physiology - Renal Physiology, 2009, 296, G482-G489.	3.4	25
134	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. Current Diabetes Reviews, 2009, 5, 266-275.	1.3	49
135	Glucagon Like Peptide-1-Directed Human Embryonic Stem Cells Differentiation Into Insulin-Producing Cells Via Hedgehog, cAMP, and PI3K Pathways. Pancreas, 2010, 39, 315-322.	1.1	19
137	Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes. Endocrine Journal, 2010, 57, 119-126.	1.6	68
138	The role of gut hormones and the hypothalamus in appetite regulation. Endocrine Journal, 2010, 57, 359-372.	1.6	241
140	Radionuclide probes for molecular imaging of pancreatic beta-cells. Advanced Drug Delivery Reviews, 2010, 62, 1125-1138.	13.7	33
141	Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass. Diabetologia, 2010, 53, 2641-2645.	6.3	55
142	Laparoscopic sleeve gastrectomy leads to rapid improvement of glucose tolerance and insulin secretion with enhanced glucagon-like peptide (GLP-1) secretion. Diabetology International, 2010, 1, 99-103.	1.4	7
143	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	4.2	42
144	Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats. Metabolism: Clinical and Experimental, 2010, 59, 123-133.	3.4	16
145	Glycaemic management of type 2 diabetes. Medicine, 2010, 38, 618-625.	0.4	2
146	Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides, 2010, 164, 58-64.	1.9	141
147	Effects of biliary and pancreatic juice diversion into the ileum on gastrointestinal motility and gut hormone secretion in conscious dogs. Surgery, 2010, 148, 1012-1019.	1.9	11
148	Glucagon-Like Peptide 1â€™A Cardiologic Dimension. Trends in Cardiovascular Medicine, 2010, 20, 8-12.	4.9	25
149	Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies. Biochemical Pharmacology, 2010, 79, 1000-1006.	4.4	105
150	Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Research, 2010, 1350, 18-34.	2.2	234
151	Leptin and the systems neuroscience of meal size control. Frontiers in Neuroendocrinology, 2010, 31, 61-78.	5.2	116

#	ARTICLE	IF	CITATIONS
152	SREBP1c, Pdx1, and GLP1R involved in palmitate-EPA regulated glucose-stimulated insulin secretion in INS1 cells. <i>Journal of Cellular Biochemistry</i> , 2010, 111, 634-642.	2.6	24
153	Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2010, 9, 17.	6.8	69
154	Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. <i>Journal of Anatomy</i> , 2010, 217, 624-630.	1.5	33
155	Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. <i>British Journal of Pharmacology</i> , 2010, 159, 495-501.	5.4	107
156	Hepatic Portal Vein Infusions of Glucagon-Like Peptide-1 Reduce Meal Size and Increase c-Fos Expression in the Nucleus Tractus Solitarius, Area Postrema and Central Nucleus of the Amygdala in Rats. <i>Journal of Neuroendocrinology</i> , 2010, 22, 557-563.	2.6	52
157	Causes and cures for endoplasmic reticulum stress in lipotoxic β -cell dysfunction. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 76-82.	4.4	120
158	Plant-derived recombinant human serum transferrin demonstrates multiple functions. <i>Plant Biotechnology Journal</i> , 2010, 8, 489-505.	8.3	21
160	Gut microbiota and metabolic diseases: myth or reality?. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010, 4, 75-77.	0.5	0
161	A GIP Receptor Agonist Exhibits β -Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β -Cell Function and Glycemic Control. <i>PLoS ONE</i> , 2010, 5, e9590.	2.5	83
162	Outcomes of Roux-en-Y gastric bypass surgery for severely obese patients with type 1 diabetes: a case series report. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 281-283.	2.4	30
163	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 263-273.	2.4	13
164	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 155-163.	2.4	34
165	Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes. <i>Journal of Receptor, Ligand and Channel Research</i> , 0, , 105.	0.7	1
166	Treatment of diabetes with glucagon-like peptide-1 gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1681-1692.	3.1	11
167	Insulin Reciprocally Regulates Glucagon Secretion in Humans. <i>Diabetes</i> , 2010, 59, 2936-2940.	0.6	112
168	Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent "Compound 2" at the GLP-1 Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 795-808.	2.5	48
169	Effects of Fat Supplementation on Postprandial GIP, GLP-1, Ghrelin and IGFBP-1 Levels: A Pilot Study on Adolescents with Type 1 Diabetes. <i>Hormone Research in Paediatrics</i> , 2010, 73, 355-362.	1.8	10
170	Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1326-1336.	1.0	10

#	ARTICLE	IF	CITATIONS
171	Novel Glucagon-like Peptide-1 Analog Delivered Orally Reduces Postprandial Glucose Excursions in Porcine and Canine Models. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 1516-1523.	2.2	15
172	Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 274-283.	0.6	15
173	Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. <i>American Journal of Clinical Nutrition</i> , 2010, 92, 810-817.	4.7	81
174	GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and Humans. <i>Endocrinology</i> , 2010, 151, 2629-2640.	2.8	72
175	GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a \hat{I}^2 -Arrestin 1-mediated ERK1/2 Activation in Pancreatic I^2 -Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 1989-2002.	3.4	156
176	Role of Fat Hydrolysis in Regulating Glucagon-Like Peptide-1 Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 879-886.	3.6	122
177	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E832-E837.	3.5	67
178	Increasing doses of fiber do not influence short-term satiety or food intake and are inconsistently linked to gut hormone levels. <i>Food and Nutrition Research</i> , 2010, 54, 5135.	2.6	26
179	Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 298, R1061-R1067.	1.8	25
180	The Corn Protein, Zein Hydrolysate, Administered into the Ileum Attenuates Hyperglycemia via Its Dual Action on Glucagon-Like Peptide-1 Secretion and Dipeptidyl Peptidase-IV Activity in Rats. <i>Endocrinology</i> , 2010, 151, 3095-3104.	2.8	79
181	Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E10-E13.	3.5	53
182	Synthesis and biological activity of artificial mRNA prepared with novel phosphorylating reagents. <i>Nucleic Acids Research</i> , 2010, 38, 7845-7857.	14.5	34
183	Therapeutic Potential of Gut Peptides. <i>Forum of Nutrition</i> , 2010, 63, 54-63.	3.7	7
184	Effect of Glucagon-Like Peptide-1 on \hat{I}^1 - and \hat{I}^2 -Cell Function in C-Peptide-Negative Type 1 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2492-2496.	3.6	45
185	Meal-Induced Hormone Responses in a Rat Model of Roux-en-Y Gastric Bypass Surgery. <i>Endocrinology</i> , 2010, 151, 1588-1597.	2.8	134
186	Reversible Hyperinsulinemic Hypoglycemia after Gastric Bypass: A Consequence of Altered Nutrient Delivery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1851-1855.	3.6	170
187	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2367-2375.	3.6	31
189	Liraglutide pour le traitement du diab�te de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2010, 4, 313-325.	0.1	2

#	ARTICLE	IF	CITATIONS
190	Central GLP-1 Actions on Energy Metabolism. <i>Vitamins and Hormones</i> , 2010, 84, 303-317.	1.7	9
191	Molecular mechanisms underlying nutrient-stimulated incretin secretion. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e1.	3.9	128
192	Pleiotropic Actions of the Incretin Hormones. <i>Vitamins and Hormones</i> , 2010, 84, 21-79.	1.7	40
195	GLP-1 antagonism with exendin (9â€“39) fails to increase spontaneous meal size in rats. <i>Physiology and Behavior</i> , 2010, 100, 291-296.	2.1	30
196	Role of the glucagon-like-peptide-1 receptor in the control of energy balance. <i>Physiology and Behavior</i> , 2010, 100, 503-510.	2.1	158
197	Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1944-1953.	3.3	157
198	Eating Slowly Increases the Postprandial Response of the Anorexigenic Gut Hormones, Peptide YY and Glucagon-Like Peptide-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 333-337.	3.6	204
199	Recombinant Expression, in Vitro Refolding, and Biophysical Characterization of the Human Glucagon-like Peptide-1 Receptor. <i>Biochemistry</i> , 2010, 49, 7956-7965.	2.5	23
200	Molecular mechanisms underlying nutrient detection by incretin-secreting cells. <i>International Dairy Journal</i> , 2010, 20, 236-242.	3.0	50
201	Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 410-413.	2.1	32
202	Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 745-761.	4.7	36
203	Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. <i>Progress in Neurobiology</i> , 2010, 92, 442-462.	5.7	114
204	Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 980-983.	4.8	18
205	New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimerâ€™s disease?. <i>Neurobiology of Aging</i> , 2010, 31, 1495-1502.	3.1	87
206	Pancreatic Î²-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2010, 160, 175-180.	1.9	6
207	Little enhancement of mealâ€“induced glucagonâ€“like peptideâ€“1 secretion in Japanese: Comparison of typeâ€“2 diabetes patients and healthy controls. <i>Journal of Diabetes Investigation</i> , 2010, 1, 56-59.	2.4	80
208	Evolution of Genes for Incretin Hormones and their Receptors. <i>Vitamins and Hormones</i> , 2010, 84, 1-20.	1.7	9
209	Dietary Effects on Incretin Hormone Secretion. <i>Vitamins and Hormones</i> , 2010, 84, 81-110.	1.7	45

#	ARTICLE	IF	CITATIONS
210	Incretin Hormone Secretion Over the Day. <i>Vitamins and Hormones</i> , 2010, 84, 203-220.	1.7	41
211	Incretin-Based Therapy and Type 2 Diabetes. <i>Vitamins and Hormones</i> , 2010, 84, 389-413.	1.7	20
212	K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease. <i>Vitamins and Hormones</i> , 2010, 84, 111-150.	1.7	74
213	In Vivo Imaging of Transplanted Islets with ⁶⁴ Cu-DO3A-VS-Cys ⁴⁰ -Exendin-4 by Targeting GLP-1 Receptor. <i>Bioconjugate Chemistry</i> , 2011, 22, 1587-1594.	3.6	80
214	Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats. <i>Applied Physiology, Nutrition and Metabolism</i> , 2011, 36, 650-659.	1.9	50
215	GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. <i>Cardiovascular Research</i> , 2011, 89, 72-78.	3.8	85
216	Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 69-77.	3.3	18
217	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 685-692.	4.7	44
218	Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. <i>Osteopathic Family Physician</i> , 2011, 3, 217-236.	0.1	1
219	Le glucagon. <i>Medecine Des Maladies Metaboliques</i> , 2011, 5, 117-118.	0.1	0
220	Surgical Treatments for Obesity. <i>Psychiatric Clinics of North America</i> , 2011, 34, 881-893.	1.3	13
221	New treatments for type 2 diabetes in the UK – An evolving landscape. <i>Primary Care Diabetes</i> , 2011, 5, 1-7.	1.8	0
222	CCK Stimulation of GLP-1 Neurons Involves ± 1 -Adrenoceptor-Mediated Increase in Glutamatergic Synaptic Inputs. <i>Diabetes</i> , 2011, 60, 2701-2709.	0.6	78
223	Emerging GLP-1 receptor agonists. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 607-618.	2.4	21
224	Common cellular and molecular mechanisms in obesity and drug addiction. <i>Nature Reviews Neuroscience</i> , 2011, 12, 638-651.	10.2	319
225	GLP-1 and energy balance: an integrated model of short-term and long-term control. <i>Nature Reviews Endocrinology</i> , 2011, 7, 507-516.	9.6	173
226	2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1409-E1417.	3.6	238
227	Type 2 diabetes mellitus – current therapies and the emergence of surgical options. <i>Nature Reviews Endocrinology</i> , 2011, 7, 408-419.	9.6	61

#	ARTICLE	IF	CITATIONS
228	Effects of Sitagliptin on 24-H Glycemic Changes in Japanese Patients with Type 2 Diabetes Assessed Using Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 699-703.	4.4	24
229	Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation. <i>Cell Metabolism</i> , 2011, 13, 320-330.	16.2	187
230	Glucagon-like peptide 1 and the brain: Central actionsâ€“central sources?. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2011, 161, 14-19.	2.8	28
231	The contribution of serotonin 5-HT _{2C} and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice. <i>Biochemical and Biophysical Research Communications</i> , 2011, 411, 445-448.	2.1	19
232	Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism?. <i>Medical Hypotheses</i> , 2011, 77, 1098-1101.	1.5	34
233	Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. <i>Journal of Hepatology</i> , 2011, 54, 1214-1223.	3.7	257
234	Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. <i>Peptides</i> , 2011, 32, 60-64.	2.4	35
235	Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes. <i>Peptides</i> , 2011, 32, 1313-1319.	2.4	8
236	Preproglucagon neurons project widely to autonomic control areas in the mouse brain. <i>Neuroscience</i> , 2011, 180, 111-121.	2.3	159
237	Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. <i>Journal of Diabetes Investigation</i> , 2011, 2, 193-199.	2.4	29
238	Multiscale Modeling of Insulin Secretion. <i>IEEE Transactions on Biomedical Engineering</i> , 2011, 58, 3020-3023.	4.2	18
239	Regulation of Energy Balance and Body Weight by the Brain: A Distributed System Prone to Disruption. <i>Psychiatric Clinics of North America</i> , 2011, 34, 733-745.	1.3	24
240	Sensing Via Intestinal Sweet Taste Pathways. <i>Frontiers in Neuroscience</i> , 2011, 5, 23.	2.8	56
241	GLP-1 signaling and the regulation of pancreatic Î²-cells mass/function. <i>Avances En DiabetologÃa</i> , 2011, 27, 3-8.	0.1	3
242	Management of type 2 diabetes: new and future developments in treatment. <i>Lancet, The</i> , 2011, 378, 182-197.	13.7	459
243	Organic consequences of ileal transposition in rats with diet-induced obesity. <i>Nature Precedings</i> , 2011,, .	0.1	0
245	Insulin Secretion and Actions. , 0, , .		0
246	Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control. <i>PLoS ONE</i> , 2011, 6, e20700.	2.5	124

#	ARTICLE	IF	CITATIONS
247	Nutrition and L and K-enteroendocrine cells. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 35-41.	2.3	35
248	Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics, 2011, 18, 117-152.	0.9	134
249	Vildagliptin for the treatment of diabetes. Therapy: Open Access in Clinical Medicine, 2011, 8, 703-719.	0.2	3
250	Liraglutide for the treatment of diabetes mellitus in Japan. Diabetes Management, 2011, 1, 451-463.	0.5	3
251	Dynamics of plasma active GLP-1 versus insulin and glucose concentrations during GLP-1 infusion in rat model of postprandial hyperglycemia. Endocrine Journal, 2011, 58, 691-698.	1.6	5
252	The Gut Hormones in Appetite Regulation. Journal of Obesity, 2011, 2011, 1-10.	2.7	62
254	Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 207-220.	4.4	61
255	Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β -cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo. Diabetes, Obesity and Metabolism, 2011, 13, 326-336.	4.4	7
256	An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes, Obesity and Metabolism, 2011, 13, 394-407.	4.4	175
257	Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?. Diabetes, Obesity and Metabolism, 2011, 13, 95-105.	4.4	160
258	Could the mechanisms of bariatric surgery hold the key for novel therapies?: report from a Pennington Scientific Symposium. Obesity Reviews, 2011, 12, 984-994.	6.5	41
259	Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. International Journal of Experimental Pathology, 2011, 92, 219-231.	1.3	223
260	Evidence for a Gut-Brain Axis Used by Glucagon-like Peptide-1 to Elicit Hyperglycaemia in Fish. Journal of Neuroendocrinology, 2011, 23, 508-518.	2.6	37
261	Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells. British Journal of Pharmacology, 2011, 163, 261-271.	5.4	24
262	Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British Journal of Pharmacology, 2011, 163, 53-67.	5.4	201
263	Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. British Journal of Pharmacology, 2011, 163, 399-412.	5.4	50
264	Guide to Receptors and Channels (GRAC), 5th edition. British Journal of Pharmacology, 2011, 164, S1-324.	5.4	827
265	Consultants. British Journal of Pharmacology, 2011, 164, S3-S3.	5.4	10

#	ARTICLE	IF	CITATIONS
266	G PROTEIN-COUPLED RECEPTORS. British Journal of Pharmacology, 2011, 164, S5.	5.4	16
267	LIGAND-GATED ION CHANNELS. British Journal of Pharmacology, 2011, 164, S115.	5.4	13
268	ION CHANNELS. British Journal of Pharmacology, 2011, 164, S137.	5.4	22
269	NUCLEAR RECEPTORS. British Journal of Pharmacology, 2011, 164, S175-S188.	5.4	0
270	CATALYTIC RECEPTORS. British Journal of Pharmacology, 2011, 164, S189-S212.	5.4	1
271	TRANSPORTERS. British Journal of Pharmacology, 2011, 164, S213.	5.4	2
273	Glucagon like-peptide 1 receptor and the liver. Liver International, 2011, 31, 1243-1245.	3.9	10
274	Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulintropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiologica, 2011, 201, 405-411.	3.8	82
275	Opposing effects of NaCl restriction and carbohydrate loading on urine volume in diabetic rats. Acta Physiologica, 2011, 202, 47-57.	3.8	4
276	Electrical activity-triggered glucagon-like peptide-1 secretion from primary murine L-cells. Journal of Physiology, 2011, 589, 1081-1093.	2.9	67
277	Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats. Obesity, 2011, 19, 1342-1349.	3.0	92
278	Individually timing high-protein preloads has no effect on daily energy intake, peptide YY and glucagon-like peptide-1. European Journal of Clinical Nutrition, 2011, 65, 55-62.	2.9	3
279	Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector. Gene Therapy, 2011, 18, 155-163.	4.5	12
280	Changes in neurohormonal gut peptides following bariatric surgery. International Journal of Obesity, 2011, 35, 153-166.	3.4	104
281	Gastric emptying, glucose metabolism and gut hormones: Evaluation of a common preoperative carbohydrate beverage. Nutrition, 2011, 27, 897-903.	2.4	21
282	Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β^2 cell preservation. Progress in Biophysics and Molecular Biology, 2011, 107, 248-256.	2.9	150
283	Role of endogenous ROS production in impaired metabolism-secretion coupling of diabetic pancreatic β^2 cells. Progress in Biophysics and Molecular Biology, 2011, 107, 304-310.	2.9	20
284	Obesity surgery and gut-brain communication. Physiology and Behavior, 2011, 105, 106-119.	2.1	74

#	ARTICLE	IF	CITATIONS
285	Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiating. Physiology and Behavior, 2011, 105, 71-76.	2.1	55
286	Nutrient sensing in the gut: interactions between chemosensory cells, visceral afferents and the secretion of satiety peptides. Physiology and Behavior, 2011, 105, 62-70.	2.1	80
287	Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 52B-58B.	1.6	22
288	The physiological roles of dietary fibre. Food Hydrocolloids, 2011, 25, 238-250.	10.7	333
289	Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorganic and Medicinal Chemistry, 2011, 19, 7221-7227.	3.0	70
290	The brainstem preproglucagon system in a non-human primate (Macaca mulatta). Brain Research, 2011, 1397, 28-37.	2.2	29
291	Emerging roles for β -arrestin-1 in the control of the pancreatic β -cell function and mass: New therapeutic strategies and consequences for drug screening. Cellular Signalling, 2011, 23, 522-528.	3.6	39
292	Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opinion on Therapeutic Targets, 2011, 15, 1153-1162.	3.4	30
293	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	4.1	70
294	Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 713-725.	1.8	13
295	A Novel Peptide Nanomedicine Against Acute Lung Injury: GLP-1 in Phospholipid Micelles. Pharmaceutical Research, 2011, 28, 662-672.	3.5	58
296	New metabolic interdependencies revealed by plasma metabolite profiling after two dietary challenges. Metabolomics, 2011, 7, 388-399.	3.0	13
297	Metabolic surgeryâ€”principles and current concepts. Langenbeck's Archives of Surgery, 2011, 396, 949-972.	1.9	30
298	The potential effects of anti-diabetic medications on myocardial ischemiaâ€”reperfusion injury. Basic Research in Cardiology, 2011, 106, 925-952.	5.9	89
299	Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males. Amino Acids, 2011, 41, 507-515.	2.7	25
300	Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells. Diabetologia, 2011, 54, 390-402.	6.3	69
301	Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia, 2011, 54, 2745-2754.	6.3	118
302	Value of the radiolabelled GLP-1 receptor antagonist exendin(9â€”39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1054-1058.	6.4	13

#	ARTICLE	IF	CITATIONS
303	Thirty-Day Morbidity and Mortality of the Laparoscopic Ileal Interposition Associated with Sleeve Gastrectomy for the Treatment of Type 2 Diabetic Patients with BMI ≤ 35 : An Analysis of 454 Consecutive Patients. <i>World Journal of Surgery</i> , 2011, 35, 102-108.	1.6	34
305	Gut microbiota and metabolic diseases: myth or reality?. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2011, 4, 75-77.	0.5	0
306	Improvement in Insulin Sensitivity and β -Cell Function Following Ileal Interposition with Sleeve Gastrectomy in Type 2 Diabetic Patients: Potential Mechanisms. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1344-1353.	1.7	50
307	Adiponectin Downregulates Hyperglycemia and Reduces Pancreatic Islet Apoptosis After Roux-En-Y Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2011, 21, 768-773.	2.1	23
308	Effects of Sleeve Gastrectomy and Medical Treatment for Obesity on Glucagon-like Peptide 1 Levels and Glucose Homeostasis in Non-diabetic Subjects. <i>Obesity Surgery</i> , 2011, 21, 902-909.	2.1	45
309	Peptide hormones regulating appetite—focus on neuroimaging studies in humans. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 104-112.	4.0	56
310	Discovery of potent dipeptidyl peptidase IV inhibitors derived from β -aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1731-1735.	2.2	24
311	Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4. <i>Endocrinology</i> , 2011, 152, 3103-3112.	2.8	282
312	Understanding the Incretin Effect. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 934-935.	3.6	28
313	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 513-525.	2.4	5
314	Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety. <i>Current Medicinal Chemistry</i> , 2011, 18, 4753-4760.	2.4	14
315	Postprandial Insulin Secretion After Gastric Bypass Surgery. <i>Diabetes</i> , 2011, 60, 2203-2205.	0.6	34
316	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S251-S257.	8.6	233
317	Beta-Arrestin2 as a Competitor for GRK2 Interaction with the GLP-1 Receptor upon Receptor Activation. <i>Pharmacology</i> , 2011, 88, 174-181.	2.2	18
318	Contributions of fat and protein to the incretin effect of a mixed meal. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 997-1003.	4.7	22
319	Exendin-4 Suppresses Src Activation and Reactive Oxygen Species Production in Diabetic Goto-Kakizaki Rat Islets in an Epac-Dependent Manner. <i>Diabetes</i> , 2011, 60, 218-226.	0.6	82
320	Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice. <i>Endocrinology</i> , 2011, 152, 3018-3029.	2.8	134
321	Eating dark and milk chocolate: a randomized crossover study of effects on appetite and energy intake. <i>Nutrition and Diabetes</i> , 2011, 1, e21-e21.	3.2	31

#	ARTICLE	IF	CITATIONS
322	Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. <i>Experimental Diabetes Research</i> , 2011, 2011, 1-10.	3.8	75
323	Glucagon-Like Peptide-1 Gene Therapy. <i>Experimental Diabetes Research</i> , 2011, 2011, 1-5.	3.8	17
324	The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2011, 4, CMED.S4086.	1.9	2
325	Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2011, 4, CMED.S5976.	1.9	16
326	Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day Three, Two Months, and One Year after Surgery: Role of Gut Peptides. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2227-2235.	3.6	281
327	Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 447-453.	3.6	152
328	Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy. <i>Neuroendocrinology</i> , 2011, 94, 291-301.	2.5	63
329	Effects of food form on food intake and postprandial appetite sensations, glucose and endocrine responses, and energy expenditure in resistance trained <i>v.</i> sedentary older adults. <i>British Journal of Nutrition</i> , 2011, 106, 1107-1116.	2.3	20
330	Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. <i>Clinical Investigation</i> , 2011, 1, 327-343.	0.0	2
331	Essential Role for Protein Kinase C α in Oleic Acid-Induced Glucagon-Like Peptide-1 Secretion in Vivo in the Rat. <i>Endocrinology</i> , 2011, 152, 1244-1252.	2.8	39
332	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β -Cell Function. <i>Diabetes</i> , 2011, 60, 1599-1607.	0.6	131
333	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β -Cell Function. <i>Diabetes Care</i> , 2011, 34, 1463-1468.	8.6	143
334	Partial Inhibition of Insulin Secretion Results in Glucose Intolerance but Not Hyperglucagonemia. <i>Diabetes</i> , 2011, 60, 1324-1328.	0.6	6
335	Transient Receptor Potential Cation Channels in Pancreatic β Cells. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2011, 161, 87-110.	1.6	61
336	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 737-745.	3.6	190
337	Obestatin: An Interesting but Controversial Gut Hormone. <i>Annals of Nutrition and Metabolism</i> , 2011, 59, 193-199.	1.9	53
338	Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients. <i>Journal of Nutrition</i> , 2011, 141, 1233-1238.	2.9	85
339	Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. <i>Experimental Diabetes Research</i> , 2011, 2011, 1-6.	3.8	29

#	ARTICLE	IF	CITATIONS
340	Glucagon-Like Peptide-1 and Diabetes. Experimental Diabetes Research, 2011, 2011, 1-1.	3.8	7
341	New Antisense Strategies: Chemical Synthesis of RNA Oligomers. Advances in Polymer Science, 2011, , 1-47.	0.8	0
342	Subthreshold \hat{I}_{\pm}^{2} -Adrenergic Activation Counteracts Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion. Experimental Diabetes Research, 2011, 2011, 1-7.	3.8	5
343	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E1038-E1046.	3.5	148
344	The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1479-R1485.	1.8	71
345	Pharmacokinetics and Pharmacodynamics of KR-66223 a Novel DPP-4 Inhibitor. Drug Metabolism and Pharmacokinetics, 2012, 27, 216-222.	2.2	1
346	Exendin-4 Protects MIN6 Cells from t-BHP-Induced Apoptosis via IRE1-JNK-Caspase-3 Signaling. International Journal of Endocrinology, 2012, 2012, 1-7.	1.5	4
347	Metabolic Effects of Short-term GLP-1 Treatment in Insulin Resistant Heart Failure Patients. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 266-272.	1.2	9
348	Meal-contingent intestinal lymph sampling from awake, unrestrained rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R1365-R1371.	1.8	15
349	Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating \hat{I}^2 -catenin and CREB activities. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E740-E751.	3.5	9
350	Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. American Journal of Physiology - Renal Physiology, 2012, 302, G352-G358.	3.4	23
351	Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2012, 16, 589.	0.4	26
352	South Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan. Indian Journal of Endocrinology and Metabolism, 2012, 16, 525.	0.4	11
353	Uncoupling protein 2 negatively regulates glucose-induced glucagon-like peptide 1 secretion. Journal of Molecular Endocrinology, 2012, 48, 151-158.	2.5	12
354	Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Therapeutic Advances in Drug Safety, 2012, 3, 185-201.	2.4	4
355	Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 13-18.	2.3	10
356	The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. Journal of Neuroscience, 2012, 32, 4812-4820.	3.6	305
357	Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus: Clinical Results in Subgroups of Patients Using Different Concomitant Medications. Postgraduate Medicine, 2012, 124, 33-40.	2.0	11

#	ARTICLE	IF	CITATIONS
358	Enhanced Differentiation of Human Adipose Tissue-derived Stromal Cells into Insulin-producing Cells with Glucagon-like Peptide-1. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 28-34.	1.2	6
359	GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy. <i>Current Clinical Pharmacology</i> , 2012, 7, 214-228.	0.6	51
360	Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. <i>Heart</i> , 2012, 98, 408-413.	2.9	97
361	GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake. <i>Endocrinology</i> , 2012, 153, 647-658.	2.8	374
362	Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1720-E1725.	3.6	96
363	Unraveling oxyntomodulin, GLP1's enigmatic brother. <i>Journal of Endocrinology</i> , 2012, 215, 335-346.	2.6	115
364	Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?. <i>Annals of Medicine</i> , 2012, 44, 338-349.	3.8	10
365	The significance of the nuclear farnesoid X receptor (FXR) in β^2 cell function. <i>Islets</i> , 2012, 4, 333-338.	1.8	34
366	Postprandial glucose, insulin and glucagon-like peptide 1 responses to sucrose ingested with berries in healthy subjects. <i>British Journal of Nutrition</i> , 2012, 107, 1445-1451.	2.3	74
367	Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, S-43-S-50.	4.4	12
368	Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1363-1370.	3.6	61
369	Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms. <i>Diabetes Spectrum</i> , 2012, 25, 200-210.	1.0	41
370	Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. <i>International Journal of Obesity</i> , 2012, 36, 1522-1528.	3.4	64
371	Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E122-E131.	3.5	274
372	Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 387-390.	1.3	14
373	A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 213-219.	2.1	3
374	Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery. <i>Isrn Endocrinology</i> , 2012, 2012, 1-13.	2.0	25
375	Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue. <i>European Journal of Endocrinology</i> , 2012, 166, 951-955.	3.7	73

#	ARTICLE	IF	CITATIONS
376	Bone: Incretin Hormones Perceiver or Receiver?. Experimental Diabetes Research, 2012, 2012, 1-5.	3.8	22
377	Obesity and Appetite Control. Experimental Diabetes Research, 2012, 2012, 1-19.	3.8	154
378	Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome. Journal of Nutrition and Metabolism, 2012, 2012, 1-28.	1.8	305
379	Whole Grains, Legumes, and Health. Journal of Nutrition and Metabolism, 2012, 2012, 1-2.	1.8	8
380	Mechanisms of current therapies for diabetes mellitus type 2. American Journal of Physiology - Advances in Physiology Education, 2012, 36, 275-283.	1.6	26
381	Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling. Journal of Biological Chemistry, 2012, 287, 6421-6430.	3.4	101
382	Biophysical and Pharmacological Properties of Glucagon-Like Peptide-1 in Rats Under Isoflurane Anesthesia. Anesthesia and Analgesia, 2012, 115, 62-69.	2.2	5
383	Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy¥. Current Vascular Pharmacology, 2012, 10, 773-780.	1.7	10
385	Different Incretin Responses After Pancreatoduodenectomy and Distal Pancreatectomy. Pancreas, 2012, 41, 455-460.	1.1	16
386	Basal Glucagonlike Peptide 1 Levels and Metabolic Syndrome in Obese Patients. Journal of Investigative Medicine, 2012, 60, 874-877.	1.6	10
387	The receptive function of hypothalamic and brainstem centres to hormonal and nutrient signals affecting energy balance. Proceedings of the Nutrition Society, 2012, 71, 463-477.	1.0	36
388	TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Scientific Reports, 2012, 2, 430.	3.3	143
389	Comparison of plasma active glucagon-like peptide-1 (GLP-1) levels assayed with or without plasma extraction in non-diabetic men. Endocrine Journal, 2012, 59, 435-438.	1.6	4
390	A Morbid Obese Japanese Woman with a Body Mass Index of 83.2 kg/m ² ; Before and after Sleeve Gastrectomy. Internal Medicine, 2012, 51, 969-975.	0.7	1
391	Type 2 diabetes: which drug as add-on to metformin?. Lancet, The, 2012, 379, 2222-2223.	13.7	2
392	Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor. Journal of Physiology, 2012, 590, 5245-5255.	2.9	4
393	From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nature Neuroscience, 2012, 15, 1350-1355.	14.8	357
394	INS1-Deficient Mice Display an Alteration in Glucose Homeostasis and an Impaired Fertility. Endocrinology, 2012, 153, 4655-4665.	2.8	60

#	ARTICLE	IF	CITATIONS
395	Satiety-enhancing products for appetite control: science and regulation of functional foods for weight management. <i>Proceedings of the Nutrition Society</i> , 2012, 71, 350-362.	1.0	122
396	Investigation of the haemodynamic effects of exenatide in healthy male subjects. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 437-444.	2.4	46
397	Recent advances in incretin-based therapies. <i>Clinical Endocrinology</i> , 2012, 77, 489-499.	2.4	58
398	A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. <i>Diabetologia</i> , 2012, 55, 3262-3272.	6.3	208
399	The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. <i>Proceedings of the Nutrition Society</i> , 2012, 71, 456-462.	1.0	79
400	Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2012, 3, 70-79.	2.4	59
401	Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin. <i>Molecular Pharmacology</i> , 2012, 82, 1066-1073.	2.3	51
402	Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 172-8.	2.3	10
403	Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions. <i>Circulation</i> , 2012, 126, 1838-1851.	1.6	153
404	Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 56, 2142-2153.	7.3	123
405	Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. <i>Clinical Pharmacokinetics</i> , 2012, 51, 501-514.	3.5	134
406	Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 445-456.	2.6	25
407	The glucagon-like peptide 1 analog liraglutide reduces TNF- α -induced oxidative stress and inflammation in endothelial cells. <i>Atherosclerosis</i> , 2012, 221, 375-382.	0.8	219
408	The microtubule associated protein syntabulin is required for glucose-stimulated and cAMP-potentiated insulin secretion. <i>FEBS Letters</i> , 2012, 586, 3674-3680.	2.8	37
409	Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat. <i>Regulatory Peptides</i> , 2012, 179, 71-76.	1.9	7
410	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. <i>Regulatory Peptides</i> , 2012, 179, 91-100.	1.9	81
411	Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. <i>Translational Research</i> , 2012, 159, 25-31.	5.0	70
412	Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes. <i>Results in Pharma Sciences</i> , 2012, 2, 58-65.	4.2	15

#	ARTICLE	IF	CITATIONS
413	Patented TGR5 modulators: a review (2006 – present). Expert Opinion on Therapeutic Patents, 2012, 22, 1399-1414.	5.0	43
414	Oral Delivery of Glucagon-like Peptide-1 and Analogs: Alternatives for Diabetes Control?. Journal of Diabetes Science and Technology, 2012, 6, 1486-1497.	2.2	39
415	Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes. Endocrinology, 2012, 153, 1039-1048.	2.8	212
416	Overlap of Endocrine Hormone Expression in the Mouse Intestine Revealed by Transcriptional Profiling and Flow Cytometry. Endocrinology, 2012, 153, 3054-3065.	2.8	317
417	Diet-induced thermogenesis and respiratory quotient after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2012, 8, 797-802.	1.2	33
418	Biaryl-Bridged Macrocyclic Peptides: Conformational Constraint via Carbogenic Fusion of Natural Amino Acid Side Chains. Journal of Organic Chemistry, 2012, 77, 3099-3114.	3.2	55
419	The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology, 2012, 62, 1916-1927.	4.1	215
420	CNS regulation of appetite. Neuropharmacology, 2012, 63, 3-17.	4.1	120
421	Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats. Peptides, 2012, 35, 14-22.	2.4	35
422	Targeting the glucagon receptor family for diabetes and obesity therapy. , 2012, 135, 247-278.		129
423	Autonomic Nervous System In Vitro: Studying Tonically Active Neurons Controlling Vagal Outflow in Rodent Brainstem Slices. Neuromethods, 2012, , 1-59.	0.3	15
424	GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. British Journal of Pharmacology, 2012, 166, 121-136.	5.4	52
425	Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts. British Journal of Pharmacology, 2012, 165, 2736-2748.	5.4	28
426	Peripheral neural targets in obesity. British Journal of Pharmacology, 2012, 166, 1537-1558.	5.4	36
427	Role of the Gut in Lipid Homeostasis. Physiological Reviews, 2012, 92, 1061-1085.	28.8	278
428	Diet: Friend or Foe of Enteroendocrine Cells: How It Interacts with Enteroendocrine Cells. Advances in Nutrition, 2012, 3, 8-20.	6.4	80
429	Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates Î²-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. Journal of Diabetes and Its Complications, 2012, 26, 266-274.	2.3	31
430	Possible involvement of melanocortin-4-receptor and AMP-activated protein kinase in the interaction of glucagon-like peptide-1 and leptin on feeding in rats. Biochemical and Biophysical Research Communications, 2012, 420, 36-41.	2.1	24

#	ARTICLE	IF	CITATIONS
431	Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 304-308.	2.1	132
432	Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet β -cells. <i>FEBS Letters</i> , 2012, 586, 2555-2562.	2.8	35
433	Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 258-266.	2.8	135
434	Diabetes Mellitus and the β Cell: The Last Ten Years. <i>Cell</i> , 2012, 148, 1160-1171.	28.9	761
435	Characterization of glucagon-like peptide 1 receptor (GLP1R) gene in chickens: functional analysis, tissue distribution, and identification of its transcript variants. <i>Domestic Animal Endocrinology</i> , 2012, 43, 1-15.	1.6	24
436	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. <i>European Journal of Internal Medicine</i> , 2012, 23, 132-136.	2.2	15
437	Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 456-463.	4.0	21
438	Bariatric surgery and T2DM improvement mechanisms: a mathematical model. <i>Theoretical Biology and Medical Modelling</i> , 2012, 9, 16.	2.1	15
439	Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide-Dependent Mechanism. <i>Diabetes</i> , 2012, 61, 888-896.	0.6	158
440	The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β -cell mass in non-obese diabetic mice. <i>Journal of Endocrinology</i> , 2012, 214, 381-387.	2.6	44
441	Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion. <i>Journal of Diabetes Investigation</i> , 2012, 3, 432-440.	2.4	40
442	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 1491-1499.	2.2	456
443	A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1646-1653.	2.4	11
444	Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2012, 32, 1-14.	2.2	29
445	Antidiabetic activities of oligosaccharides of <i>Ophiopogon japonicus</i> in experimental type 2 diabetic rats. <i>International Journal of Biological Macromolecules</i> , 2012, 51, 749-755.	7.5	32
446	Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1796-1806.	3.8	70
447	Hindbrain Neurons as an Essential Hub in the Neuroanatomically Distributed Control of Energy Balance. <i>Cell Metabolism</i> , 2012, 16, 296-309.	16.2	362
448	Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2012, 6, 125-131.	3.6	28

#	ARTICLE	IF	CITATIONS
449	Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β -cell line. <i>Peptides</i> , 2012, 37, 18-24.	2.4	28
450	Action of glucagon-like peptide 1 and glucose levels on corticotropin-releasing factor and vasopressin gene expression in rat hypothalamic 4B cells. <i>Molecular and Cellular Endocrinology</i> , 2012, 362, 221-226.	3.2	13
451	Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2. <i>Diabetes</i> , 2012, 61, 364-371.	0.6	1,644
452	Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. <i>Journal of Diabetes Investigation</i> , 2012, 3, 517-525.	2.4	28
453	Recombinant production of mGLP-1 by coupling of refolding and intein-mediated self-cleavage (CRIS). <i>Applied Microbiology and Biotechnology</i> , 2012, 96, 1283-1290.	3.6	4
454	Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener. <i>Journal of Diabetes Investigation</i> , 2012, 3, 156-163.	2.4	18
456	Discovery of a Novel Glucagon-like Peptide (GCGL) and Its Receptor (GCGLR) in Chickens: Evidence for the Existence of GCGL and GCGLR Genes in Nonmammalian Vertebrates. <i>Endocrinology</i> , 2012, 153, 5247-5260.	2.8	27
457	Nonalcoholic fatty liver disease and atherosclerosis. <i>Internal and Emergency Medicine</i> , 2012, 7, 297-305.	2.0	44
458	Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. <i>Diabetologia</i> , 2012, 55, 2445-2455.	6.3	175
459	Physiology of Glucose Homeostasis and Insulin Therapy in Type 1 and Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 25-39.	3.2	21
460	Serotonin Conflict in Sleep-Feeding. <i>Vitamins and Hormones</i> , 2012, 89, 223-239.	1.7	15
461	Regulation of Gastric Acid Secretion. , 2012, , 1281-1309.		5
462	Na ⁺ -glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion. <i>Diabetes</i> , 2012, 61, 187-196.	0.6	550
463	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012, 10, 92.	5.5	24
464	Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes. <i>Diabetes Therapy</i> , 2012, 3, 11.	2.5	7
465	GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis. <i>PLoS ONE</i> , 2012, 7, e40156.	2.5	125
466	The Delay in the Development of Experimental Colitis from Isomaltosyloligosaccharides in Rats Is Dependent on the Degree of Polymerization. <i>PLoS ONE</i> , 2012, 7, e50658.	2.5	14
467	The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes. <i>Journal of Korean Medical Science</i> , 2012, 27, 1364.	2.5	73

#	ARTICLE	IF	CITATIONS
468	Interaction of Herbal Compounds with Biological Targets: A Case Study with Berberine. Scientific World Journal, The, 2012, 2012, 1-31.	2.1	47
469	Authors' reply to de Oliveira and Iverson. BMJ: British Medical Journal, 2012, 344, e1459-e1459.	2.3	0
470	Optimizing glycemic control: clinical utility of exenatide prolonged release injection. Research and Reports in Endocrine Disorders, 0, , 41.	0.4	0
471	Fiber intake Inconsistently Alters Gut Hormone Levels in Humans Following Acute or Chronic Intake. Journal of Food Research, 2012, 1, .	0.3	9
472	Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes, Obesity and Metabolism, 2012, 14, 531-538.	4.4	146
473	Anorexigenic Effects of GLP-1 and Its Analogues. Handbook of Experimental Pharmacology, 2012, , 185-207.	1.8	33
474	The effect of glucagon-like peptide 1 on cardiovascular risk. Nature Reviews Cardiology, 2012, 9, 209-222.	13.7	131
475	Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults. Annals of Pharmacotherapy, 2012, 46, 68-78.	1.9	20
476	Normalization of fasting hyperglycemia is beneficial for successful introduction of small amount of the GLP-1 analog liraglutide in an obese patient with type 2 diabetes mellitus. Diabetology International, 2012, 3, 61-64.	1.4	3
477	Effectiveness of the glucagon test in estimating islet function for liraglutide treatment in a lean diabetic patient with impaired insulin response to glucose. Diabetology International, 2012, 3, 103-108.	1.4	2
478	Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia, 2012, 55, 1406-1416.	6.3	53
479	Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia, 2012, 55, 1890-1901.	6.3	208
480	Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia, 2012, 55, 2096-2108.	6.3	116
481	Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe $\alpha^{\sim}/\alpha^{\sim}$ mice. Diabetologia, 2012, 55, 2267-2275.	6.3	81
482	Effect of Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy on Glucose and Gut Hormones: a Prospective Randomised Trial. Journal of Gastrointestinal Surgery, 2012, 16, 1116-1122.	1.7	151
483	Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects. Obesity Surgery, 2012, 22, 1084-1096.	2.1	287
484	Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 2231-2239.	2.4	150
485	Incretin based therapies: Do they hold their promise?. Journal of Diabetes, 2012, 4, 4-7.	1.8	1

#	ARTICLE	IF	CITATIONS
486	Using albumin to improve the therapeutic properties of diabetes treatments. Diabetes, Obesity and Metabolism, 2012, 14, 121-129.	4.4	11
487	Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation. Transplant International, 2012, 25, 242-249.	1.6	8
488	Functional importance of GLP-1 receptor species and expression levels in cell lines. Regulatory Peptides, 2012, 175, 21-29.	1.9	29
489	Circulating ghrelin and GLP-1 are not affected by habitual diet. Regulatory Peptides, 2012, 176, 1-5.	1.9	7
490	Beginnings: A reflection on the history of gastrointestinal endocrinology. Regulatory Peptides, 2012, 177, S1-S5.	1.9	33
491	Nutrient detection by incretin hormone secreting cells. Physiology and Behavior, 2012, 106, 387-393.	2.1	97
492	Cognitive and neuronal systems underlying obesity. Physiology and Behavior, 2012, 106, 337-344.	2.1	65
493	Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiology and Behavior, 2012, 106, 413-416.	2.1	59
494	Exendin-4 decreases amphetamine-induced locomotor activity. Physiology and Behavior, 2012, 106, 574-578.	2.1	74
495	Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer. Journal of Controlled Release, 2012, 157, 243-248.	9.9	14
496	Propionate absorbed from the colon acts as gluconeogenic substrate in a strict carnivore, the domestic cat (<i>Felis catus</i>). Journal of Animal Physiology and Animal Nutrition, 2012, 96, 1054-1064.	2.2	21
497	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes, Obesity and Metabolism, 2012, 14, 41-49.	4.4	24
498	Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2012, 14, 709-716.	4.4	86
499	Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism, 2013, 15, 3-14.	4.4	56
500	Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men. Nutrition and Metabolism, 2013, 10, 33.	3.0	17
501	Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. International Journal of Clinical Pharmacy, 2013, 35, 159-172.	2.1	58
502	Dual factor delivery of CXCL12 and Exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions. Biotechnology and Bioengineering, 2013, 110, 2292-2300.	3.3	15
503	DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets. BMC Medical Genetics, 2013, 14, 76.	2.1	86

#	ARTICLE	IF	CITATIONS
504	Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population. BMC Medical Genetics, 2013, 14, 8.	2.1	29
505	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy, 2013, 14, 2047-2058.	1.8	102
506	The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid- β^2 Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. NeuroMolecular Medicine, 2013, 15, 102-114.	3.4	134
507	Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?. Diabetologia, 2013, 56, 1869-1872.	6.3	6
508	Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia, 2013, 56, 1980-1986.	6.3	40
509	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia, 2013, 56, 965-972.	6.3	199
510	Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia, 2013, 56, 156-161.	6.3	117
511	Clues from Bariatric Surgery: Reversing Insulin Resistance to Heal the Heart. Current Diabetes Reports, 2013, 13, 245-251.	4.2	9
512	Is there a place for incretin therapies in obesity and prediabetes?. Trends in Endocrinology and Metabolism, 2013, 24, 145-152.	7.1	38
513	Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Archives of Physiology and Biochemistry, 2013, 119, 170-178.	2.1	28
514	Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients. International Urology and Nephrology, 2013, 45, 1733-1740.	1.4	2
515	The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Translational Research, 2013, 162, 309-316.	5.0	24
516	Old and New Peptide Receptor Targets in Cancer: Future Directions. Recent Results in Cancer Research, 2013, 194, 567-576.	1.8	22
517	Oral L-Arginine Stimulates GLP-1 Secretion to Improve Glucose Tolerance in Male Mice. Endocrinology, 2013, 154, 3978-3983.	2.8	58
518	Effects on Glucagon-Like Peptide-1 Secretion by Distal Ileal Administration of Nutrients. Obesity Surgery, 2013, 23, 1774-1782.	2.1	2
519	Significant Weight Loss and Rapid Resolution of Diabetes and Dyslipidemia During Short-Term Follow-Up After Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2013, 23, 1966-1972.	2.1	21
520	Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicology and Applied Pharmacology, 2013, 266, 375-384.	2.8	8
522	Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Current Opinion in Pharmacology, 2013, 13, 983-988.	3.5	96

#	ARTICLE	IF	CITATIONS
523	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal, 2013, 166, 823-830.e5.	2.7	182
524	Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2013, 7, 223-225.	3.6	2
525	Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor. Peptides, 2013, 48, 36-44.	2.4	30
526	Role of central glucagon-like peptide-1 in stress regulation. Physiology and Behavior, 2013, 122, 201-207.	2.1	76
527	Swim training restores glucagon-like peptide-1 insulinotropic action in pancreatic islets from monosodium glutamate-obese rats. Acta Physiologica, 2013, 209, 34-44.	3.8	19
528	Brain delivery of proteins via their fatty acid and block copolymer modifications. Journal of Drug Targeting, 2013, 21, 940-955.	4.4	19
529	The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups. Advances in Therapy, 2013, 30, 1067-1085.	2.9	10
530	Microbial Modulation of Energy Availability in the Colon Regulates Intestinal Transit. Cell Host and Microbe, 2013, 14, 582-590.	11.0	306
531	Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: Role of GLP-1 and GLP-1 receptor. European Journal of Pharmacology, 2013, 720, 158-165.	3.5	33
532	Development of a C-Terminal Site-Specific PEGylated Analog of GLP-1 with Improved Anti-Diabetic Effects in Diabetic Mice. Drug Development Research, 2013, 74, 186-193.	2.9	2
533	Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor. Diabetologia, 2013, 56, 2688-2696.	6.3	158
534	Copenhagen study of overweight patients with coronary artery disease undergoing low energy diet or interval training: the randomized CUT-IT trial protocol. BMC Cardiovascular Disorders, 2013, 13, 106.	1.7	15
535	Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity. Diabetes Care, 2013, 36, 1933-1940.	8.6	68
536	Effects of Chenodeoxycholic Acid on the Secretion of Gut Peptides and Fibroblast Growth Factors in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3351-3358.	3.6	41
538	Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes, Obesity and Metabolism, 2013, 15, 871-881.	4.4	28
539	The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 1339-1363.	5.0	37
540	The gut as a sensory organ. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 729-740.	17.8	386
541	Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut, 2013, 62, 1724-1733.	12.1	50

#	ARTICLE	IF	CITATIONS
542	Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 105-121.	2.4	8
543	Unique roles of glucagon and glucagon-like peptides: Parallels in understanding the functions of adipokinetic hormones in stress responses in insects. <i>Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology</i> , 2013, 164, 91-100.	1.8	49
544	Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic Î²-cell impairments in type 2 diabetes. <i>Cellular Signalling</i> , 2013, 25, 570-579.	3.6	54
545	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 17-29.	3.3	49
546	Regulation of Insulin Secretion in Human Pancreatic Islets. <i>Annual Review of Physiology</i> , 2013, 75, 155-179.	13.1	496
547	Traitement du diabète de type 2 : l'exénatide, en alternative ou en association à l'insuline ?. <i>Medecine Des Maladies Metaboliques</i> , 2013, 7, 449-463.	0.1	0
548	The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. <i>Psychoneuroendocrinology</i> , 2013, 38, 1259-1270.	2.7	122
549	The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. <i>Regulatory Peptides</i> , 2013, 181, 17-21.	1.9	17
551	Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. <i>European Journal of Pharmacology</i> , 2013, 698, 74-86.	3.5	60
552	Glucose homeostasis can be differentially modulated by varying individual components of a western diet. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1251-1257.	4.2	21
553	Anneau, bypass ou sleeve: que choisir?. <i>Journal De Chirurgie Viscérale</i> , 2013, 150, 104-115.	0.0	0
554	Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids. <i>International Journal of Cardiology</i> , 2013, 168, 4085-4092.	1.7	13
555	Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 483-490.	2.8	24
556	Adjustable gastric banding, sleeve gastrectomy or gastric bypass. Can evidence-based medicine help us to choose?. <i>Journal of Visceral Surgery</i> , 2013, 150, 85-95.	0.8	17
557	Acute differential effects of dietary protein quality on postprandial lipemia in obese non-diabetic subjects. <i>Nutrition Research</i> , 2013, 33, 34-40.	2.9	56
558	Phenotypic and functional characterization of glucagon-positive cells derived from spontaneous differentiation of D3-mouse embryonic stem cells. <i>Cytotherapy</i> , 2013, 15, 122-131.	0.7	1
559	Incretin actions beyond the pancreas: lessons from knockout mice. <i>Current Opinion in Pharmacology</i> , 2013, 13, 946-953.	3.5	42
560	Recompensa alimentar: mecanismos envolvidos e implicações para a obesidade. <i>Revista Portuguesa De Endocrinologia Diabetes E Metabolismo</i> , 2013, 8, 82-88.	0.1	7

#	ARTICLE	IF	CITATIONS
561	Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. <i>Molecular Metabolism</i> , 2013, 2, 142-152.	6.5	54
562	Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, e55-e58.	2.8	90
563	Review article: a comparison of glucagon-like peptides 1 and 2. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 18-36.	3.7	90
564	Design, Synthesis, Structure-Activity Relationships, and Docking Studies of 1,2,3-Triazol Substituted) Tj ETQq1 Inhibitors. <i>Chemical Biology and Drug Design</i> , 2013, 81, 198-207.	1 0.7843 3.2 9	14
565	A mutated glucagon-like peptide-1 with improved glucose-lowering activity in diabetic mice. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 539-546.	2.4	1
566	<scp>GLP</scp>-1 analogue prevents <scp>NAFLD</scp> in ApoE <scp>KO</scp> mice with diet and Acpr30 knockdown by inhibiting <scp>JNK</scp>. <i>Liver International</i> , 2013, 33, 794-804.	3.9	52
567	Latest research and development trends in non-insulin anti-diabetics. <i>Archives of Pharmacal Research</i> , 2013, 36, 145-153.	6.3	5
568	Incretins: What is known, new and controversial in 2013?. <i>Diabetes and Metabolism</i> , 2013, 39, 89-93.	2.9	5
570	Oral administration of <i>Lactobacillus reuteri</i> GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. <i>Nutrition and Metabolism</i> , 2013, 10, 35.	3.0	193
572	Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors. <i>Annals of Pharmacotherapy</i> , 2013, 47, 490-505.	1.9	30
573	Metformin decreases meal size and number and increases c-Fos expression in the nucleus tractus solitarius of obese mice. <i>Physiology and Behavior</i> , 2013, 110-111, 213-220.	2.1	18
574	Synthesis, Characterization and Pharmacodynamics of Vitamin B ₁₂ -Conjugated Glucagon-Like Peptide-1. <i>ChemMedChem</i> , 2013, 8, 582-586.	3.2	28
575	Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 229-238.	2.4	4
576	Development and Evaluation of ¹⁸ F-TTCO-Cys ⁴⁰ -Exendin-4: A PET Probe for Imaging Transplanted Islets. <i>Journal of Nuclear Medicine</i> , 2013, 54, 244-251.	5.0	98
577	GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. <i>European Journal of Endocrinology</i> , 2013, 168, 699-706.	3.7	101
578	Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular risk management in Type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 593-606.	4.4	42
579	Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. <i>Journal of Endocrinology</i> , 2013, 217, 185-196.	2.6	55
580	Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabetes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4011-4018.	2.2	116

#	ARTICLE	IF	CITATIONS
581	Glucagon-like peptides 1 and 2 in health and disease: A review. <i>Peptides</i> , 2013, 44, 75-86.	2.4	76
582	The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: Just a sidestep?. <i>Epilepsy Research</i> , 2013, 104, 285-288.	1.6	5
583	Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1641-1652.	2.8	136
584	Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem. <i>Neuroscience</i> , 2013, 229, 130-143.	2.3	52
585	Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. <i>Journal of Diabetes Investigation</i> , 2013, 4, 108-130.	2.4	207
586	The <i>CTRB1/2</i> Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway. <i>Diabetes</i> , 2013, 62, 3275-3281.	0.6	96
587	Thyroid safety in patients treated with liraglutide. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 140-145.	3.3	24
588	Meal induced gut hormone secretion is altered in aerobically trained compared to sedentary young healthy males. <i>European Journal of Applied Physiology</i> , 2013, 113, 2737-2747.	2.5	9
589	Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice. <i>Endocrinology</i> , 2013, 154, 4503-4511.	2.8	93
590	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , 2013, 3, e003834.	1.9	9
591	Gustducin couples fatty acid receptors to GLP-1 release in colon. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E651-E660.	3.5	33
592	Activation of Prostaglandin E Receptor 4 Triggers Secretion of Gut Hormone Peptides GLP-1, GLP-2, and PYY. <i>Endocrinology</i> , 2013, 154, 45-53.	2.8	18
593	Role of Secretin Peptide Family and their Receptors in the Hypothalamic Control of Energy Homeostasis. <i>Hormone and Metabolic Research</i> , 2013, 45, 945-954.	1.5	9
595	Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H131-H141.	3.2	21
596	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G413-G419.	3.4	43
597	Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E376-E387.	3.5	51
598	The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E1367-E1374.	3.5	136
599	Bile Acid-Mediated Control of Liver Triglycerides. <i>Seminars in Liver Disease</i> , 2013, 33, 330-342.	3.6	55

#	ARTICLE	IF	CITATIONS
600	An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	3.0	20
601	Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E132-E139.	3.5	1
602	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G1117-G1127.	3.4	138
603	Role of GLP-1 in the Hypoglycemic Effects of Wild Bitter Gourd. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-13.	1.2	33
604	Mechanism of Metabolic Advantages After Bariatric Surgery. <i>Diabetes Care</i> , 2013, 36, S287-S291.	8.6	70
605	Incretin-stimulated interaction between I^2 -cell Kv1.5 and Kv I^2 channel proteins involves acetylation/deacetylation by CBP/Sirt1. <i>Biochemical Journal</i> , 2013, 451, 227-234.	3.7	18
606	Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E222-E228.	3.5	53
607	Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. <i>Frontiers in Endocrinology</i> , 2013, 4, 50.	3.5	15
608	Effect of the GLP-1 Analog Exendin-4 and Oxaliplatin on Intrahepatic Cholangiocarcinoma Cell Line and Mouse Model. <i>International Journal of Molecular Sciences</i> , 2013, 14, 24293-24304.	4.1	11
609	Glucose metabolism is altered after loss of L cells and I^{\pm} -cells but not influenced by loss of K cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E60-E73.	3.5	37
610	Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E751-E759.	3.5	31
611	Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1). <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	27
612	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. <i>European Journal of Endocrinology</i> , 2013, 169, 187-201.	3.7	51
613	Persistent C-peptide. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 279-284.	2.3	9
614	Islet Neogenesis-Associated Protein (INGAP)-Positive Cell Mass, I^2 -Cell Mass, and Insulin Secretion. <i>Pancreas</i> , 2013, 42, 422-428.	1.1	5
615	Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 72-77.	2.0	58
616	Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, S127-S138.	8.6	232
617	Cardiovascular effects of alpha-linolenic acid – a possible role of glucagon-like peptide-1. <i>Experimental Biology and Medicine</i> , 2013, 238, 1116-1117.	2.4	0

#	ARTICLE	IF	CITATIONS
618	Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1470-1479.	3.3	20
619	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β^2 -Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 3044-3052.	0.6	262
620	In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)-Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2148-2157.	3.3	29
621	Liraglutide Suppresses the Plasma Levels of Active and Des-Acyl Ghrelin Independently of Active Glucagon-Like Peptide-1 Levels in Mice. <i>Isrn Endocrinology</i> , 2013, 2013, 1-5.	2.0	3
622	Improved transplantation outcome through delivery of DNA encoding secretion signal peptide-linked glucagon-like peptide-1 into mouse islets. <i>Transplant International</i> , 2013, 26, 443-452.	1.6	4
623	Endogenous <scp>PYY</scp> and <scp>GLP</scp>-1 mediate <scp> </scp>-glutamine responses in intestinal mucosa. <i>British Journal of Pharmacology</i> , 2013, 170, 1092-1101.	5.4	31
624	Glucagon-like peptide-1 in the rat brain: Distribution of expression and functional implication. <i>Journal of Comparative Neurology</i> , 2013, 521, 2235-2261.	1.6	90
625	Glucagon-like Peptide-1 Receptor Agonist Administration Suppresses Both Water and Saline Intake in Rats. <i>Journal of Neuroendocrinology</i> , 2013, 25, 929-938.	2.6	25
626	Energy loss via urine and faeces - a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 324-334.	4.4	12
627	Presence and dynamics of leptin, GLP-1, and PYY in human breast milk at early postpartum. <i>Obesity</i> , 2013, 21, 1451-1458.	3.0	45
628	Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2013, 41, 159-164.	2.8	5
629	Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. <i>Obesity</i> , 2013, 21, E660-8.	3.0	162
630	Cardioprotective Effects of Exenatide in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2252-2260.	2.4	185
631	GLP 1/2, Enteroglucagon, Glicentin, and Oxyntomodulin. , 2013, , 1241-1250.		2
632	Incretin hormones and the satiation signal. <i>International Journal of Obesity</i> , 2013, 37, 1161-1168.	3.4	137
633	Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men. <i>Nutrition and Diabetes</i> , 2013, 3, e78-e78.	3.2	20
634	Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E664-E671.	3.6	151
636	Effects of thirty-times chewing per bite on secretion of glucagon-like peptide-1 in healthy volunteers and type 2 diabetic patients. <i>Endocrine Journal</i> , 2013, 60, 311-319.	1.6	26

#	ARTICLE	IF	CITATIONS
637	Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective study. <i>Critical Care</i> , 2013, 17, R123.	5.8	15
638	Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E1105-E1117.	3.5	22
639	Dietary galacto-oligosaccharides and calcium: effects on energy intake, fat-pad weight and satiety-related, gastrointestinal hormones in rats. <i>British Journal of Nutrition</i> , 2013, 109, 1338-1348.	2.3	54
640	GLP-1. , 2013, , 1111-1117.		1
641	Alterations in Gut Hormones After Laparoscopic Sleeve Gastrectomy. <i>Annals of Surgery</i> , 2013, 257, 647-654.	4.2	110
642	GLP-1 and the Long-Term Outcome of Type 2 Diabetes Mellitus After Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Subjects. <i>Annals of Surgery</i> , 2013, 257, 894-899.	4.2	54
643	Duodenal-jejunal Bypass Improves Glycemia and Decreases SGLT1-Mediated Glucose Absorption in Rats With Streptozotocin-Induced Type 2 Diabetes. <i>Annals of Surgery</i> , 2013, 258, 89-97.	4.2	34
644	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 435.	2.4	8
645	Long segment ileal transposition leads to early amelioration of glucose control in the diabetic obese Zucker rat. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 2013, 2, 130-138.	0.7	9
646	Comparison of DPP-4 Inhibitors. <i>Journal of Korean Diabetes</i> , 2013, 14, 111.	0.3	2
647	DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Secretion of gastrointestinal hormones and eating control1. <i>Journal of Animal Science</i> , 2013, 91, 1963-1973.	0.5	46
648	Enhanced Intestinal Motility during Oral Glucose Tolerance Test after Laparoscopic Sleeve Gastrectomy: Preliminary Results Using Cine Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2013, 8, e65739.	2.5	30
649	Cell Lineage Identification and Stem Cell Culture in a Porcine Model for the Study of Intestinal Epithelial Regeneration. <i>PLoS ONE</i> , 2013, 8, e66465.	2.5	120
650	The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice. <i>PLoS ONE</i> , 2013, 8, e69010.	2.5	109
651	Exendin-4 Protects Mitochondria from Reactive Oxygen Species Induced Apoptosis in Pancreatic Beta Cells. <i>PLoS ONE</i> , 2013, 8, e76172.	2.5	23
652	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 187.	2.4	75
653	Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain. <i>Frontiers in Neuroenergetics</i> , 2013, 5, 2.	5.3	25
654	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 217.	2.4	37

#	ARTICLE	IF	CITATIONS
655	Natural Products: Bioactivity, Biochemistry, and Biological Effects in Cancer and Disease Therapy. Scientific World Journal, The, 2013, 2013, 1-1.	2.1	4
656	DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Gut chemosensing and the regulation of nutrient absorption and energy supply1. Journal of Animal Science, 2013, 91, 1932-1945.	0.5	32
657	Effects of exercise on glucagon-like peptide-1 (GLP-1). The Journal of Physical Fitness and Sports Medicine, 2013, 2, 221-224.	0.3	2
659	Is it time for algorism in clinical procedure of surgical treatment of type 2 diabetes as a component of metabolic syndrome?. Przegląd Gastroenterologiczny, 2013, 1, 31-37.	0.7	0
660	The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation, 2014, 124, 4473-4488.	8.2	617
661	Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e87488.	2.5	84
662	A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor. PLoS ONE, 2014, 9, e93746.	2.5	24
663	Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy. PLoS ONE, 2014, 9, e96863.	2.5	64
664	The GIP Receptor Displays Higher Basal Activity than the GLP-1 Receptor but Does Not Recruit GRK2 or Arrestin3 Effectively. PLoS ONE, 2014, 9, e106890.	2.5	42
665	Obesity: Pathophysiology and Intervention. Nutrients, 2014, 6, 5153-5183.	4.1	120
666	Vaccines for metabolic diseases: current perspectives. Vaccine (Auckland, N Z), 0, , 55.	1.7	0
668	Changes in RFamide-Related Peptide-1 (RFRP-1)-Immunoreactivity During Postnatal Development and the Estrous Cycle. Endocrinology, 2014, 155, 4402-4410.	2.8	22
669	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. Clinical Investigation, 2014, 4, 729-743.	0.0	3
670	Peptides and Food Intake. Frontiers in Endocrinology, 2014, 5, 58.	3.5	174
671	GLP-1: benefits beyond pancreas. Journal of Endocrinological Investigation, 2014, 37, 1143-1153.	3.3	25
672	MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. European Journal of Endocrinology, 2014, 171, R47-R65.	3.7	62
673	Quantitation of human peptides and proteins via MS: review of analytically validated assays. Bioanalysis, 2014, 6, 1843-1857.	1.5	35
674	Progressive change of intra-islet GLP-1 production during diabetes development. Diabetes/Metabolism Research and Reviews, 2014, 30, 661-668.	4.0	36

#	ARTICLE	IF	CITATIONS
675	GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering. <i>Diabetes</i> , 2014, 63, 3221-3229.	0.6	155
676	GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action. <i>Physiology</i> , 2014, 29, 108-121.	3.1	18
677	The role of gut hormones in appetite regulation (review). <i>Acta Physiologica Hungarica</i> , 2014, 101, 395-407.	0.9	35
678	Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. <i>Xenobiotica</i> , 2014, 44, 842-848.	1.1	4
679	Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH). <i>International Journal of Molecular Sciences</i> , 2014, 15, 7352-7379.	4.1	106
680	Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014, 306, R157-R163.	1.8	11
681	Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model. <i>Diabetes</i> , 2014, 63, 1224-1233.	0.6	345
682	Novel Formulations for Antimicrobial Peptides. <i>International Journal of Molecular Sciences</i> , 2014, 15, 18040-18083.	4.1	112
683	Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide. <i>Journal of Diabetes Research</i> , 2014, 2014, 1-7.	2.3	19
684	Glucagon-Like Peptide-1 Secreting Cell Function as well as Production of Inflammatory Reactive Oxygen Species Is Differently Regulated by Glycated Serum and High Levels of Glucose. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	13
685	Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	3.0	232
686	Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKA ^y Mice. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	40
687	Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC- β pathway and modulated by endogenous H ₂ S. <i>Frontiers in Physiology</i> , 2014, 5, 420.	2.8	86
688	Ileal Glucose Infusion Leads to Increased Insulin Sensitivity and Decreased Blood Glucose Levels in Wistar Rats. <i>Journal of Investigative Surgery</i> , 2014, 27, 332-337.	1.3	5
689	Glucagon-like peptide-1 stimulates type 3 iodothyronine deiodinase expression in a mouse insulinoma cell line. <i>Life Sciences</i> , 2014, 115, 22-28.	4.3	3
690	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. <i>BMJ Open</i> , 2014, 4, e004158.	1.9	20
691	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2014, 4, e004227.	1.9	15
692	Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy. <i>Endocrinology</i> , 2014, 155, 1175-1177.	2.8	3

#	ARTICLE	IF	CITATIONS
693	Glucagon-Like Peptide-1 Receptor Activation in the Nucleus Accumbens Core Suppresses Feeding by Increasing Glutamatergic AMPA/Kainate Signaling. <i>Journal of Neuroscience</i> , 2014, 34, 6985-6992.	3.6	91
694	Glutamate Acts as a Key Signal Linking Glucose Metabolism to Incretin/cAMP Action to Amplify Insulin Secretion. <i>Cell Reports</i> , 2014, 9, 661-673.	6.4	128
695	Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 880-886.	2.3	42
696	The incretin effect does not differ in trained and untrained, young, healthy men. <i>Acta Physiologica</i> , 2014, 210, 565-572.	3.8	11
697	Endogenous Glucagon-Like Peptide-1 Reduces Drinking Behavior and Is Differentially Engaged by Water and Food Intakes in Rats. <i>Journal of Neuroscience</i> , 2014, 34, 16417-16423.	3.6	35
698	The Expression of Glucagon-Like Peptide-1 Receptor and Dipeptidyl Peptidase-IV in Neuroendocrine Neoplasms of the Pancreas and Gastrointestinal Tract. <i>Endocrine Pathology</i> , 2014, 25, 390-396.	9.0	2
699	<sc>DPP</sc> 4 Inhibitors increase differentially the expression of surfactant proteins in Fischer 344 rats. <i>Acta Physiologica</i> , 2014, 212, 248-261.	3.8	9
700	Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 241-248.	1.2	18
701	Cardioprotection for percutaneous coronary intervention “ Reperfusion quality as well as quantity. <i>International Journal of Cardiology</i> , 2014, 177, 786-793.	1.7	14
702	GLP-1 improves neuropathology after murine cold lesion brain trauma. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 721-732.	3.7	20
703	At the Centennial of Michaelis and Menten, Competing Michaelis-Menten Steps Explain Effect of <sc>GLP-1</sc> on Blood-Brain Transfer and Metabolism of Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 162-171.	2.5	23
704	Incretins, amylin and other gut-brain axis hormones in children with coeliac disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 74-82.	3.4	14
705	The extra-pancreatic effects of <sc>GLP-1</sc> receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 673-688.	4.4	103
706	Impact of Acute Hyperglycemia on Myocardial Infarct Size, Area at Risk, and Salvage in Patients With STEMI and the Association With Exenatide Treatment: Results From a Randomized Study. <i>Diabetes</i> , 2014, 63, 2474-2485.	0.6	59
707	Cooperation between <sc>cAMP</sc> signalling and sulfonylurea in insulin secretion. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 118-125.	4.4	37
708	GLP-1 Receptor Stimulation of the Lateral Parabrachial Nucleus Reduces Food Intake: Neuroanatomical, Electrophysiological, and Behavioral Evidence. <i>Endocrinology</i> , 2014, 155, 4356-4367.	2.8	71
709	Corticotropin-Releasing Hormone and the Sympathoadrenal System Are Major Mediators in the Effects of Peripherally Administered Exendin-4 on the Hypothalamic-Pituitary-Adrenal Axis of Male Rats. <i>Endocrinology</i> , 2014, 155, 2511-2523.	2.8	21
710	Lixisenatide resensitizes the insulin secretory response to intravenous glucose challenge in people with type 2 diabetes—A study in both people with type 2 diabetes and healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 793-800.	4.4	23

#	ARTICLE	IF	CITATIONS
711	Glucagon-like peptide 1 potentiates insulin secretion and proliferation of pancreatic β cells. <i>Journal of Diabetes</i> , 2014, 6, 394-402.	1.8	25
712	Regulation of Glucose Homeostasis by GLP-1. <i>Progress in Molecular Biology and Translational Science</i> , 2014, 121, 23-65.	1.7	184
713	Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 659-670.	2.4	14
714	Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 61-72.	2.4	24
715	Circulating Glucagon-like Peptide-1 (GLP-1) Inhibits Eating in Male Rats by Acting in the Hindbrain and Without Inducing Avoidance. <i>Endocrinology</i> , 2014, 155, 1690-1699.	2.8	47
716	PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. <i>Laboratory Investigation</i> , 2014, 94, 63-78.	3.7	20
717	Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014, 307, R465-R470.	1.8	73
718	Gastric Bypass Increases Postprandial Insulin and GLP-1 in Nonobese Minipigs. <i>European Surgical Research</i> , 2014, 52, 41-49.	1.3	19
719	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. <i>European Journal of Endocrinology</i> , 2014, 170, 529-538.	3.7	116
720	GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery. <i>Diabetes</i> , 2014, 63, 3172-3174.	0.6	49
721	Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study. <i>Clinical Therapeutics</i> , 2014, 36, 101-114.	2.5	6
722	Gut hormones – Team workers or solo trippers?. <i>Regulatory Peptides</i> , 2014, 190-191, 39-40.	1.9	1
724	Systematic ileal transposition in Zucker rats shows advantage for long segment distal transposition. <i>Surgery</i> , 2014, 155, 165-172.	1.9	12
725	GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 447, 133-138.	2.1	15
726	Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – preclinical evidence. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 110-114.	2.3	39
727	Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. <i>Neuropharmacology</i> , 2014, 84, 31-45.	4.1	61
728	Intact neural system of the portal vein is important for maintaining normal glucose metabolism by regulating glucagon-like peptide-1 and insulin sensitivity. <i>Peptides</i> , 2014, 52, 38-43.	2.4	4
729	Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. <i>Acta Diabetologica</i> , 2014, 51, 147-150.	2.5	38

#	ARTICLE	IF	CITATIONS
730	The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes, Obesity and Metabolism, 2014, 16, 9-21.	4.4	113
731	Calcium co-ingestion augments postprandial glucose-dependent insulinotropic peptide1â€“42, glucagon-like peptide-1 and insulin concentrations in humans. European Journal of Nutrition, 2014, 53, 375-385.	3.9	30
732	Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by <sc>GLP</sc>â€“<sc>1R</sc> activation. British Journal of Pharmacology, 2014, 171, 1114-1128.	5.4	60
733	Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes. Diabetes Therapy, 2014, 5, 323-332.	2.5	4
734	Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovascular Diabetology, 2014, 13, 12.	6.8	22
735	Distal Gastrectomy in Pancreaticoduodenectomy is Associated with Accelerated Gastric Emptying, Enhanced Postprandial Release of GLP-1, and Improved Insulin Sensitivity. Journal of Gastrointestinal Surgery, 2014, 18, 52-59.	1.7	12
736	Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Molecular and Cellular Endocrinology, 2014, 382, 938-949.	3.2	131
737	A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors. Journal of Biomolecular Screening, 2014, 19, 847-858.	2.6	12
738	A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides, 2014, 54, 19-26.	2.4	97
739	Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Molecular Biology Reports, 2014, 41, 4313-4320.	2.3	12
740	Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. Psychopharmacology, 2014, 231, 3729-3744.	3.1	6
741	Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes. Advances in Therapy, 2014, 31, 247-263.	2.9	9
742	Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1166-1171.	6.4	24
743	Neuroendocrine Circuits Governing Energy Balance and Stress Regulation: Functional Overlap and Therapeutic Implications. Cell Metabolism, 2014, 19, 910-925.	16.2	87
744	Effects of GLP-1 in the Kidney. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 197-207.	5.7	72
745	Integrative Weight Management. , 2014, , .		2
746	Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 306, R490-R498.	1.8	24
747	Assessment of Insulin and Glucose Dynamics by Using an Oral Sugar Test in Horses. Journal of Equine Veterinary Science, 2014, 34, 465-470.	0.9	93

#	ARTICLE	IF	CITATIONS
748	Could capsaicinoids help to support weight management? A systematic review and meta-analysis of energy intake data. <i>Appetite</i> , 2014, 73, 183-188.	3.7	72
749	Involvement of cAMP/EPAC/TRPM2 Activation in Glucose- and Incretin-Induced Insulin Secretion. <i>Diabetes</i> , 2014, 63, 3394-3403.	0.6	55
750	Pharmacotherapy for Obesity. , 2014, , 261-277.		0
751	Acute Exercise and Hormones Related to Appetite Regulation: A Meta-Analysis. <i>Sports Medicine</i> , 2014, 44, 387-403.	6.5	155
752	Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes. <i>Proceedings of the Nutrition Society</i> , 2014, 73, 34-46.	1.0	132
753	Chronic Exendin-4 Treatment Prevents the Development of Cancer Cachexia Symptoms in Male Rats Bearing the Yoshida Sarcoma. <i>Hormones and Cancer</i> , 2014, 5, 33-41.	4.9	13
754	Industrial natural product chemistry for drug discovery and development. <i>Natural Product Reports</i> , 2014, 31, 35-60.	10.3	210
755	Glucagon-Like Peptide-1 Receptor Signaling in the Lateral Parabrachial Nucleus Contributes to the Control of Food Intake and Motivation to Feed. <i>Neuropsychopharmacology</i> , 2014, 39, 2233-2243.	5.4	103
756	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. <i>European Journal of Endocrinology</i> , 2014, 171, 407-419.	3.7	56
757	Add-On Treatment with Tenuliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 840-845.	4.4	25
758	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 1223-1251.	5.0	23
760	Lixisenatide, a novel <sc>GLP</sc>-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 588-601.	4.4	31
761	Novel Agents for the Treatment of Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2014, 27, 100-112.	1.0	56
762	Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials. <i>Advances in Therapy</i> , 2014, 31, 861-872.	2.9	15
763	Nutrition and Metabolic Support Recommendations for the Bariatric Patient. <i>Nutrition in Clinical Practice</i> , 2014, 29, 718-739.	2.4	57
764	Research Resource: Gene Profiling of G Protein-Coupled Receptors in the Arcuate Nucleus of the Female. <i>Molecular Endocrinology</i> , 2014, 28, 1362-1380.	3.7	21
765	for Its Potent and Specific Action on Stimulating TSH mRNA Expression and Secretion in the Pituitary. <i>Endocrinology</i> , 2014, 155, 4568-4580.	2.8	24
766	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). <i>Diabetes Care</i> , 2014, 37, 2149-2158.	8.6	236

#	ARTICLE	IF	CITATIONS
767	Glucagon-Like Peptide 1 Stimulates Insulin Secretion via Inhibiting RhoA/ROCK Signaling and Disassembling Glucotoxicity-Induced Stress Fibers. <i>Endocrinology</i> , 2014, 155, 4676-4685.	2.8	33
768	Incretins and Amylin: Neuroendocrine Communication Between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose. <i>Annual Review of Nutrition</i> , 2014, 34, 237-260.	10.1	73
769	GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E355-E362.	3.5	51
770	The Blood-Brain Barrier as a Regulator of the Gut-Brain Axis. <i>Frontiers of Hormone Research</i> , 2014, 42, 29-49.	1.0	11
772	Effects of PYY ₃₋₃₆ and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E1248-E1256.	3.5	114
773	Effects of Meal Size on the Release of GLP-1 and PYY After Roux-en-Y Gastric Bypass Surgery in Obese Subjects With or Without Type 2 Diabetes. <i>Obesity Surgery</i> , 2014, 24, 1969-1974.	2.1	22
774	Ability of GLP-1 to decrease food intake is dependent on nutritional status. <i>Physiology and Behavior</i> , 2014, 135, 222-229.	2.1	32
775	Insulin-like peptide 5 is an orexigenic gastrointestinal hormone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11133-11138.	7.1	120
776	Neuropeptides and the Microbiota-Gut-Brain Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 195-219.	1.6	321
777	Incretins: Their physiology and application in the treatment of diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 354-371.	4.0	84
778	The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β -Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 657-664.	2.5	53
779	<i>Lactobacillus paracasei</i> subsp <i>paracasei</i> L. casei W8 suppresses energy intake acutely. <i>Appetite</i> , 2014, 82, 111-118.	3.7	26
780	Treatment of the Obese Patient. , 2014, , .		3
781	Body weight loss, reduced urge for palatable food and increased release of GLP-1 through daily supplementation with green-plant membranes for three months in overweight women. <i>Appetite</i> , 2014, 81, 295-304.	3.7	55
782	Therapies for inter-relating diabetes and obesity â€“ GLP-1 and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2487-2500.	1.8	37
783	Different types of soluble fermentable dietary fibre decrease food intake, body weight gain and adiposity in young adult male rats. <i>Nutrition and Metabolism</i> , 2014, 11, 36.	3.0	84
784	Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes â€“ a retrospective cohort study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2014, 13, 89.	1.9	45
785	Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E627-E634.	3.5	8

#	ARTICLE	IF	CITATIONS
786	The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. <i>European Journal of Pharmacology</i> , 2014, 741, 254-263.	3.5	36
787	Whey Protein Delays Gastric Emptying and Suppresses Plasma Fatty Acids and Their Metabolites Compared to Casein, Gluten, and Fish Protein. <i>Journal of Proteome Research</i> , 2014, 13, 2396-2408.	3.7	66
788	Diabetes, incretin hormones and cardioprotection. <i>Heart</i> , 2014, 100, 1550-1561.	2.9	7
789	Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1342-1351.	3.4	27
790	Histological analysis of glucagon-like peptide-1 receptor expression in chicken pancreas. <i>Cell and Tissue Research</i> , 2014, 357, 55-61.	2.9	12
791	Glucagon-like peptide 1 and peptide YY are in separate storage organelles in enteroendocrine cells. <i>Cell and Tissue Research</i> , 2014, 357, 63-69.	2.9	55
792	Agile delivery of protein therapeutics to CNS. <i>Journal of Controlled Release</i> , 2014, 190, 637-663.	9.9	88
793	Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2014, , .	1.6	59
794	GLP-1R activation for the treatment of stroke: Updating and future perspectives. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2014, 15, 233-242.	5.7	21
795	Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2014, 15, 219-231.	5.7	10
796	Effects of GLP-1 on appetite and weight. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2014, 15, 181-187.	5.7	182
797	Laparoscopic Greater Curvature Plication in Morbidly Obese Women with Type 2 Diabetes: Effects on Glucose Homeostasis, Postprandial Triglyceridemia and Selected Gut Hormones. <i>Obesity Surgery</i> , 2014, 24, 718-726.	2.1	39
798	Extra-pancreatic effects of incretin-based therapies. <i>Endocrine</i> , 2014, 47, 360-371.	2.3	28
799	Physiological Functions of Peroxisome Proliferator-Activated Receptor β . <i>Physiological Reviews</i> , 2014, 94, 795-858.	28.8	133
800	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. <i>Journal of Endocrinology</i> , 2014, 221, T1-T16.	2.6	191
801	Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial. <i>Diabetes Care</i> , 2014, 37, 1797-1805.	8.6	94
802	Activation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity. <i>Journal of Neuroscience</i> , 2014, 34, 5322-5334.	3.6	98
803	Plasma Level of Glucagon-like Peptide 1 in Obese Egyptians with Normal and Impaired Glucose Tolerance. <i>Archives of Medical Research</i> , 2014, 45, 58-62.	3.3	22

#	ARTICLE	IF	CITATIONS
804	Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. <i>Journal of Physiology and Biochemistry</i> , 2014, 70, 667-674.	3.0	21
805	Intravenous GLP-1 (7-36) Amide for Prevention of Hyperglycemia During Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 618-625.	1.3	30
806	Evolution of receptors for peptides similar to glucagon. <i>General and Comparative Endocrinology</i> , 2014, 209, 50-60.	1.8	18
807	Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 800-811.	3.4	35
808	Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. <i>Physiology and Behavior</i> , 2014, 136, 135-144.	2.1	63
809	GLP-1 infusion reduces IGFBP-1 serum level in humans. <i>Growth Hormone and IGF Research</i> , 2014, 24, 67-70.	1.1	8
810	Liraglutide Enhances Insulin Sensitivity by Activating AMP-Activated Protein Kinase in Male Wistar Rats. <i>Endocrinology</i> , 2014, 155, 3288-3301.	2.8	39
811	An ultrasensitive method for the quantitation of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS. <i>Bioanalysis</i> , 2014, 6, 33-42.	1.5	30
812	Mechanism of the beneficial and protective effects of exenatide in diabetic rats. <i>Journal of Endocrinology</i> , 2014, 220, 291-304.	2.6	41
813	Diabetes, oxidative stress and therapeutic strategies. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 2709-2729.	2.4	375
814	Role of the neural pathway from hindbrain to hypothalamus in interaction of GLP1 and leptin in rats. <i>Journal of Endocrinology</i> , 2014, 220, 109-116.	2.6	5
815	Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1022-1030.	3.4	30
816	Surgical control of obesity and diabetes: The role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. <i>Obesity</i> , 2014, 22, 159-169.	3.0	40
817	Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity. <i>Internal Medicine</i> , 2014, 53, 1791-1795.	0.7	24
818	Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells. <i>Endocrinology and Metabolism</i> , 2014, 29, 567.	3.0	27
819	Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e100778.	2.5	218
820	Management of Type 2 diabetes with liraglutide. <i>Diabetes Management</i> , 2014, 4, 189-201.	0.5	1
821	Evaluation of Intragastric Vs Intraperitoneal Glucose Tolerance Tests in the Evaluation of Insulin Resistance in a Rodent Model of Burn Injury and Glucagon-Like Polypeptide-1 Treatment. <i>Journal of Burn Care and Research</i> , 2014, 35, e66-e72.	0.4	13

#	ARTICLE	IF	CITATIONS
822	The Incretin Response After Successful Islet Transplantation. Transplantation, 2014, 97, e9-e11.	1.0	5
823	Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats. British Journal of Nutrition, 2015, 113, 1477-1488.	2.3	33
824	Increased gut hormones and insulin sensitivity index following a 3-d intervention with a barley kernel-based product: a randomised cross-over study in healthy middle-aged subjects. British Journal of Nutrition, 2015, 114, 899-907.	2.3	81
825	Lipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiation. Journal of Nutritional Science, 2015, 4, e22.	1.9	34
826	Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. Diabetes/Metabolism Research and Reviews, 2015, 31, 610-618.	4.0	39
827	The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression. Scientific Reports, 2015, 4, 7410.	3.3	20
828	Sardine protein diet increases plasma glucagon-like peptide-1 levels and prevents tissue oxidative stress in rats fed a high-fructose diet. Molecular Medicine Reports, 2015, 12, 7017-26.	2.4	11
829	The aglycone of ginsenoside Rg3 enables glucagon-like peptide-1 secretion in enteroendocrine cells and alleviates hyperglycemia in type 2 diabetic mice. Scientific Reports, 2015, 5, 18325.	3.3	49
830	The Rationale for use of Incretins in the Management of new Onset Diabetes After Transplantation (NODAT). Endocrine Practice, 2015, 21, 814-822.	2.1	13
832	The incretin effect in critically ill patients: a caseâ€“control study. Critical Care, 2015, 19, 402.	5.8	22
833	Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 102.	6.8	20
834	Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovascular Diabetology, 2015, 14, 29.	6.8	17
835	A novel insulinotropic mechanism of whole grainâ€“derived Î³â€“oryzanol via the suppression of local dopamine D_2 receptor signalling in mouse islet. British Journal of Pharmacology, 2015, 172, 4519-4534.	5.4	15
836	Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging. Molecular Imaging, 2015, 14, 1-16.	1.4	22
837	Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. BJPsych Open, 2015, 1, 67-73.	0.7	12
838	Glucagon-like peptides 1 and 2. Current Opinion in Supportive and Palliative Care, 2015, 9, 196-202.	1.3	15
839	Relation of the rs6923761 Gene Variant in Glucagon-Like Peptide 1 Receptor with Weight, Cardiovascular Risk Factor, and Serum Adipokine Levels in Obese Female Subjects. Journal of Clinical Laboratory Analysis, 2015, 29, 100-105.	2.1	14
840	Effect of Breakfast Omission on Energy Intake and Evening Exercise Performance. Medicine and Science in Sports and Exercise, 2015, 47, 2645-2652.	0.4	47

#	ARTICLE	IF	CITATIONS
841	L-Glutamine and Whole Protein Restore First-Phase Insulin Response and Increase Glucagon-Like Peptide-1 in Type 2 Diabetes Patients. <i>Nutrients</i> , 2015, 7, 2101-2108.	4.1	17
842	Effects of iron overload and exenatide on erythrocyte deformability in a rat model. <i>Bratislava Medical Journal</i> , 2015, 116, 751-753.	0.8	0
843	Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs. <i>Cardiovascular Pharmacology: Open Access</i> , 2015, 04, .	0.1	1
844	GLP-1 based therapeutics: simultaneously combating T2DM and obesity. <i>Frontiers in Neuroscience</i> , 2015, 9, 92.	2.8	95
845	Dose-Dependent Effects of a Soluble Dietary Fibre (Pectin) on Food Intake, Adiposity, Gut Hypertrophy and Gut Satiety Hormone Secretion in Rats. <i>PLoS ONE</i> , 2015, 10, e0115438.	2.5	58
846	Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice. <i>PLoS ONE</i> , 2015, 10, e0126003.	2.5	55
847	Changes in Metabolic Hormones in Malaysian Young Adults following <i>Helicobacter pylori</i> Eradication. <i>PLoS ONE</i> , 2015, 10, e0135771.	2.5	9
848	Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes. <i>Journal of Menopausal Medicine</i> , 2015, 21, 93.	1.1	32
849	Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-17.	2.3	9
850	Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	1.2	16
851	Nutrient Induced Type 2 and Chemical Induced Type 1 Experimental Diabetes Differently Modulate Gastric GLP-1 Receptor Expression. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-10.	2.3	4
852	Peripheral Signals Mediate the Beneficial Effects of Gastric Surgery in Obesity. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-12.	1.5	13
853	Modulation of Hippocampal Neural Plasticity by Glucose-Related Signaling. <i>Neural Plasticity</i> , 2015, 2015, 1-10.	2.2	67
854	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A â€œMe Tooâ€ or â€œthe Special Oneâ€•Antidiabetic Class?. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-28.	2.3	65
855	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-9.	2.3	87
856	Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-11.	1.5	35
857	New pharmacological approaches to diabetes management. <i>Practice Nursing</i> , 2015, 26, 140-146.	0.1	1
858	Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. <i>World Journal of Diabetes</i> , 2015, 6, 807.	3.5	62

#	ARTICLE	IF	CITATIONS
859	Laparoscopic sleeve gastrectomy: More than a restrictive bariatric surgery procedure?. World Journal of Gastroenterology, 2015, 21, 11804.	3.3	165
860	Responses of GLP1-secreting L-cells to cytotoxicity resemble pancreatic β -cells but not δ -cells. Journal of Molecular Endocrinology, 2015, 54, 91-104.	2.5	12
861	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet, The, 2015, 385, 2057-2066.	13.7	180
862	Current Recommendations for Surgical Treatment of Diabetes. , 2015, , .		0
864	Unraveling the environmental and genetic interactions in Atherosclerosis: Central role of the gut microbiota. Atherosclerosis, 2015, 241, 387-399.	0.8	67
865	Taste perception, associated hormonal modulation, and nutrient intake. Nutrition Reviews, 2015, 73, 83-91.	5.8	101
866	β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians. Current Diabetes Reports, 2015, 15, 602.	4.2	231
867	GLP-1 and Exendin-4 Transiently Enhance GABAA Receptor-Mediated Synaptic and Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons. Diabetes, 2015, 64, 79-89.	0.6	79
868	Incretin-Based Drugs and Adverse Pancreatic Events: Almost a Decade Later and Uncertainty Remains. Diabetes Care, 2015, 38, 951-953.	8.6	25
869	Regulation of Appetite, Satiation, and Body Weight by Enteroendocrine Cells. Part 1: Characteristics of Enteroendocrine Cells and Their Capability of Weight Regulation. Hormone Research in Paediatrics, 2015, 83, 1-10.	1.8	29
870	Does Nutrient Sensing Determine How We "See" Food?. Current Diabetes Reports, 2015, 15, 604.	4.2	11
871	Liraglutide and obesity: a review of the data so far. Drug Design, Development and Therapy, 2015, 9, 1867.	4.3	87
872	The Impact of Food Bioactives on Health. , 2015, , .		208
873	GLP-1R expression in the major salivary glands of rats. Journal of Oral Biosciences, 2015, 57, 200-204.	2.2	2
874	Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocrine Connections, 2015, 4, 50-57.	1.9	65
875	Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity. Growth Hormone and IGF Research, 2015, 25, 298-303.	1.1	3
876	Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. Diabetes Research and Clinical Practice, 2015, 110, 291-300.	2.8	25
877	Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. Diabetes and Metabolism, 2015, 41, 6S28-6S35.	2.9	16

#	ARTICLE	IF	CITATIONS
878	The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition. American Journal of Physiology - Renal Physiology, 2015, 309, G431-G442.	3.4	9
879	Prevention of Myocardial Stunning During Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions, 2015, 8, 302-304.	2.9	7
880	Glucotoxicity inhibits <sc>cAMP</sc>-protein kinase <sc>A</sc>-potentiated glucose-stimulated insulin secretion in pancreatic <i>Î</i>-cells</i>. α-cAMP-EPKα-adrenergic</i> <i>Î</i>-cells</i>. α-adrenergic</i> <i>Î</i>-cells</i>.	1.8	38
881	Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 3-18.	3.2	41
882	Glucagon-Like Peptide 1 Interacts with Ghrelin and Leptin to Regulate Glucose Metabolism and Food Intake through Vagal Afferent Neuron Signaling. Journal of Nutrition, 2015, 145, 672-680.	2.9	82
883	GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Molecular Metabolism, 2015, 4, 3-14.	6.5	175
884	Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization. JACC: Cardiovascular Interventions, 2015, 8, 292-301.	2.9	44
885	Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. Journal of Diabetes and Its Complications, 2015, 29, 413-421.	2.3	53
886	Glucagon-like peptide-1 is specifically involved in sweet taste transmission. FASEB Journal, 2015, 29, 2268-2280.	0.5	75
887	Incretin and Islet Hormone Responses to Meals of Increasing Size in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 561-568.	3.6	29
888	Electrostatic Interaction on Loading of Therapeutic Peptide GLP-1 into Porous Silicon Nanoparticles. Langmuir, 2015, 31, 1722-1729.	3.5	32
889	Partial Blockade of Kv2.1 Channel Potentiates GLP-1's Insulinotropic Effects in Islets and Reduces Its Dose Required for Improving Glucose Tolerance in Type 2 Diabetic Male Mice. Endocrinology, 2015, 156, 114-123.	2.8	8
890	Anti-obesogenic effects of calcium prevent changes in the GLP-1 profile in adult rats primed by early weaning. Molecular Nutrition and Food Research, 2015, 59, 773-783.	3.3	8
891	Metabonomics and Gut Microbiota in Nutrition and Disease. Molecular and Integrative Toxicology, 2015, , .	0.5	5
892	Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety, 2015, 14, 207-218.	2.4	41
893	Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of Diabetes and Its Complications, 2015, 29, 445-450.	2.3	61
894	Functional Consequences of Glucagon-like Peptide-1 Receptor Cross-talk and Trafficking. Journal of Biological Chemistry, 2015, 290, 1233-1243.	3.4	63
895	Transformation of Oligomers of Lipidated Peptide Induced by Change in pH. Molecular Pharmaceutics, 2015, 12, 411-419.	4.6	50

#	ARTICLE	IF	CITATIONS
896	Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells. <i>Molecular and Cellular Endocrinology</i> , 2015, 406, 60-67.	3.2	5
897	Homeostasis, Inflammation, and Disease Susceptibility. <i>Cell</i> , 2015, 160, 816-827.	28.9	872
898	Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. <i>FASEB Journal</i> , 2015, 29, 2397-2411.	0.5	177
899	Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1206-1214.	2.4	18
900	Systemic arteriosclerosis and eating behavior in Japanese type 2 diabetic patients with visceral fat accumulation. <i>Cardiovascular Diabetology</i> , 2015, 14, 8.	6.8	17
901	Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. <i>Diabetologia</i> , 2015, 58, 920-928.	6.3	27
902	Feeding critically ill patients the right "whey": thinking outside of the box. A personal view. <i>Annals of Intensive Care</i> , 2015, 5, 51.	4.6	57
903	Incretin-based therapies for obesity treatment. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 967-981.	3.4	31
904	Enteric Nervous System: Structure, Relationships and Functions†. , 2015, , .		1
905	GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1538-1543.	2.4	23
906	Dietary vitamin D3 improves postprandial hyperglycemia in aged mice. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 165-171.	2.1	17
907	The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs. <i>International Journal of Cardiology</i> , 2015, 189, 188-193.	1.7	34
908	Should the pharmacological actions of dietary fatty acids in cardiometabolic disorders be classified based on biological or chemical function?. <i>Progress in Lipid Research</i> , 2015, 59, 172-200.	11.6	30
909	Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis. <i>Current Diabetes Reports</i> , 2015, 15, 63.	4.2	23
910	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2909-2917.	3.6	116
911	Liraglutide for Type 2 diabetes and obesity: a 2015 update. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 753-767.	1.5	62
912	GLP-1 Receptor Mediated Targeting of a Fluorescent Zn2+ Sensor to Beta Cell Surface for Imaging Insulin/Zn2+ Release. <i>Bioconjugate Chemistry</i> , 2015, 26, 1443-1450.	3.6	16
913	Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. <i>International Journal of Eating Disorders</i> , 2015, 48, 199-205.	4.0	40

#	ARTICLE	IF	CITATIONS
914	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer. Expert Opinion on Drug Safety, 2015, 14, 171-180.	2.4	24
915	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	3.3	13
916	Glucoregulatory Relevance of Small Intestinal Nutrient Sensing in Physiology, Bariatric Surgery, and Pharmacology. Cell Metabolism, 2015, 22, 367-380.	16.2	51
917	Hormone Response Pathways as Responders to Environmental Contaminants and Their Roles in Disease. , 2015, , 225-238.		3
918	Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E641-E649.	3.5	63
919	Glucose Metabolism in Critically Ill Patients. Journal of Intensive Care Medicine, 2015, 30, 201-208.	2.8	7
920	Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus. Clinical Therapeutics, 2015, 37, 1172-1177.	2.5	46
921	The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine. Peptides, 2015, 67, 20-28.	2.4	40
922	Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance. Journal of Physiology, 2015, 593, 2185-2198.	2.9	20
923	The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology, 2015, 14, 10.	6.8	51
924	Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve coronary haemodynamics during Exercise stress (LIONESS) crossover study. Cardiovascular Diabetology, 2015, 14, 27.	6.8	2
925	Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. Journal of Medicinal Chemistry, 2015, 58, 4080-4085.	6.4	38
926	Incretins. Handbook of Experimental Pharmacology, 2015, 233, 137-171.	1.8	45
927	Urinary 1H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. International Journal of Obesity, 2015, 39, 1118-1125.	3.4	54
928	Pharmacologic Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2015, 49, 700-714.	1.9	23
929	Calcium Ingestion Suppresses Appetite and Produces Acute Overcompensation of Energy Intake Independent of Protein in Healthy Adults. Journal of Nutrition, 2015, 145, 476-482.	2.9	18
930	Cardiometabolic Effects of a New Class of Antidiabetic Agents. Clinical Therapeutics, 2015, 37, 1178-1194.	2.5	39
931	NUTRALYS® pea protein: characterization of in vitro gastric digestion and in vivo gastrointestinal peptide responses relevant to satiety. Food and Nutrition Research, 2015, 59, 25622.	2.6	34

#	ARTICLE	IF	CITATIONS
932	Gut Microbiota and Metabolic Diseases: From Pathogenesis to Therapeutic Perspective. Molecular and Integrative Toxicology, 2015, , 199-234.	0.5	7
933	Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacologica Sinica, 2015, 36, 200-208.	6.1	21
939	Bile acids as metabolic regulators. Current Opinion in Gastroenterology, 2015, 31, 159-165.	2.3	226
940	Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 67-73.	2.0	13
941	Neomorphic effects of recurrent somatic mutations in <i>Yin Yang 1</i> in insulin-producing adenomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4062-4067.	7.1	59
942	<i>glucagon</i> is essential for alpha cell transdifferentiation and beta cell neogenesis. Development (Cambridge), 2015, 142, 1407-1417.	2.5	108
943	Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. Journal of Nutritional Biochemistry, 2015, 26, 571-584.	4.2	105
944	Glucagon – Early breakthroughs and recent discoveries. Peptides, 2015, 67, 74-81.	2.4	91
945	Gastrointestinal hormone research – with a Scandinavian annotation. Scandinavian Journal of Gastroenterology, 2015, 50, 668-679.	1.5	10
946	Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion, 2015, 31, 901-911.	1.9	11
947	Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease. Physiological Reviews, 2015, 95, 513-548.	28.8	340
948	Identification and characterization of sORF-encoded polypeptides. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 134-141.	5.2	68
949	Selecting probiotics with the abilities of enhancing GLP-1 to mitigate the progression of type 1 diabetes in vitro and in vivo. Journal of Functional Foods, 2015, 18, 473-486.	3.4	45
950	Improving healthspan via changes in gut microbiota and fermentation. Age, 2015, 37, 98.	3.0	33
951	Effect of placental restriction and neonatal exendin-4 treatment on postnatal growth, adult body composition, and in vivo glucose metabolism in the sheep. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E589-E600.	3.5	18
952	GLP-1 secretion is stimulated by 1,10-phenanthroline via colocalized T2R5 signal transduction in human enteroendocrine L cell. Biochemical and Biophysical Research Communications, 2015, 468, 306-311.	2.1	24
953	Ileal interposition surgery for treatment of type 2 diabetes mellitus-pros and cons. Journal of Diabetes and Metabolic Disorders, 2015, 14, 77.	1.9	1
954	Gut Hormones and Obesity. , 2015, , 1-28.		0

#	ARTICLE	IF	CITATIONS
955	Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Proteinâ€‘Coupled Bile Acid Receptors. <i>Endocrinology</i> , 2015, 156, 3961-3970.	2.8	253
956	Stretch-Triggered Drug Delivery from Wearable Elastomer Films Containing Therapeutic Depots. <i>ACS Nano</i> , 2015, 9, 9407-9415.	14.6	196
957	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 600-607.	4.7	50
958	Insulinâ€‘independent actions of glucagonâ€‘like peptideâ€‘1 in wethers. <i>Animal Science Journal</i> , 2015, 86, 385-391.	1.4	2
959	The nonâ€‘peptide <scp>GLP</scp>â€‘1 receptor agonist <scp>WB</scp>4â€‘24 blocks inflammatory nociception by stimulating <scp>Î²</scp>â€‘endorphin release from spinal microglia. <i>British Journal of Pharmacology</i> , 2015, 172, 64-79.	5.4	51
960	Time course and mechanisms of the antiâ€‘hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015, 32, 343-352.	2.3	61
961	Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity. <i>Journal of Endocrinology</i> , 2015, 227, 25-36.	2.6	10
962	Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. <i>BioDrugs</i> , 2015, 29, 215-239.	4.6	320
963	In vitro bioactive properties of intact and enzymatically hydrolysed whey protein: targeting the enteroinsular axis. <i>Food and Function</i> , 2015, 6, 972-980.	4.6	44
964	The double trouble of metabolic diseases: the diabetesâ€‘cancer link. <i>Molecular Biology of the Cell</i> , 2015, 26, 3129-3139.	2.1	20
965	New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide. <i>Analytical Biochemistry</i> , 2015, 491, 23-30.	2.4	10
966	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. <i>BMJ Open</i> , 2015, 5, e009579.	1.9	30
967	Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide â€‘ A pilot study. <i>Obesity Research and Clinical Practice</i> , 2015, 9, 301-304.	1.8	49
968	Spinally projecting preproglucagon axons preferentially innervate sympathetic preganglionic neurons. <i>Neuroscience</i> , 2015, 284, 872-887.	2.3	27
969	Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 394-399.	2.1	36
970	Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 900-905.	2.1	25
971	Molecular pathophysiology of hepatic glucose production. <i>Molecular Aspects of Medicine</i> , 2015, 46, 21-33.	6.4	212
972	Inability to match energy intake with energy expenditure at sustained near-maximal rates of energy expenditure in older men during a 14-d cycling expedition. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1398-1405.	4.7	21

#	ARTICLE	IF	CITATIONS
973	Dietary obacunone supplementation stimulates muscle hypertrophy, and suppresses hyperglycemia and obesity through the TGR5 and PPAR γ pathway. Biochemical and Biophysical Research Communications, 2015, 463, 846-852.	2.1	31
975	Cholecystokinin regulates satiation independently of the abdominal vagal nerve in a pig model of total subdiaphragmatic vagotomy. Physiology and Behavior, 2015, 139, 167-176.	2.1	29
976	Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Modern Pathology, 2015, 28, 391-402.	5.5	76
977	Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 308-315.	2.8	17
978	Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications. Journal of Medicinal Chemistry, 2015, 58, 1020-1037.	6.4	129
979	Acute Exercise and Gastric Emptying: A Meta-Analysis and Implications for Appetite Control. Sports Medicine, 2015, 45, 659-678.	6.5	95
980	Hippocampal GLP-1 Receptors Influence Food Intake, Meal Size, and Effort-Based Responding for Food through Volume Transmission. Neuropsychopharmacology, 2015, 40, 327-337.	5.4	124
981	Pharmacological Management of the Obese Patient. American Journal of Lifestyle Medicine, 2015, 9, 137-156.	1.9	0
982	Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings. Diabetology International, 2015, 6, 26-32.	1.4	3
983	GLP-1 Plays a Limited Role in Improved Glycemia Shortly After Roux-en-Y Gastric Bypass: A Comparison With Intensive Lifestyle Modification. Diabetes, 2015, 64, 434-446.	0.6	63
984	Serotonin controlling feeding and satiety. Behavioural Brain Research, 2015, 277, 14-31.	2.2	231
985	Nutritional Impact on Anabolic and Catabolic Signaling. , 2016, , 189-204.		1
986	Peptide Signaling in Taste Transduction. , 2016, , 299-317.		3
987	Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway <i>in vivo</i> and <i>in vitro</i> . Oncotarget, 2016, 7, 81077-81089.	1.8	25
988	Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?. Journal of Diabetes Research, 2016, 2016, 1-10.	2.3	16
989	Properties of Flavonoids Isolated from the Bark of <i>Eysenhardtia polystachya</i> and Their Effect on Oxidative Stress in Streptozotocin-Induced Diabetes Mellitus in Mice. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	4.0	18
990	The Improvement of Hyperglycemia after RYGB Surgery in Diabetic Rats Is Related to Elevated Hypothalamus GLP-1 Receptor Expression. International Journal of Endocrinology, 2016, 2016, 1-5.	1.5	2
991	Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature. Journal of Obesity, 2016, 2016, 1-27.	2.7	202

#	ARTICLE	IF	CITATIONS
992	Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World Journal of Gastroenterology, 2016, 22, 8698.	3.3	84
993	Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Frontiers in Immunology, 2016, 7, 154.	4.8	95
994	Role of n-3 Polyunsaturated Fatty Acids in Ameliorating the Obesity-Induced Metabolic Syndrome in Animal Models and Humans. International Journal of Molecular Sciences, 2016, 17, 1689.	4.1	85
995	Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders. Nutrients, 2016, 8, 173.	4.1	216
996	The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes. PLoS ONE, 2016, 11, e0150745.	2.5	30
997	Effects of Dietary Fibre (Pectin) and/or Increased Protein (Casein or Pea) on Satiety, Body Weight, Adiposity and Caecal Fermentation in High Fat Diet-Induced Obese Rats. PLoS ONE, 2016, 11, e0155871.	2.5	55
998	LPS-Enhanced Glucose-Stimulated Insulin Secretion Is Normalized by Resveratrol. PLoS ONE, 2016, 11, e0146840.	2.5	22
999	Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0156208.	2.5	84
1000	Exenatide Treatment Alone Improves β -Cell Function in a Canine Model of Pre-Diabetes. PLoS ONE, 2016, 11, e0158703.	2.5	3
1001	Structural Mapping and Functional Characterization of Zebrafish Class B G-Protein Coupled Receptor (GPCR) with Dual Ligand Selectivity towards GLP-1 and Glucagon. PLoS ONE, 2016, 11, e0167718.	2.5	9
1002	Glucagon-Like Peptide-1. , 2016, , 135-e17C-5.		0
1003	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmacogenomics and Personalized Medicine, 2016, 9, 17.	0.7	16
1004	Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World Journal of Diabetes, 2016, 7, 572.	3.5	51
1005	Role of bile acids in the regulation of the metabolic pathways. World Journal of Diabetes, 2016, 7, 260.	3.5	58
1006	Glucagon-like peptide-1 drives energy metabolism on the synaptic highway. FEBS Journal, 2016, 283, 4413-4423.	4.7	19
1007	Increased myocardial vulnerability to ischemia-reperfusion injury in the presence of left ventricular hypertrophy. Journal of Hypertension, 2016, 34, 513-523.	0.5	17
1008	The incretin hormone GLP-1 and mechanisms underlying its secretion. Journal of Diabetes, 2016, 8, 753-765.	1.8	72
1009	The Enteric Nervous System. Advances in Experimental Medicine and Biology, 2016, , .	1.6	210

#	ARTICLE	IF	CITATIONS
1010	The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond. <i>Obesity Reviews</i> , 2016, 17, 553-572.	6.5	33
1011	Preproglucagon neurons in the hindbrain have IL-6 receptor- β and show Ca^{2+} influx in response to IL-6. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 311, R115-R123.	1.8	21
1012	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. <i>Journal of Internal Medicine</i> , 2016, 279, 485-493.	6.0	58
1013	Integrated Neural and Endocrine Control of Gastrointestinal Function. <i>Advances in Experimental Medicine and Biology</i> , 2016, 891, 159-173.	1.6	65
1014	Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 224-235.	4.4	51
1015	Effect of nitrate supplementation on hepatic blood flow and glucose homeostasis: a double-blind, placebo-controlled, randomized control trial. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G356-G364.	3.4	19
1016	The Gomez equations and renal hemodynamic function in kidney disease research. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F967-F975.	2.7	35
1017	Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E744-E753.	3.5	31
1018	Obesity diabetes and the role of bile acids in metabolism. <i>Journal of Translational Internal Medicine</i> , 2016, 4, 73-80.	2.5	39
1019	Attenuation by incretins of thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. <i>Biomedical Reports</i> , 2016, 5, 771-775.	2.0	4
1020	GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H1214-H1224.	3.2	14
1021	The insulinotropic effect of exogenous glucagon-like peptide-1 is not affected by acute vagotomy in anaesthetized pigs. <i>Experimental Physiology</i> , 2016, 101, 895-912.	2.0	4
1022	The Effect of Pumpkin on GLP-1 and HOMA- β in Hypercholesterolemic Rats. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2016, 23, 19-25.	0.3	1
1023	Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. <i>Cardiovascular Diabetology</i> , 2016, 15, 99.	6.8	15
1024	Neuropeptides, Microbiota, and Behavior. <i>International Review of Neurobiology</i> , 2016, 131, 67-89.	2.0	41
1025	Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling. <i>Nutrition and Diabetes</i> , 2016, 6, e235-e235.	3.2	19
1026	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. <i>Cell Reports</i> , 2016, 17, 2845-2856.	6.4	22
1027	Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. <i>Nutrition and Metabolism</i> , 2016, 13, 92.	3.0	76

#	ARTICLE	IF	CITATIONS
1028	Effects of whole-grain rye porridge with added inulin and wheat gluten on appetite, gut fermentation and postprandial glucose metabolism: a randomised, cross-over, breakfast study. British Journal of Nutrition, 2016, 116, 2139-2149.	2.3	29
1029	The Stress Response of Critical Illness: Metabolic and Hormonal Aspects. , 2016, , .		6
1030	Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats. Appetite, 2016, 96, 254-259.	3.7	16
1031	Functionality and antidiabetic utility of β^2 - and L-cell containing pseudoislets. Experimental Cell Research, 2016, 344, 201-209.	2.6	10
1032	Sensory Neurons that Detect Stretch and Nutrients in the Digestive System. Cell, 2016, 166, 209-221.	28.9	420
1033	Critical review evaluating the pig as a model for human nutritional physiology. Nutrition Research Reviews, 2016, 29, 60-90.	4.1	204
1034	Cerebral cortex: a target and source of insulin?. Diabetologia, 2016, 59, 1609-1615.	6.3	48
1035	Positron Emission Tomography and Autoradiography of ^{18}F -Fluorodeoxyglucose Labeled Islets With or Without Warm Ischemic Stress in Portal Transplanted Rats. Transplantation Proceedings, 2016, 48, 229-233.	0.6	2
1036	Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 833-842.	5.0	18
1037	The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats. Pharmacology Biochemistry and Behavior, 2016, 142, 48-55.	2.9	11
1038	Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients. Diabetes and Metabolism, 2016, 42, 242-248.	2.9	24
1039	Enterohormones and the Response to Critical Illness. , 2016, , 153-168.		0
1040	Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers. Pharmacogenomics, 2016, 17, 795-804.	1.3	8
1041	Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opinion on Investigational Drugs, 2016, 25, 871-890.	4.1	78
1042	Glucosensing in the gastrointestinal tract: Impact on glucose metabolism. American Journal of Physiology - Renal Physiology, 2016, 310, G645-G658.	3.4	40
1043	GLP-1 and weight loss: unraveling the diverse neural circuitry. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R885-R895.	1.8	172
1044	The regulation of function, growth and survival of GLP-1-producing L-cells. Clinical Science, 2016, 130, 79-91.	4.3	31
1045	Glucagon-Like Peptide-1. JACC Basic To Translational Science, 2016, 1, 267-276.	4.1	25

#	ARTICLE	IF	CITATIONS
1046	Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens. <i>Journal of Neurochemistry</i> , 2016, 139, 576-585.	3.9	20
1047	Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugsâ€”A mechanistic revisit to understand their mode of action. <i>Pharmacological Research</i> , 2016, 113, 636-674.	7.1	53
1048	Drug therapies in type 2 diabetes: an era of personalised medicine. <i>Clinical Medicine</i> , 2016, 16, 441-447.	1.9	5
1049	Ultrasonography reveals in vivo dose-dependent inhibition of end systolic and diastolic volumes, heart rate and cardiac output by nesfatin-1 in zebrafish. <i>General and Comparative Endocrinology</i> , 2016, 234, 142-150.	1.8	20
1050	Albiglutide: a unique GLP-1 receptor agonist. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1557-1569.	3.1	16
1051	Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in Male Mice. <i>Endocrinology</i> , 2016, 157, 1071-1081.	2.8	24
1052	Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning. <i>Cardiovascular Research</i> , 2016, 112, 669-676.	3.8	81
1053	Stimuliâ€”responsive delivery of therapeutics for diabetes treatment. <i>Bioengineering and Translational Medicine</i> , 2016, 1, 323-337.	7.1	80
1054	Opposite Regulation of Ghrelin and Glucagon-like Peptide-1 by Metabolite G-Protein-Coupled Receptors. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 665-675.	7.1	39
1055	Insulin degludec + liraglutide: a complementary combination. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1171-1177.	3.1	1
1056	Antiâ€”atherogenic and antiâ€”inflammatory properties of glucagonâ€”like peptideâ€”1, glucoseâ€”dependent insulinotropic polypeptide, and dipeptidyl peptidaseâ€”4 inhibitors in experimental animals. <i>Journal of Diabetes Investigation</i> , 2016, 7, 80-86.	2.4	44
1057	Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors. , 2016, 167, 100-107.		47
1058	Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. <i>Frontiers in Neuroendocrinology</i> , 2016, 42, 76-92.	5.2	51
1059	Glucagonâ€”like peptideâ€”1 and vitamin D: antiâ€”inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 805-815.	4.0	21
1060	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 776-790.	4.0	105
1061	Incretinâ€”based drugs for type 2 diabetes: Focus on East Asian perspectives. <i>Journal of Diabetes Investigation</i> , 2016, 7, 102-109.	2.4	144
1062	Review of headâ€”toâ€”head comparisons of glucagonâ€”like peptideâ€”1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 317-332.	4.4	211
1063	Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52â€”week, openâ€”label, parallelâ€”group trial. <i>Journal of Diabetes Investigation</i> , 2016, 7, 76-84.	2.4	23

#	ARTICLE	IF	CITATIONS
1064	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Internal Medicine, 2016, 176, 1464.	5.1	87
1065	The Contributing Role of Bile Acids to Metabolic Improvements After Obesity and Metabolic Surgery. Obesity Surgery, 2016, 26, 2492-2502.	2.1	22
1066	Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs, 2016, 25, 1167-1179.	4.1	16
1067	GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2125-2132.	2.4	24
1068	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Annals of Pharmacotherapy, 2016, 50, 1041-1050.	1.9	12
1069	Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats. Biochemistry and Cell Biology, 2016, 94, 451-458.	2.0	3
1070	Exendin-4 decreases ghrelin levels through mTOR signaling. Molecular and Cellular Endocrinology, 2016, 437, 201-212.	3.2	14
1073	Peptide Hormones. , 2016, , 309-400.		0
1074	Microbial regulation of GLP-1 and L-cell biology. Molecular Metabolism, 2016, 5, 753-758.	6.5	95
1075	Safety of Biologics Therapy. , 2016, , .		14
1076	Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties. British Journal of Pharmacology, 2016, 173, 3443-3453.	5.4	26
1077	The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel. Journal of Physiology, 2016, 594, 2607-2628.	2.9	43
1078	Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest. Circulation, 2016, 134, 2115-2124.	1.6	42
1079	Gut Hormone Regulation and Secretion via FFA1 and FFA4. Handbook of Experimental Pharmacology, 2016, 236, 181-203.	1.8	26
1080	Discovery and Structure-Activity Relationship Study of 4-Phenoxythiazol-5-carboxamides as Highly Potent TGR5 Agonists. Chemical and Pharmaceutical Bulletin, 2016, 64, 326-339.	1.3	3
1081	Glucose and GTP-binding protein-coupled receptor cooperatively regulate transient receptor potential-channels to stimulate insulin secretion [Review]. Endocrine Journal, 2016, 63, 867-876.	1.6	12
1082	Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews, 2016, 68, 954-1013.	16.0	252
1083	GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight. Neuropharmacology, 2016, 110, 396-406.	4.1	60

#	ARTICLE	IF	CITATIONS
1084	Medicago sativa L., a functional food to relieve hypertension and metabolic disorders in a spontaneously hypertensive rat model. <i>Journal of Functional Foods</i> , 2016, 26, 470-484.	3.4	16
1085	Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators. <i>BioFactors</i> , 2016, 42, 600-611.	5.4	33
1086	Bariatric surgery and obesity: influence on the incretins. <i>International Journal of Obesity Supplements</i> , 2016, 6, S32-S36.	12.6	34
1088	Ischaemic conditioning and targeting reperfusion injury: a 30-year voyage of discovery. <i>Basic Research in Cardiology</i> , 2016, 111, 70.	5.9	257
1089	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. <i>Metabolomics</i> , 2016, 12, 1.	3.0	0
1090	CCK, gastrin and diabetes mellitus. <i>Biomarkers in Medicine</i> , 2016, 10, 1125-1127.	1.4	12
1091	An update on DPP-4 inhibitors in the management of type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 409-419.	2.4	52
1092	Synthetic small molecule GLP-1 secretagogues prepared by means of a three-component indole annulation strategy. <i>Scientific Reports</i> , 2016, 6, 28934.	3.3	18
1093	Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. <i>European Journal of Pharmacology</i> , 2016, 791, 735-740.	3.5	62
1094	The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 32714.	3.3	13
1095	Effect of 24-h severe energy restriction on appetite regulation and ad libitum energy intake in lean men and women. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 1545-1553.	4.7	19
1096	Dose-dependent effect of glucose on GLP-1 secretion involves sweet taste receptor in isolated perfused rat ileum [Rapid Communication]. <i>Endocrine Journal</i> , 2016, 63, 1141-1147.	1.6	8
1097	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. <i>BMJ</i> , The, 2016, 355, i5340.	6.0	13
1098	Gastrointestinal hormones and the gut connectome. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 9-14.	2.3	20
1100	GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2078-2097.	1.9	62
1101	The physiological role of the brain GLP-1 system in stress. <i>Cogent Biology</i> , 2016, 2, 1229086.	1.7	35
1102	Gut hormones and gastric bypass. <i>Cardiovascular Endocrinology</i> , 2016, 5, 69-74.	0.8	3
1103	Glucometabolic gut hormones: beyond the incretin effect. <i>Cardiovascular Endocrinology</i> , 2016, 5, 68-68.	0.8	0

#	ARTICLE	IF	CITATIONS
1104	Enteroendocrine cells: a review of their role in brain-gut communication. <i>Neurogastroenterology and Motility</i> , 2016, 28, 620-630.	3.0	241
1105	Dynamics of L cells along the crypt-villous axis in the chicken ileum. <i>Domestic Animal Endocrinology</i> , 2016, 56, 70-74.	1.6	3
1106	Blood-Brain Barrier Transport of Alzheimer's Amyloid β -Peptide. , 2016, , 251-270.		5
1107	Grapes and Gastrointestinal Health: Implications with Intestinal and Systemic Diseases. , 2016, , 119-138.		1
1108	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2076-2083.	3.6	24
1109	No effect of 24-h severe energy restriction on appetite regulation and ad libitum energy intake in overweight and obese males. <i>International Journal of Obesity</i> , 2016, 40, 1662-1670.	3.4	11
1110	Histoire des incrustines : Du chien brun au monstre de Gila. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 285-290.	0.1	1
1111	Grapes and Health. , 2016, , .		8
1112	Comparison of Plasma Active Glucagon-Like Peptide 1 Concentrations in Normal Horses and Those With Equine Metabolic Syndrome and in Horses Placed on a High-Grain Diet. <i>Journal of Equine Veterinary Science</i> , 2016, 40, 16-25.	0.9	20
1113	Intra-islet glucagon-like peptide 1. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1651-1658.	2.3	33
1114	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β -cell function in the GetGoal-M and GetGoal-S trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1385-1392.	2.3	15
1115	Total gastrectomy-induced reductions in food intake and weight are counteracted by rikkunshito by attenuating glucagon-like peptide-1 elevation in rats. <i>Surgery</i> , 2016, 159, 1342-1350.	1.9	8
1116	Genetic determinants of pig birth weight variability. <i>BMC Genetics</i> , 2016, 17, 15.	2.7	24
1117	Sex and estrogens alter the action of glucagon-like peptide-1 on reward. <i>Biology of Sex Differences</i> , 2016, 7, 6.	4.1	53
1118	The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. <i>BMC Research Notes</i> , 2016, 9, 60.	1.4	59
1119	A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. <i>Obesity</i> , 2016, 24, 1222-1225.	3.0	42
1120	Mechanisms for the cardiovascular effects of glucagon-like peptide-1. <i>Acta Physiologica</i> , 2016, 216, 277-313.	3.8	22
1121	Energy-Dense Formulae May Slow Gastric Emptying in the Critically Ill. <i>Journal of Parenteral and Enteral Nutrition</i> , 2016, 40, 1050-1056.	2.6	19

#	ARTICLE	IF	CITATIONS
1122	G protein-coupled receptors as targets for anti-diabetic therapeutics. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 161-172.	46.4	90
1123	The function of glucagon-like peptide-1 in the mouse peripheral taste system. <i>Journal of Oral Biosciences</i> , 2016, 58, 10-15.	2.2	3
1124	Functional neuroimaging in obesity and the potential for development of novel treatments. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 695-705.	11.4	36
1125	Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. <i>Journal of Psychopharmacology</i> , 2016, 30, 227-236.	4.0	37
1126	GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies. <i>Pancreatology</i> , 2016, 16, 2-7.	1.1	15
1127	Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. <i>Diabetologia</i> , 2016, 59, 453-461.	6.3	69
1128	Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. <i>Bioconjugate Chemistry</i> , 2016, 27, 54-58.	3.6	25
1129	Construction of a Fusion Peptide 5 α olGLP-HV and Analysis of its Therapeutic Effect on Type 2 Diabetes Mellitus and Thrombosis in Mice. <i>Applied Biochemistry and Biotechnology</i> , 2016, 179, 59-74.	2.9	12
1130	Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. <i>Diabetologia</i> , 2016, 59, 363-370.	6.3	37
1131	Novel insights into the effects of diabetes on gastric motility. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 581-593.	3.0	11
1132	G protein-coupled receptors as new therapeutic targets for type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 229-233.	6.3	56
1133	Oleic acid stimulates glucagon-like peptide-1 release from enteroendocrine cells by modulating cell respiration and glycolysis. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 8-17.	3.4	22
1134	Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β -Catenin. <i>Stem Cell Reports</i> , 2016, 6, 579-591.	4.8	93
1135	The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers. <i>Journal of Applied Physiology</i> , 2016, 120, 608-614.	2.5	9
1136	Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review. <i>Clinical Drug Investigation</i> , 2016, 36, 433-441.	2.2	16
1137	Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 116-118.	1.5	18
1139	Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells. <i>Journal of Molecular Endocrinology</i> , 2016, 56, 201-211.	2.5	76
1140	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. <i>BMJ</i> , 2016, 352, i581.	6.0	78

#	ARTICLE	IF	CITATIONS
1141	GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. <i>Diabetologia</i> , 2016, 59, 954-965.	6.3	176
1142	Effect of Bariatric Surgery on Incretin Function. , 2016, , 125-139.		1
1143	GLP-1 based therapies: clinical implications for gastroenterologists. <i>Gut</i> , 2016, 65, 702-711.	12.1	34
1144	Gut Hormones and Obesity. , 2016, , 423-445.		0
1145	The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. <i>Brain Research</i> , 2016, 1634, 158-170.	2.2	67
1146	Abundance and turnover of GLP-1 producing L-cells in ileal mucosa are not different in patients with and without type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 84-91.	3.4	12
1147	Activation of Short and Long Chain Fatty Acid Sensing Machinery in the Ileum Lowers Glucose Production in Vivo. <i>Journal of Biological Chemistry</i> , 2016, 291, 8816-8824.	3.4	37
1148	Novel Therapeutic Approaches in Diabetes. <i>Endocrine Development</i> , 2016, 31, 43-56.	1.3	15
1149	Liraglutide for treating type 1 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 579-590.	3.1	15
1150	Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 766-780.	11.4	74
1151	Oral delivery of diabetes peptides â€” Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 196-222.	13.7	56
1152	Insulin-like peptide 5 is a microbially regulated peptide that promotes hepatic glucose production. <i>Molecular Metabolism</i> , 2016, 5, 263-270.	6.5	48
1153	The effects of short-chain fatty acids on the cardiovascular system. <i>PharmaNutrition</i> , 2016, 4, 68-111.	1.7	51
1154	Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic Î²-cells during type 2 diabetes. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2016, 26, 87-95.	0.7	6
1155	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G43-G51.	3.4	45
1156	GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. <i>Psychoneuroendocrinology</i> , 2016, 65, 54-66.	2.7	100
1157	Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine. <i>Neuropsychopharmacology</i> , 2016, 41, 1917-1928.	5.4	97
1158	Effects of exercise intensity on plasma concentrations of appetite-regulating hormones: Potential mechanisms. <i>Appetite</i> , 2016, 98, 80-88.	3.7	132

#	ARTICLE	IF	CITATIONS
1159	Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2122-2129.	3.6	37
1160	GLP-1 and Amylin in the Treatment of Obesity. <i>Current Diabetes Reports</i> , 2016, 16, 1.	4.2	56
1161	Altered Appetite-Mediating Hormone Concentrations Precede Compensatory Overeating After Severe, Short-Term Energy Deprivation in Healthy Adults. <i>Journal of Nutrition</i> , 2016, 146, 209-217.	2.9	27
1162	Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 737-755.	5.4	156
1163	Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. <i>Physiology and Behavior</i> , 2016, 153, 109-114.	2.1	25
1164	Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 241-265.	3.1	25
1165	An overview of new GLP-1 receptor agonists for type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 145-158.	4.1	41
1167	The Aversive Agent Lithium Chloride Suppresses Phasic Dopamine Release Through Central GLP-1 Receptors. <i>Neuropsychopharmacology</i> , 2016, 41, 906-915.	5.4	30
1168	MANAGEMENT OF ENDOCRINE DISEASE: Metabolic effects of bariatric surgery. <i>European Journal of Endocrinology</i> , 2016, 174, R19-R28.	3.7	27
1169	Bariatric surgery: beta cells in type 2 diabetes remission. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 122-131.	4.0	5
1170	Intestinal GLP-1 and satiation: from man to rodents and back. <i>International Journal of Obesity</i> , 2016, 40, 198-205.	3.4	54
1171	The Effect of Transplacental Administration of Glucagon-Like Peptide-1 on Fetal Lung Development in the Rabbit Model of Congenital Diaphragmatic Hernia. <i>Fetal Diagnosis and Therapy</i> , 2016, 39, 125-133.	1.4	6
1172	Clinical use of GLP-1 agonists and DPP4 inhibitors. <i>Pancreatology</i> , 2016, 16, 8-9.	1.1	7
1173	Biochemical consequences of bariatric surgery for extreme clinical obesity. <i>Annals of Clinical Biochemistry</i> , 2016, 53, 21-31.	1.6	14
1174	Effect of breakfast omission on subjective appetite, metabolism, acylated ghrelin and GLP-17-36 during rest and exercise. <i>Nutrition</i> , 2016, 32, 179-185.	2.4	26
1175	High fat diet impairs the function of glucagon-like peptide-1 producing L-cells. <i>Peptides</i> , 2016, 77, 21-27.	2.4	104
1176	Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β^2 cell Imaging. <i>Molecular Imaging and Biology</i> , 2016, 18, 90-98.	2.6	14
1177	Regulation of body fat mass by the gut microbiota: Possible mediation by the brain. <i>Peptides</i> , 2016, 77, 54-59.	2.4	20

#	ARTICLE	IF	CITATIONS
1178	Hippocampus Contributions to Food Intake Control: Mnemonic, Neuroanatomical, and Endocrine Mechanisms. <i>Biological Psychiatry</i> , 2017, 81, 748-756.	1.3	181
1179	The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. <i>Molecular Neurobiology</i> , 2017, 54, 4432-4451.	4.0	191
1180	Post-prandial anorexigenic gut peptide, appetite and glucometabolic responses at different eating rates in obese patients undergoing laparoscopic sleeve gastrectomy. <i>Endocrine</i> , 2017, 55, 113-123.	2.3	12
1181	Ascending mechanisms of stress integration: Implications for brainstem regulation of neuroendocrine and behavioral stress responses. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 366-375.	6.1	103
1182	Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats. <i>Neuroscience Letters</i> , 2017, 641, 1-7.	2.1	23
1183	GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. <i>Clinical Science</i> , 2017, 131, 343-353.	4.3	32
1184	A nutritional perspective on UCP1-dependent thermogenesis. <i>Biochimie</i> , 2017, 134, 99-117.	2.6	53
1185	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. <i>Diabetes Research and Clinical Practice</i> , 2017, 124, 1-10.	2.8	15
1186	Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. <i>Diabetes and Metabolism</i> , 2017, 43, 110-124.	2.9	9
1187	Spatiotemporal Modeling of Triggering and Amplifying Pathways in GLP-1 Secreting Intestinal L Cells. <i>Biophysical Journal</i> , 2017, 112, 162-171.	0.5	9
1188	Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. <i>Gut</i> , 2017, 66, 180-190.	12.1	342
1189	Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance. <i>Physiology and Behavior</i> , 2017, 173, 9-14.	2.1	10
1190	Qing-Hua Granule induces GLP-1 secretion via bitter taste receptor in db/db mice. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 10-17.	5.6	10
1191	Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 116-123.	2.1	22
1192	Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. <i>Clinical Biochemistry</i> , 2017, 50, 746-749.	1.9	26
1193	The New Biology and Pharmacology of Glucagon. <i>Physiological Reviews</i> , 2017, 97, 721-766.	28.8	264
1194	Islet amyloid polypeptide: Another key molecule in Alzheimer's pathogenesis?. <i>Progress in Neurobiology</i> , 2017, 153, 100-120.	5.7	64
1195	Resistant starch lowers postprandial glucose and leptin in overweight adults consuming a moderate-to-high-fat diet: a randomized-controlled trial. <i>Nutrition Journal</i> , 2017, 16, 14.	3.4	55

#	ARTICLE	IF	CITATIONS
1196	Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity. International Journal of Cardiology, 2017, 232, 40-47.	1.7	36
1197	Peptide hormones and lipopeptides: from self-assembly to therapeutic applications. Journal of Peptide Science, 2017, 23, 82-94.	1.4	76
1198	Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC- δ -dependent neurocircuitry. Cell Death and Disease, 2017, 8, e2609-e2609.	6.3	29
1199	Signalling in the gut endocrine axis. Physiology and Behavior, 2017, 176, 183-188.	2.1	49
1200	Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis. Journal of Immunology, 2017, 198, 3089-3098.	0.8	17
1201	No cognitive-enhancing effect of <scp>GLP</scp>-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 52-62.	4.5	36
1202	Regulation of GIP and Ghrelin in Healthy Subjects Fed on Sun-Dried Raisins: A Pilot Study with a Crossover Trial Design. Journal of Medicinal Food, 2017, 20, 301-308.	1.5	11
1203	The Importance of the Gastrointestinal Tract in Controlling Food Intake and Regulating Energy Balance. Gastroenterology, 2017, 152, 1707-1717.e2.	1.3	77
1204	Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis, 2017, 261, 44-51.	0.8	75
1205	Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors. Journal of Cardiovascular Pharmacology, 2017, 70, 74-86.	1.9	15
1206	Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice. Acta Diabetologica, 2017, 54, 685-693.	2.5	1
1207	Combination therapy with <scp>GLP</scp>-1 receptor agonist and <scp>SGLT2</scp> inhibitor. Diabetes, Obesity and Metabolism, 2017, 19, 1353-1362.	4.4	120
1208	Systematic Synergy of Glucose and GLP-1 to Stimulate Insulin Secretion Revealed by Quantitative Phosphoproteomics. Scientific Reports, 2017, 7, 1018.	3.3	6
1209	Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. The Cochrane Library, 2017, 5, CD012204.	2.8	31
1210	A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metabolism, 2017, 25, 1075-1090.e5.	16.2	179
1211	Molecular docking analysis and antidiabetic activity of Rifabutin against STZ-NA induced diabetes in albino wistar rats. Beni-Suef University Journal of Basic and Applied Sciences, 2017, 6, 269-284.	2.0	7
1212	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	3.5	13
1213	Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. Journal of Cardiology, 2017, 69, 511-517.	1.9	8

#	ARTICLE	IF	CITATIONS
1214	Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Diabetes Therapy</i> , 2017, 8, 727-738.	2.5	55
1215	Central administration of GLP-1 and GIP decreases feeding in mice. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 247-252.	2.1	73
1216	The modulatory roles of oxyntomodulin and glucagon-like peptide 1 administered spinally in the regulation of the blood glucose level. <i>Neurochemical Journal</i> , 2017, 11, 57-62.	0.5	0
1217	Role of Glucagon-Like Peptide-1 and Gastric Inhibitory Peptide in Anorexia Induction Following Oral Exposure to the Trichothecene Mycotoxin Deoxynivalenol (Vomitoxin). <i>Toxicological Sciences</i> , 2017, 159, 16-24.	3.1	16
1218	Ghrelin suppresses cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) in the intestine, and attenuates the anorectic effects of CCK, PYY and GLP-1 in goldfish (<i>Carassius auratus</i>). <i>Hormones and Behavior</i> , 2017, 93, 62-71.	2.1	28
1219	The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. <i>Diabetologia</i> , 2017, 60, 1731-1739.	6.3	66
1220	Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. <i>Neuropeptides</i> , 2017, 65, 77-82.	2.2	20
1221	Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2558-2564.	1.8	21
1222	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	11.0	135
1223	The Gut: A Key to the Pathogenesis of Type 2 Diabetes?. <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 259-262.	1.3	10
1224	Development of a UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon and dosed GLP-1 from human plasma. <i>Bioanalysis</i> , 2017, 9, 733-751.	1.5	11
1225	Pancreas and Not Gut Mediates the GLP-1-Induced Glucoincretin Effect. <i>Cell Metabolism</i> , 2017, 25, 757-758.	16.2	11
1226	CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin. <i>Pharmacological Reports</i> , 2017, 69, 822-829.	3.3	10
1227	Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 290-297.	2.5	8
1228	Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?. <i>Endocrine Practice</i> , 2017, 23, 89-99.	2.1	10
1229	Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G367-G373.	3.4	42
1230	Increase in cortisol/ACTH ratio after chronic treatment with liraglutide in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 398-399.	2.9	4
1231	Remote Sensing Between Liver and Intestine: Importance of Microbial Metabolites. <i>Current Pharmacology Reports</i> , 2017, 3, 101-113.	3.0	49

#	ARTICLE	IF	CITATIONS
1232	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 31-41.	4.0	101
1233	Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1214-1222.	4.4	14
1234	Coordinated activation of mitochondrial respiration and exocytosis mediated by PKC signaling in pancreatic β^2 cells. <i>FASEB Journal</i> , 2017, 31, 1028-1045.	0.5	17
1235	Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy. <i>Molecular Pharmaceutics</i> , 2017, 14, 193-205.	4.6	24
1236	Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. <i>Diabetes Care</i> , 2017, 40, 301-308.	8.6	15
1237	Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. <i>Physiological Reviews</i> , 2017, 97, 411-463.	28.8	414
1238	Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice. <i>Physiology and Behavior</i> , 2017, 171, 158-164.	2.1	10
1239	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. <i>Clinical Pharmacokinetics</i> , 2017, 56, 719-731.	3.5	18
1240	Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 273-279.	1.9	2
1241	What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus. <i>Journal of Diabetes</i> , 2017, 9, 562-574.	1.8	2
1242	Cardioprotection by remote ischemic conditioning and its signal transduction. <i>Pflügers Archiv European Journal of Physiology</i> , 2017, 469, 159-181.	2.8	151
1243	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 734-738.	4.4	16
1244	Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies. <i>Journal of Psychopharmacology</i> , 2017, 31, 1460-1474.	4.0	61
1245	Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?. <i>Current Diabetes Reports</i> , 2017, 17, 128.	4.2	18
1246	Effect of meal size and texture on gastric pouch emptying and glucagon-like peptide 1 after gastric bypass surgery. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 1975-1983.	1.2	33
1247	Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. <i>Hormone and Metabolic Research</i> , 2017, 49, 886-891.	1.5	113
1248	Acute effects of glucagon-like peptide-1, GLP-1 ₉₋₃₆ amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers. <i>Physiological Reports</i> , 2017, 5, e13102.	1.7	12
1249	Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. <i>Cell Reports</i> , 2017, 21, 1160-1168.	6.4	139

#	ARTICLE	IF	CITATIONS
1250	Role of Incretin Hormones in Bowel Diseases. <i>Endocrine Development</i> , 2017, 32, 49-73.	1.3	9
1251	L-phenylalanine modulates gut hormone release and glucose tolerance, and suppresses food intake through the calcium-sensing receptor in rodents. <i>International Journal of Obesity</i> , 2017, 41, 1693-1701.	3.4	92
1252	Fenugreek Compound (N55) Lowers Plasma Glucose through the Enhancement of Response of Physiological Glucagon-like peptide-1. <i>Scientific Reports</i> , 2017, 7, 12265.	3.3	3
1253	Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus. <i>Neuron</i> , 2017, 96, 897-909.e5.	8.1	133
1254	Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents. <i>Scientific Reports</i> , 2017, 7, 13523.	3.3	16
1255	GUB06046, a novel secretin/glucagon-like peptide 1 coagonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice. <i>Journal of Peptide Science</i> , 2017, 23, 845-854.	1.4	22
1256	GLP-1 increases Kiss-1 mRNA expression in kisspeptin-expressing neuronal cells. <i>Biology of Reproduction</i> , 2017, 97, 240-248.	2.7	18
1257	Recombinant <i>Lactococcus lactis</i> expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 7177-7186.	3.6	17
1258	Beta-glucans and cancer: The influence of inflammation and gut peptide. <i>European Journal of Medicinal Chemistry</i> , 2017, 142, 486-492.	5.5	42
1259	Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Increase Bifidobacterium but Reduce Butyrate Producing Bacteria with Adverse Glycemic Metabolism in healthy young population. <i>Scientific Reports</i> , 2017, 7, 11789.	3.3	181
1260	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017, 180, 68-75.	3.2	34
1261	Glucagon-like peptide (GLP)-1 analogues for normoglycaemic, overweight or obese adults. <i>The Cochrane Library</i> , 2017, , .	2.8	0
1262	Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. <i>Scientific Reports</i> , 2017, 7, 7964.	3.3	10
1263	Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic <i>db/db</i> mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 540-548.	2.0	14
1264	CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017, 52, S37-S43.	2.0	43
1265	Bile acid receptors link nutrient sensing to metabolic regulation. <i>Liver Research</i> , 2017, 1, 17-25.	1.4	9
1266	Serotonergic modulation of the activity of GLP-1 producing neurons in the nucleus of the solitary tract in mouse. <i>Molecular Metabolism</i> , 2017, 6, 909-921.	6.5	22
1267	Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survival. <i>Peptides</i> , 2017, 95, 68-75.	2.4	21

#	ARTICLE	IF	CITATIONS
1268	Acute effects of exercise on appetite, ad libitum energy intake and appetite-regulatory hormones in lean and overweight/obese men and women. <i>International Journal of Obesity</i> , 2017, 41, 1737-1744.	3.4	70
1269	Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1113-1131.	5.0	4
1270	Optogenetic Analysis of Depolarization-Dependent Glucagonlike Peptide-1 Release. <i>Endocrinology</i> , 2017, 158, 3426-3434.	2.8	2
1271	Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. <i>Diabetologia</i> , 2017, 60, 2285-2298.	6.3	67
1272	Hydrogen Sulfide and Sulfate Prebiotic Stimulates the Secretion of GLP-1 and Improves Glycemia in Male Mice. <i>Endocrinology</i> , 2017, 158, 3416-3425.	2.8	72
1273	The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. <i>Obesity Science and Practice</i> , 2017, 3, 434-445.	1.9	27
1274	Addition of Rye Bran and Pea Fiber to Pork Meatballs Enhances Subjective Satiety in Healthy Men, but Does Not Change Glycemic or Hormonal Responses: A Randomized Crossover Meal Test Study. <i>Journal of Nutrition</i> , 2017, 147, jn250332.	2.9	7
1276	GLP-1 response to sequential mixed meals: influence of insulin resistance. <i>Clinical Science</i> , 2017, 131, 2901-2910.	4.3	9
1277	Acute activation of GLP-1-expressing neurons promotes glucose homeostasis and insulin sensitivity. <i>Molecular Metabolism</i> , 2017, 6, 1350-1359.	6.5	32
1278	Glucagon-like peptide-1 is co-localized with neurotensin in the chicken ileum. <i>Cell and Tissue Research</i> , 2017, 368, 277-286.	2.9	12
1279	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. <i>Advances in Therapy</i> , 2017, 34, 1791-1814.	2.9	21
1280	Potential involvement of lactate and interleukin-6 in the appetite-regulatory hormonal response to an acute exercise bout. <i>Journal of Applied Physiology</i> , 2017, 123, 614-623.	2.5	60
1281	The safety of albiglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1089-1097.	2.4	4
1282	Intestinal lymphatic vasculature: structure, mechanisms and functions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 510-526.	17.8	163
1283	One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	87
1284	Remote ischemic preconditioning differentially attenuates post-ischemic cardiac arrhythmia in streptozotocin-induced diabetic versus nondiabetic rats. <i>Cardiovascular Diabetology</i> , 2017, 16, 57.	6.8	20
1285	Bioactivities of hemorphins released from bovine haemoglobin gastrointestinal digestion: Dual effects on intestinal hormones and DPP-IV regulations. <i>Journal of Functional Foods</i> , 2017, 36, 9-17.	3.4	10
1286	The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. <i>Scientific Reports</i> , 2017, 7, 4351.	3.3	26

#	ARTICLE	IF	CITATIONS
1287	Effects of Aerobic, Strength or Combined Exercise on Perceived Appetite and Appetite-Related Hormones in Inactive Middle-Aged Men. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2017, 27, 389-398.	2.1	24
1288	Plasticity of gastrointestinal vagal afferent satiety signals. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12973.	3.0	26
1289	Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice. <i>Canadian Journal of Physiology and Pharmacology</i> , 2017, 95, 129-139.	1.4	14
1290	Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1237-1242.	2.3	62
1291	Effects of acute dietary weight loss on postprandial plasma bile acid responses in obese insulin resistant subjects. <i>Clinical Nutrition</i> , 2017, 36, 1615-1620.	5.0	14
1292	The Na ⁺ -D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. , 2017, 170, 148-165.		96
1293	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the <sc>GetGoal</sc> programme. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 248-256.	4.4	6
1294	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 88-103.	7.1	88
1295	Endogenous Glucagon-like Peptide-1 Receptor Signaling in the Nucleus Tractus Solitarius is Required for Food Intake Control. <i>Neuropsychopharmacology</i> , 2017, 42, 1471-1479.	5.4	62
1296	Effect of Laparoscopic Sleeve Gastrectomy on Fasting Gastrointestinal, Pancreatic, and Adipose-Derived Hormones and on Non-Esterified Fatty Acids. <i>Obesity Surgery</i> , 2017, 27, 399-407.	2.1	31
1297	GLP-1 nanomedicine alleviates gut inflammation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 659-665.	3.3	45
1298	Effect of <sc>GLP</sc>-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: <sc>a</sc> randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 162-171.	4.4	53
1299	Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 345-351.	1.2	31
1300	Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. <i>Obesity Reviews</i> , 2017, 18, 86-98.	6.5	56
1301	Clinical relevance of the bile acid receptor TGR5 in metabolism. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 224-233.	11.4	105
1302	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. <i>Cardiovascular Endocrinology</i> , 2018, 7, 18-23.	0.8	7
1304	Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial. <i>Endocrine Journal</i> , 2017, 64, 923-931.	1.6	33
1305	Comparison of the response using ICR mice derived from three different sources to multiple low-dose streptozotocin-induced diabetes mellitus. <i>Laboratory Animal Research</i> , 2017, 33, 150.	2.5	0

#	ARTICLE	IF	CITATIONS
1306	Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food Ingredients. <i>Frontiers in Pharmacology</i> , 2017, 8, 387.	3.5	85
1307	Potential mechanisms linking probiotics to diabetes: a narrative review of the literature. <i>Sao Paulo Medical Journal</i> , 2017, 135, 169-178.	0.9	42
1308	Orange Pomace Improves Postprandial Glycemic Responses: An Acute, Randomized, Placebo-Controlled, Double-Blind, Crossover Trial in Overweight Men. <i>Nutrients</i> , 2017, 9, 130.	4.1	17
1309	The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling. <i>Molecules</i> , 2017, 22, 903.	3.8	83
1310	Polyphenols and Intestinal Health. , 2017, , 191-210.		34
1311	Gut microbiota–derived short-chain fatty acids and kidney diseases. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3531-3542.	4.3	108
1312	Incretins amplify TNF- α -stimulated IL-6 synthesis in osteoblasts: Suppression of the $\text{I}\kappa\text{B}/\text{NF-}\kappa\text{B}$ pathway. <i>International Journal of Molecular Medicine</i> , 2017, 39, 1053-1060.	4.0	10
1313	Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor. <i>Molecules</i> , 2017, 22, 22.	3.8	13
1314	The Effect of <i>Lupinus albus</i> on Growth Performance, Body Composition and Satiety Hormones of Male Pigs Immunized against Gonadotrophin Releasing Factor. <i>Animals</i> , 2017, 7, 15.	2.3	4
1315	Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides. <i>Frontiers in Endocrinology</i> , 2017, 8, 18.	3.5	19
1316	Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice. <i>Frontiers in Endocrinology</i> , 2017, 8, 135.	3.5	16
1317	Visceral Inflammation and Immune Activation Stress the Brain. <i>Frontiers in Immunology</i> , 2017, 8, 1613.	4.8	50
1318	The Impact of Microbiota-Gut-Brain Axis on Diabetic Cognition Impairment. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 106.	3.4	39
1319	Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. <i>Frontiers in Neuroscience</i> , 2017, 11, 617.	2.8	196
1320	Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-13.	2.3	21
1321	Bioactivity of a modified human Glucagon-like peptide-1. <i>PLoS ONE</i> , 2017, 12, e0171601.	2.5	4
1322	Modified human glucagon-like peptide-1 (GLP-1) produced in <i>E. coli</i> has a long-acting therapeutic effect in type 2 diabetic mice. <i>PLoS ONE</i> , 2017, 12, e0181939.	2.5	5
1323	Metabolic regulation of GLP-1 and PC1/3 in pancreatic β -cell line. <i>PLoS ONE</i> , 2017, 12, e0187836.	2.5	31

#	ARTICLE	IF	CITATIONS
1324	The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance. BMC Endocrine Disorders, 2017, 17, 60.	2.2	7
1325	Elevated circulating fasting glucagon-like peptide-1 in surgical patients with aortic valve disease and diabetes. Diabetology and Metabolic Syndrome, 2017, 9, 79.	2.7	7
1326	Liraglutide modulates GABAergic signaling in rat hippocampal CA3 pyramidal neurons predominantly by presynaptic mechanism. BMC Pharmacology & Toxicology, 2017, 18, 83.	2.4	13
1327	Bariatric Surgery: A Perspective for Primary Care. Diabetes Spectrum, 2017, 30, 265-276.	1.0	13
1328	GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity. , 2017, , 481-490.		1
1329	Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Annals of Pediatric Endocrinology and Metabolism, 2017, 22, 15.	2.3	38
1330	Differences in leptin, ghrelin, and glucagon-like peptide-1 levels between religious fasting and normal fasting. Turkish Journal of Medical Sciences, 2017, 47, 1152-1156.	0.9	3
1331	The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. International Journal of Molecular Sciences, 2017, 18, 2493.	4.1	52
1332	Cross-Talk Between Bile Acids and Gastro-Intestinal and Thermogenic Hormones: Clues from Bariatric Surgery. Annals of Hepatology, 2017, 16, S68-S82.	1.5	16
1333	The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes. Annals of Hepatology, 2017, 16, S15-S20.	1.5	123
1334	Diabetes-induced mechanophysiological changes in the small intestine and colon. World Journal of Diabetes, 2017, 8, 249.	3.5	49
1335	Signalling from the periphery to the brain that regulates energy homeostasis. Nature Reviews Neuroscience, 2018, 19, 185-196.	10.2	124
1336	GPR142 prompts glucagon-like Peptide-1 release from islets to improve β^2 cell function. Molecular Metabolism, 2018, 11, 205-211.	6.5	28
1337	Evaluating the effects of IADHFL on inhibiting DPP-IV activity and expression in Caco-2 cells and contributing to the amount of insulin released from INS-1 cells <i>in vitro</i> . Food and Function, 2018, 9, 2240-2250.	4.6	17
1338	Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Scientific Reports, 2018, 8, 3749.	3.3	35
1339	Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. Journal of Psychopharmacology, 2018, 32, 578-590.	4.0	28
1340	CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ Open, 2018, 8, e021000.	1.9	14
1341	Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease. Neuropharmacology, 2018, 135, 48-62.	4.1	39

#	ARTICLE	IF	CITATIONS
1342	Glucagon-Like Peptide 1 and Human Obesity. , 2018, , 17-36.		1
1343	EJE PRIZE 2018: A gut feeling about glucagon. European Journal of Endocrinology, 2018, 178, R267-R280.	3.7	38
1344	Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nature Communications, 2018, 9, 1602.	12.8	162
1345	Overview of Glucose Homeostasis. Endocrinology, 2018, , 1-23.	0.1	0
1346	Novel role of GLP-1 receptor signaling in energy expenditure during chronic high fat diet feeding in rats. Physiology and Behavior, 2018, 192, 194-199.	2.1	15
1347	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	4.4	3
1348	Neuroendocrinology of Energy Homeostasis. Endocrinology, 2018, , 473-496.	0.1	0
1349	Functional Characterization of Native, High-Affinity GABAA Receptors in Human Pancreatic Î² Cells. EBioMedicine, 2018, 30, 273-282.	6.1	42
1350	Pathogenesis of Type 2 Diabetes Mellitus. Endocrinology, 2018, , 1-74.	0.1	0
1351	GLP-1 and Insulin Recruit Muscle Microvasculature and Dilate Conduit Artery Individually But Not Additively in Healthy Humans. Journal of the Endocrine Society, 2018, 2, 190-206.	0.2	15
1352	Intestinal and Gastric Origins for Diabetes Resolution After Bariatric Surgery. Current Obesity Reports, 2018, 7, 139-146.	8.4	9
1353	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. Surgery for Obesity and Related Diseases, 2018, 14, 708-714.	1.2	144
1354	Recent advances in polysaccharides from Ophiopogon japonicus and Liriope spicata var. prolifera. International Journal of Biological Macromolecules, 2018, 114, 1257-1266.	7.5	35
1355	Palmitic Acid Hydroxystearic Acids Activate GPR40, Which Is Involved in Their Beneficial Effects on Glucose Homeostasis. Cell Metabolism, 2018, 27, 419-427.e4.	16.2	127
1356	Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology, 2018, 43, 2000-2008.	5.4	79
1357	Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. Peptides, 2018, 100, 158-164.	2.4	36
1358	Glucagon receptor signaling in metabolic diseases. Peptides, 2018, 100, 42-47.	2.4	23
1359	Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism. Peptides, 2018, 100, 94-100.	2.4	17

#	ARTICLE	IF	CITATIONS
1360	Ileal Transposition (IT) Surgery Changing the Ultrastructure of the Transposed Segment as well as Jejunum. Histomorphometric and Electron Microscopy Analysis. Obesity Surgery, 2018, 28, 1232-1239.	2.1	4
1361	Pharmacotherapy for obesity in individuals with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2018, 19, 223-231.	1.8	15
1362	Effects of a galacto-oligosaccharide-rich diet on fecal microbiota and metabolite profiles in mice. Food and Function, 2018, 9, 1612-1620.	4.6	70
1363	Fractalkine. , 2018, , 1867-1867.		0
1364	Fused. , 2018, , 1875-1875.		0
1365	Sepsis-induced activation of endogenous GLP-1 system is enhanced in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e2982.	4.0	22
1366	Oxyntomodulin: Actions and role in diabetes. Peptides, 2018, 100, 48-53.	2.4	59
1367	Intestinal peptide changes after bariatric and minimally invasive surgery: Relation to diabetes remission. Peptides, 2018, 100, 114-122.	2.4	24
1368	Incretins: Beyond type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 59-67.	4.4	8
1369	Brain metabolic sensing and metabolic signaling at the level of an astrocyte. Glia, 2018, 66, 1185-1199.	4.9	86
1370	The effects of incretin hormones on cerebral glucose metabolism in health and disease. Neuropharmacology, 2018, 136, 243-250.	4.1	5
1371	Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiology of Aging, 2018, 64, 33-43.	3.1	49
1372	Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. Journal of Allergy and Clinical Immunology, 2018, 142, 1515-1528.e8.	2.9	63
1373	Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells. Molecular Metabolism, 2018, 7, 90-101.	6.5	46
1374	Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 427-432.	7.1	74
1375	Polyphenol-rich curry made with mixed spices and vegetables increases postprandial plasma GLP-1 concentration in a dose-dependent manner. European Journal of Clinical Nutrition, 2018, 72, 297-300.	2.9	13
1376	Albiglutide for the management of type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2018, 13, 1-8.	2.4	11
1377	The role of gut in type 2 diabetes mellitus during whole body gamma irradiation in high-fat diet Wistar rats. International Journal of Radiation Biology, 2018, 94, 137-149.	1.8	3

#	ARTICLE	IF	CITATIONS
1378	Pharmacological management of cystic fibrosis related diabetes. Expert Review of Clinical Pharmacology, 2018, 11, 185-191.	3.1	13
1379	Therapeutic potential of spinal GLP-1 receptor signaling. Peptides, 2018, 101, 89-94.	2.4	6
1380	Cell-specific resetting of mouse islet cellular clocks by glucagon, glucagon-like peptide 1 and somatostatin. Acta Physiologica, 2018, 222, e13021.	3.8	26
1381	Comparison of glycemic control and β -cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. BMC Endocrine Disorders, 2018, 18, 14.	2.2	27
1382	Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic mice. RSC Advances, 2018, 8, 14967-14974.	3.6	39
1383	A surface plasmon resonance assay for characterisation and epitope mapping of anti-GLP-1 antibodies. Journal of Molecular Recognition, 2018, 31, e2711.	2.1	3
1384	Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology, 2018, 14, 390-403.	9.6	304
1385	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. Diabetes Care, 2018, 41, 1260-1267.	8.6	13
1386	Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry, 2018, 151, 145-157.	5.5	70
1387	Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Molecular Metabolism, 2018, 11, 84-95.	6.5	135
1388	GPR40-Mediated G_{i1}/G_{i2} Activation by Allosteric Full Agonists Highly Efficacious at Potentiating Glucose-Stimulated Insulin Secretion in Human Islets. Molecular Pharmacology, 2018, 93, 581-591.	2.3	21
1389	A sensitive method for the quantitation of the peptide-based glucagon-like peptide-1 receptor agonist liraglutide in plasma using microfluidics chromatography tandem MS. Bioanalysis, 2018, 10, 357-368.	1.5	4
1390	Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiology and Behavior, 2018, 192, 72-81.	2.1	30
1391	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Advances in Therapy, 2018, 35, 531-544.	2.9	12
1392	Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor. Clinical Oral Investigations, 2018, 22, 3113-3120.	3.0	1
1393	Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 232-239.	2.8	34
1394	Distribution and hormonal characterization of primary murine L cells throughout the gastrointestinal tract. Journal of Diabetes Investigation, 2018, 9, 25-32.	2.4	23
1395	A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling. Molecular Psychiatry, 2018, 23, 1555-1565.	7.9	84

#	ARTICLE	IF	CITATIONS
1396	Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 288-299.e6.	1.0	22
1397	Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. <i>Medicinal Research Reviews</i> , 2018, 38, 381-425.	10.5	67
1398	Do we know the true mechanism of action of the DPP-4 inhibitors?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 34-41.	4.4	89
1399	Recent advances in biosensor technology in assessment of early diabetes biomarkers. <i>Biosensors and Bioelectronics</i> , 2018, 99, 122-135.	10.1	123
1400	Evolution of the glucagon-like system across fish. <i>General and Comparative Endocrinology</i> , 2018, 264, 113-130.	1.8	9
1401	Obesity as a risk factor for Alzheimer's disease: weighing the evidence. <i>Obesity Reviews</i> , 2018, 19, 269-280.	6.5	164
1402	Parboiled rice metabolism differs in healthy and diabetic individuals with similar improvement in glycemic response. <i>Nutrition</i> , 2018, 47, 43-49.	2.4	23
1403	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. <i>Diabetologia</i> , 2018, 61, 284-294.	6.3	107
1404	Alteration in the liver metabolome of rats with metabolic syndrome after treatment with Hydroxytyrosol. A Mass Spectrometry And Nuclear Magnetic Resonance - based metabolomics study. <i>Talanta</i> , 2018, 178, 246-257.	5.5	14
1405	Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2882-2887.	3.0	50
1406	Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway. <i>Biyokimya Dergisi</i> , 2018, 43, 119-125.	0.5	0
1407	CREB/CRTC2 controls GLP-1-dependent regulation of glucose homeostasis. <i>FASEB Journal</i> , 2018, 32, 1566-1578.	0.5	27
1408	rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon. <i>Clinical Nutrition</i> , 2018, 37, 2144-2148.	5.0	6
1409	Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. <i>Neurotherapeutics</i> , 2018, 15, 36-59.	4.4	358
1410	Nutrition, inflammation and liver-spleen axis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 3141-3158.	10.3	74
1411	L'Internista ospedaliero nella gestione del paziente diabetico complesso. <i>Italian Journal of Medicine</i> , 2018, 6, 1.	0.3	1
1412	Hyperlipidemias and Obesity. <i>Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems</i> , 2018, , 331-548.	0.1	10
1413	Glucagon-like peptide (GLP)-1 analogues as an add-on to insulin for adults with type 1 diabetes mellitus. <i>The Cochrane Library</i> , 2018, , .	2.8	0

#	ARTICLE	IF	CITATIONS
1415	Impact of rye-based evening meals on cognitive functions, mood and cardiometabolic risk factors: a randomized controlled study in healthy middle-aged subjects. <i>Nutrition Journal</i> , 2018, 17, 102.	3.4	19
1416	Neuronal cAMP/PKA Signaling and Energy Homeostasis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1090, 31-48.	1.6	16
1418	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1429-1432.	1.5	17
1419	Diabetic Cardiomyopathy: Current and Future Therapies. <i>Beyond Glycemic Control. Frontiers in Physiology</i> , 2018, 9, 1514.	2.8	154
1420	Neural Regulation of Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	1.6	1
1421	Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs. <i>Frontiers in Endocrinology</i> , 2018, 9, 719.	3.5	22
1422	Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , 2018, 8, e022517.	1.9	6
1423	Unravelling the role and mechanism of adipokine and gastrointestinal signals in animal models in the nonhomeostatic control of energy homeostasis: Implications for binge eating disorder. <i>European Eating Disorders Review</i> , 2018, 26, 551-568.	4.1	14
1424	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2180-2193.	13.7	528
1425	Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Pharmacological Research</i> , 2018, 137, 219-229.	7.1	54
1426	Addition of high load of lysophosphatidic acid to standard and high-fat chows causes no significant changes of its circulating and peripheral tissue levels but affects body weight and visceral fat mass of mice. <i>BioFactors</i> , 2018, 44, 548-557.	5.4	2
1427	Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. <i>Frontiers in Endocrinology</i> , 2018, 9, 584.	3.5	54
1428	Pathogenesis of Type 2 Diabetes Mellitus. <i>Endocrinology</i> , 2018, , 181-253.	0.1	7
1429	Overview of Glucose Homeostasis. <i>Endocrinology</i> , 2018, , 1-22.	0.1	0
1430	Hormones and Gastrointestinal Function of Newborns. , 2018, , 535-555.		0
1431	Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study. <i>Scientific Reports</i> , 2018, 8, 13679.	3.3	25
1432	Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract. , 2018, 8, 1603-1638.		25
1433	GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca ²⁺ channels. <i>Physiological Reports</i> , 2018, 6, e13852.	1.7	71

#	ARTICLE	IF	CITATIONS
1434	Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms. Expert Review of Endocrinology and Metabolism, 2018, 13, 251-262.	2.4	33
1435	Renoprotective effects of dulaglutide in patients with T2DM and CKD. Nature Reviews Nephrology, 2018, 14, 659-660.	9.6	4
1436	Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. PLoS ONE, 2018, 13, e0198024.	2.5	18
1437	Stimulus for Glucagon-Like Peptide 1 Secretion in Rats. Doklady Biological Sciences, 2018, 479, 57-59.	0.6	3
1438	Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of Glucagon-Like Peptide-1. ACS Omega, 2018, 3, 5346-5354.	3.5	10
1439	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2042-2049.	3.6	18
1440	Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilot study. Diabetes, Obesity and Metabolism, 2018, 20, 2330-2338.	4.4	14
1441	Effects of walking in water on gut hormone concentrations and appetite: comparison with walking on land. Endocrine Connections, 2018, 7, 97-106.	1.9	5
1442	Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2238-2245.	4.4	23
1443	Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2131-2135.	2.2	22
1444	Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons. Diabetes, 2018, 67, 1538-1548.	0.6	84
1445	Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. Journal of Neurogastroenterology and Motility, 2018, 24, 367-386.	2.4	79
1446	Enterendocrine profile of δ -transducin and δ -gustducin immunoreactive cells in the chicken (Gallus) Tj ETQq0 0 0 rgBT /Overlock 10 Tj	3.4	5
1447	The Effects of Sleeve Gastrectomy on Glucose Metabolism and Glucagon-Like Peptide 1 in Goto-Kakizaki Rats. Journal of Diabetes Research, 2018, 2018, 1-11.	2.3	8
1448	DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Research, 2018, 2018, 1-10.	2.3	30
1449	Farnesoid X Receptor (FXR) Interacts with Camp Response Element Binding Protein (CREB) to Modulate Glucagon-Like Peptide-1 (7â€“36) Amide (GLP-1) Secretion by Intestinal L Cell. Cellular Physiology and Biochemistry, 2018, 47, 1442-1452.	1.6	6
1450	Venous blood provides lower glucagon-like peptide-1 concentrations than arterialized blood in the postprandial but not the fasted state: Consequences of sampling methods. Experimental Physiology, 2018, 103, 1200-1205.	2.0	9
1451	The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF- α Expression in Macrophages. Journal of Immunology Research, 2018, 2018, 1-10.	2.2	29

#	ARTICLE	IF	CITATIONS
1452	Inhibition of SNAT5 Induces Incretin-Responsive State From Incretin-Unresponsive State in Pancreatic β -Cells: Study of β -Cell Spheroid Clusters as a Model. <i>Diabetes</i> , 2018, 67, 1795-1806.	0.6	10
1453	Vagal Interoceptive Modulation of Motivated Behavior. <i>Physiology</i> , 2018, 33, 151-167.	3.1	65
1454	Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2018, 315, R708-R720.	1.8	39
1455	Genetic interaction effects reveal lipid-metabolic and inflammatory pathways underlying common metabolic disease risks. <i>BMC Medical Genomics</i> , 2018, 11, 54.	1.5	13
1456	The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity. <i>Frontiers in Physiology</i> , 2018, 9, 900.	2.8	122
1457	Gastrointestinal Hormones Controlling Energy Homeostasis and Their Potential Role in Obesity. , 2018, , 183-203.		1
1458	The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G53-G65.	3.4	235
1459	Intake of Polydextrose Alters Hematology and the Profile of Short Chain Fatty Acids in Partially Gastrectomized Rats. <i>Nutrients</i> , 2018, 10, 792.	4.1	7
1460	Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G671-G684.	3.4	10
1461	Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus. <i>Biomaterials Research</i> , 2018, 22, 19.	6.9	7
1462	Adapentronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 214.	3.7	13
1463	Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier. <i>Frontiers in Endocrinology</i> , 2018, 9, 62.	3.5	1
1464	Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity. <i>Scientific Reports</i> , 2018, 8, 10644.	3.3	19
1465	Effects of Glutamine on Gastric Emptying of Low- and High-Nutrient Drinks in Healthy Young Subjects—Impact on Glycaemia. <i>Nutrients</i> , 2018, 10, 739.	4.1	7
1466	Non-insulin pharmacological therapies for treating type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 947-960.	1.8	25
1467	Battle of GLP-1 delivery technologies. <i>Advanced Drug Delivery Reviews</i> , 2018, 130, 113-130.	13.7	84
1468	Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2018, 8, e019562.	1.9	22
1469	Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. <i>Cardiovascular Diabetology</i> , 2018, 17, 85.	6.8	18

#	ARTICLE	IF	CITATIONS
1470	Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovascular Diabetology, 2018, 17, 8.	6.8	102
1471	Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios. Diabetes Therapy, 2018, 9, 1775-1789.	2.5	43
1472	Microbial tryptophan catabolites in health and disease. Nature Communications, 2018, 9, 3294.	12.8	1,067
1473	High amylose cornstarch preloads stabilized postprandial blood glucose but failed to reduce appetite or food intake in healthy women. Appetite, 2018, 131, 1-6.	3.7	11
1474	Effects of dietary pectin on the profile and transport of intestinal bile acids in young pigs. Journal of Animal Science, 2018, 96, 4743-4754.	0.5	28
1475	Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. Pharmacological Reviews, 2018, 70, 712-746.	16.0	137
1476	Intestinal bitter taste receptor activation alters hormone secretion and imparts metabolic benefits. Molecular Metabolism, 2018, 16, 76-87.	6.5	78
1477	Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects. Basic Research in Cardiology, 2018, 113, 25.	5.9	59
1478	The combined administration of EGCG and caffeine induces not only suppression of fat accumulation but also anorexigenic action in mice. Journal of Functional Foods, 2018, 47, 156-162.	3.4	11
1479	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 2018, 20, 2557-2564.	4.4	28
1480	Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor. International Journal of Pharmaceutics, 2018, 547, 563-571.	5.2	35
1481	Hypothalamic Integration of the Endocrine Signaling Related to Food Intake. Current Topics in Behavioral Neurosciences, 2018, 43, 239-269.	1.7	25
1482	Solid-phase extraction treatment is required for measurement of active glucagon-like peptide-1 by enzyme-linked immunosorbent assay kit affected by heterophilic antibodies. Journal of Diabetes Investigation, 2019, 10, 302-308.	2.4	3
1483	Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. Diabetes, Obesity and Metabolism, 2019, 21, 43-51.	4.4	17
1484	Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. Clinical Physiology and Functional Imaging, 2019, 39, 122-127.	1.2	4
1485	Extrapankreatic glucagon: Present status. Diabetes Research and Clinical Practice, 2019, 147, 19-28.	2.8	9
1486	New Avenues in the Regulation of Gallbladder Motility—Implications for the Use of Glucagon-Like Peptide-Derived Drugs. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2463-2472.	3.6	16
1487	Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?. European Journal of Neuroscience, 2019, 49, 422-439.	2.6	2

#	ARTICLE	IF	CITATIONS
1488	Levels of Glucagon-like Peptide 1 are Decreased in Macrosomic Neonates from Non-Diabetic Mothers. Zeitschrift Fur Geburtshilfe Und Neonatologie, 2019, 223, 48-53.	0.4	1
1489	Silibinin ameliorates amylin-induced pancreatic β -cell apoptosis partly via upregulation of GLP-1R/PKA pathway. Molecular and Cellular Biochemistry, 2019, 452, 83-94.	3.1	17
1490	Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?. American Journal of Physiology - Renal Physiology, 2019, 317, F1010-F1021.	2.7	14
1491	Putting the Hindgut Hypothesis to the Test in a Diabetic Zucker Rat Model. Obesity Surgery, 2019, 29, 4000-4007.	2.1	2
1492	Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3868-3876.	3.6	18
1493	Demystifying the Pizza Bolus: The Effect of Dough Fermentation on Glycemic Responseâ€”A Sensor-Augmented Pump Intervention Trial in Children with Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2019, 21, 721-726.	4.4	5
1494	Current and future clinical utilities of Parkinsonâ€™s disease and dementia biomarkers: can they help us conquer the disease?. Expert Review of Neurotherapeutics, 2019, 19, 1149-1161.	2.8	2
1495	<p>GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 873-881.	2.4	4
1496	Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice. European Journal of Pharmacology, 2019, 859, 172521.	3.5	1
1497	Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes, Obesity and Metabolism, 2019, 21, 2459-2464.	4.4	35
1498	Glucagon Receptor Signaling and Glucagon Resistance. International Journal of Molecular Sciences, 2019, 20, 3314.	4.1	113
1499	Glucagon, GLP-1 and Thermogenesis. International Journal of Molecular Sciences, 2019, 20, 3445.	4.1	33
1500	Anti-incretin effect: The other face of Janus in human glucose homeostasis. Obesity Reviews, 2019, 20, 1597-1607.	6.5	4
1501	Enhanced postprandial glucagon-like peptide-1 secretion during obesity development has a protective role against glucose intolerance induction in rats. British Journal of Nutrition, 2019, 122, 411-422.	2.3	14
1502	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Therapy, 2019, 10, 1645-1717.	2.5	32
1503	Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. Drugs, 2019, 79, 1187-1197.	10.9	15
1504	Tobacco Smoking, Eating Behaviors, and Body Weight: a Review. Current Addiction Reports, 2019, 6, 191-199.	3.4	27
1505	Serum Levels of Incretin Hormones â€” GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus. Folia Medica, 2019, 61, 76-83.	0.5	1

#	ARTICLE	IF	CITATIONS
1506	Obesity in the Pathophysiology of Diabetes. , 2019, , 185-213.		0
1507	Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy. Experimental and Therapeutic Medicine, 2019, 18, 342-351.	1.8	6
1509	Fructose Consumption Contributes to Hyperinsulinemia in Adolescents With Obesity Through a GLP-1-Mediated Mechanism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3481-3490.	3.6	20
1510	The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial. American Heart Journal, 2019, 215, 41-51.	2.7	5
1511	Effects of newly introduced antidiabetic drugs on autophagy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2445-2449.	3.6	33
1512	Hepatocyte-specific HIF-1 α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. Science Advances, 2019, 5, eaaw4176.	10.3	20
1513	Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 793-810.	2.6	38
1514	Incretin Therapies: Current Use and Emerging Possibilities. , 2019, , 515-529.		0
1515	Changes in Weight and Substrate Oxidation in Overweight Adults Following Isomaltulose Intake During a 12-Week Weight Loss Intervention: A Randomized, Double-Blind, Controlled Trial. Nutrients, 2019, 11, 2367.	4.1	13
1516	Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. Journal of Microencapsulation, 2019, 36, 747-758.	2.8	14
1517	Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties. Bioorganic and Medicinal Chemistry, 2019, 27, 115070.	3.0	2
1518	Physiology of the Incretin Hormones, <sc>GLP</sc> and <sc>GLP</sc> "Regulation of Release and Posttranslational Modifications. , 2019, 9, 1339-1381.		38
1519	Enteroinular axis response to carbohydrates and fasting in healthy newborn foals. Journal of Veterinary Internal Medicine, 2019, 33, 2752-2764.	1.6	9
1520	Glucagon-like peptide-1 increased the vascular relaxation response via AMPK/Akt signaling in diabetic mice aortas. European Journal of Pharmacology, 2019, 865, 172776.	3.5	9
1521	Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months. Diabetes Research and Clinical Practice, 2019, 158, 107916.	2.8	7
1522	Penalized regression models to select biomarkers of environmental enteric dysfunction associated with linear growth acquisition in a Peruvian birth cohort. PLoS Neglected Tropical Diseases, 2019, 13, e0007851.	3.0	3
1523	Apocynin alleviates lung injury by suppressing NLRP3 inflammasome activation and NF- κ B signaling in acute pancreatitis. International Immunopharmacology, 2019, 75, 105821.	3.8	39
1524	Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons " Implications for energy balance and glucose control. Molecular Metabolism, 2019, 28, 120-134.	6.5	61

#	ARTICLE	IF	CITATIONS
1525	Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. <i>General Physiology and Biophysics</i> , 2019, 38, 343-352.	0.9	1
1526	Racial Variations in Appetite-Related Hormones, Appetite, and Laboratory-Based Energy Intake from the E-MECHANIC Randomized Clinical Trial. <i>Nutrients</i> , 2019, 11, 2018.	4.1	4
1527	Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and β 1 Antitrypsin. <i>Scientific Reports</i> , 2019, 9, 13427.	3.3	6
1528	Appetite-Suppressing and Satiety-Increasing Bioactive Phytochemicals: A Systematic Review. <i>Nutrients</i> , 2019, 11, 2238.	4.1	22
1529	Peptidylglycine monooxygenase activity of monomeric species of growth hormone. <i>Heliyon</i> , 2019, 5, e02436.	3.2	2
1530	Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes. <i>Nutrients</i> , 2019, 11, 2185.	4.1	115
1531	Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure. <i>International Urology and Nephrology</i> , 2019, 51, 2305-2313.	1.4	14
1532	Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome – A Systematic Review. <i>Nutrients</i> , 2019, 11, 2291.	4.1	132
1533	Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.	6.5	850
1534	Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis. <i>Clinical Therapeutics</i> , 2019, 41, 2057-2065.	2.5	0
1535	Perioperative Cardioprotection by Remote Ischemic Conditioning. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4839.	4.1	24
1536	Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 79.	2.7	9
1537	Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka. <i>Journal of Health, Population and Nutrition</i> , 2019, 38, 3.	2.0	2
1538	Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 101.	2.9	33
1539	Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2581-2592.	3.6	7
1540	A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach. <i>Current Diabetes Reviews</i> , 2019, 15, 255-258.	1.3	5
1541	Glutamate as intracellular and extracellular signals in pancreatic islet functions. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2019, 95, 246-260.	3.8	22
1542	Antihyperglycemic effect of a chicken feet hydrolysate via the incretin system: DPP-IV-inhibitory activity and GLP-1 release stimulation. <i>Food and Function</i> , 2019, 10, 4062-4070.	4.6	24

#	ARTICLE	IF	CITATIONS
1543	Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2). <i>Diabetes Therapy</i> , 2019, 10, 1435-1452.	2.5	9
1544	Effects of a Lactulose-Rich Diet on Fecal Microbiome and Metabolome in Pregnant Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 7674-7683.	5.2	19
1545	Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2685-2694.	3.6	6
1546	Postprandial hypoglycaemia after Roux- <i>Y</i> gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2142-2151.	4.4	38
1547	Vector-free in vivo trans-determination of adult hepatic stem cells to insulin-producing cells. <i>Molecular Biology Reports</i> , 2019, 46, 5501-5509.	2.3	2
1548	Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice. <i>Biochemical Pharmacology</i> , 2019, 166, 222-230.	4.4	6
1549	Are There Any Sensors in Oral Cavity for Gut Hormone Release?. <i>Current Oral Health Reports</i> , 2019, 6, 76-81.	1.6	0
1550	Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs. <i>Drug Research</i> , 2019, 69, 479-486.	1.7	0
1551	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2509-2519.	3.6	29
1552	<i>H. pylori</i> Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans. <i>Journal of Clinical Medicine</i> , 2019, 8, 451.	2.4	52
1553	GLP-1: Molecular mechanisms and outcomes of a complex signaling system. <i>Neurochemistry International</i> , 2019, 128, 94-105.	3.8	66
1554	Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. <i>Scientific Reports</i> , 2019, 9, 6274.	3.3	24
1555	Fish as models for understanding the vertebrate endocrine regulation of feeding and weight. <i>Molecular and Cellular Endocrinology</i> , 2019, 497, 110437.	3.2	56
1556	Using the Avocado to Test the Satiety Effects of a Fat-Fiber Combination in Place of Carbohydrate Energy in a Breakfast Meal in Overweight and Obese Men and Women: A Randomized Clinical Trial. <i>Nutrients</i> , 2019, 11, 952.	4.1	13
1557	Interleukin-6 in the central amygdala is bioactive and co-localised with glucagon-like peptide-1 receptor. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12722.	2.6	7
1558	Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide. <i>Molecular Pharmaceutics</i> , 2019, 16, 2153-2161.	4.6	10
1559	In vitro probiotic properties of selected lactobacilli and multi-strain consortium on immune function, gut barrier strengthening and gut hormone secretion. <i>Journal of Functional Foods</i> , 2019, 57, 382-391.	3.4	10
1560	Peptone-mediated glucagon-like peptide-1 secretion depends on intestinal absorption and activation of basolaterally located Calcium-Sensing Receptors. <i>Physiological Reports</i> , 2019, 7, e14056.	1.7	36

#	ARTICLE	IF	CITATIONS
1561	The incretin system in healthy humans: The role of GIP and GLP-1. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 46-55.	3.4	127
1562	Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice. <i>Endocrine</i> , 2019, 64, 349-366.	2.3	8
1564	Pharmacologic treatment options for type 1 diabetes: what's new?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 471-479.	3.1	13
1565	Stimuli-responsive polymers for oral insulin delivery. , 2019, , 525-546.		2
1566	A Preventive Prebiotic Supplementation Improves the Sweet Taste Perception in Diet-Induced Obese Mice. <i>Nutrients</i> , 2019, 11, 549.	4.1	17
1567	Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis. <i>Cells</i> , 2019, 8, 204.	4.1	173
1568	Impact of Nutrient Type and Sequence on Glucose Tolerance: Physiological Insights and Therapeutic Implications. <i>Frontiers in Endocrinology</i> , 2019, 10, 144.	3.5	34
1569	Central GLP-1 receptors: Novel molecular targets for cocaine use disorder. <i>Physiology and Behavior</i> , 2019, 206, 93-105.	2.1	33
1570	Farnesoid X receptor: An important factor in blood glucose regulation. <i>Clinica Chimica Acta</i> , 2019, 495, 29-34.	1.1	14
1571	Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. <i>Frontiers in Endocrinology</i> , 2019, 10, 75.	3.5	70
1572	Obesity, Motility, Diet, and Intestinal Microbiota—Connecting the Dots. <i>Current Gastroenterology Reports</i> , 2019, 21, 15.	2.5	22
1573	Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1837-1848.	4.4	10
1574	Peptide Drug Design for Diabetes and Related Metabolic Diseases. , 2019, , 351-368.		0
1575	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. <i>Drug Safety</i> , 2019, 42, 957-971.	3.2	22
1576	Endocrine Control of Food Intake. , 2019, , .		0
1577	The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. <i>Frontiers in Physiology</i> , 2019, 10, 428.	2.8	228
1578	Glucagon-Like Peptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT2c) Receptor Agonists in the Ventral Tegmental Area (VTA) Inhibit Ghrelin-Stimulated Appetitive Reward. <i>International Journal of Molecular Sciences</i> , 2019, 20, 889.	4.1	22
1579	Regulation of microbiota—GLP1 axis by sennoside A in diet-induced obese mice. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 758-768.	12.0	41

#	ARTICLE	IF	CITATIONS
1580	Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 78-88.	2.8	7
1581	Functional Magnetic Resonance Imaging (fMRI) of Neural Responses to Visual and Auditory Food Stimuli Pre and Post Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG). <i>Neuroscience</i> , 2019, 409, 290-298.	2.3	33
1582	The Gut Microbiome After Bariatric Surgery. , 2019, , 235-242.		2
1583	The effect of DPP-4-protected GLP-1 (7â€³36) on coronary microvascular function in obese adults. <i>IJC Heart and Vasculature</i> , 2019, 22, 139-144.	1.1	5
1584	Natural compounds with DPPâ€³4 inhibitory effects: Implications for the treatment of diabetes. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 10909-10913.	2.6	14
1585	Targeting the Gut Microbiota to Investigate the Mechanism of Lactulose in Negating the Effects of a Highâ€³Salt Diet on Hypertension. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1800941.	3.3	52
1586	Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. <i>Neuropharmacology</i> , 2019, 149, 124-132.	4.1	26
1587	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019, 20, 805-815.	6.5	71
1588	Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?. <i>Current Clinical Pharmacology</i> , 2019, 14, 247-248.	0.6	0
1589	A Pilot Study Showing Acute Inhibitory Effect of GLPâ€³1 on the Bone Resorption Marker CTX in Humans. <i>JBM Plus</i> , 2019, 3, e10209.	2.7	19
1590	Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1448-1451.	1.5	7
1591	Perioperative Infusion of Glucagon-Like Peptide-1 Prevents Insulin Resistance After Surgical Trauma in Female Pigs. <i>Endocrinology</i> , 2019, 160, 2892-2902.	2.8	4
1592	GLP-1 Gene-Modified Human Umbilical Cord Mesenchymal Stem Cell Line Improves Blood Glucose Level in Type 2 Diabetic Mice. <i>Stem Cells International</i> , 2019, 2019, 1-9.	2.5	3
1593	Black soybean seed coat polyphenols promote nitric oxide production in the aorta through glucagon-like peptide-1 secretion from the intestinal cells. <i>Food and Function</i> , 2019, 10, 7875-7882.	4.6	15
1594	Global transcriptome analysis of rat hypothalamic arcuate nucleus demonstrates reversal of hypothalamic gliosis following surgically and diet induced weight loss. <i>Scientific Reports</i> , 2019, 9, 16161.	3.3	7
1595	The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-9.	2.3	2
1596	Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology. <i>Obesity</i> , 2019, 27, 2005-2010.	3.0	29
1597	Hypoglycemia in cystic fibrosis: Prevalence, impact and treatment. <i>Journal of Cystic Fibrosis</i> , 2019, 18, S19-S24.	0.7	13

#	ARTICLE	IF	CITATIONS
1598	<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	2.4	20
1599	Reduced Expression of PLCXD3 Associates With Disruption of Glucose Sensing and Insulin Signaling in Pancreatic I ² -Cells. Frontiers in Endocrinology, 2019, 10, 735.	3.5	18
1600	<p>Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways</p>. Drug Design, Development and Therapy, 2019, Volume 13, 4065-4074.	4.3	23
1601	Effects of Duodenal Infusion of Lauric Acid and L-Tryptophan, Alone and Combined, on Fasting Glucose, Insulin and Glucagon in Healthy Men. Nutrients, 2019, 11, 2697.	4.1	5
1602	Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy. Pancreas, 2019, 48, 953-957.	1.1	0
1603	Diabetic Gastroparesis and Glycaemic Control. Current Diabetes Reports, 2019, 19, 153.	4.2	23
1604	Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model. Transplantation, 2019, 103, 502-511.	1.0	15
1605	The Potential of Hibiscus sabdariffa Linn in Inducing Glucagon-Like Peptide-1 via SGLT-1 and GLPR in DM Rats. BioMed Research International, 2019, 2019, 1-8.	1.9	7
1606	The role of liraglutide in the management of obesity. Journal of Aesthetic Nursing, 2019, 8, 322-326.	0.1	0
1607	Supplementation with cod protein hydrolysate in older adults: a dose range cross-over study. Journal of Nutritional Science, 2019, 8, e40.	1.9	16
1608	Glucagon-like peptide-1 receptor action in the vasculature. Peptides, 2019, 111, 26-32.	2.4	50
1609	Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle. Peptides, 2019, 112, 48-55.	2.4	15
1610	GLP-1 modulates the supramammillary nucleus-lateral hypothalamic neurocircuit to control ingestive and motivated behavior in a sexÂdivergent manner. Molecular Metabolism, 2019, 20, 178-193.	6.5	24
1611	Effects of active commuting and leisure-time exercise on appetite in individuals with overweight and obesity. Journal of Applied Physiology, 2019, 126, 941-951.	2.5	16
1612	Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?. Diabetes, 2019, 68, 15-17.	0.6	25
1613	Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice. Biomedicine and Pharmacotherapy, 2019, 109, 167-173.	5.6	10
1614	A low GLP-1 response among patients treated for acute organophosphate and carbamate poisoning: a comparative cross-sectional study from an agrarian region of Sri Lanka. Environmental Science and Pollution Research, 2019, 26, 2864-2872.	5.3	5
1615	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectrums, 2019, 24, 441-452.	1.2	15

#	ARTICLE	IF	CITATIONS
1616	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. Expert Opinion on Pharmacotherapy, 2019, 20, 585-593.	1.8	11
1617	Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes. Frontiers in Physiology, 2018, 9, 1857.	2.8	75
1618	A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β -Cell Function and Reduces β -Cell Proliferation in Streptozotocin-Induced Diabetic Mice. International Journal of Molecular Sciences, 2019, 20, 322.	4.1	29
1619	Toll-like receptor 4 is necessary for glucose-dependent glucagon-like peptide-1 secretion in male mice. Biochemical and Biophysical Research Communications, 2019, 510, 104-109.	2.1	5
1620	Liraglutide effects in a paediatric (7-11 Åy) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatric Obesity, 2019, 14, e12495.	2.8	45
1621	Evaluation and management of ketosis-prone diabetes. Expert Review of Endocrinology and Metabolism, 2019, 14, 43-48.	2.4	10
1622	Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex. Diabetologia, 2019, 62, 717-725.	6.3	7
1623	Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology, 2019, 236, 603-611.	3.1	36
1624	Relationship between the insulin resistance and circulating predictive biochemical markers in metabolic syndrome among young adults in western Algeria. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 504-509.	3.6	6
1625	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatrica Scandinavica, 2019, 139, 26-36.	4.5	30
1626	Learning one's genetic risk changes physiology independent of actual genetic risk. Nature Human Behaviour, 2019, 3, 48-56.	12.0	91
1627	Farnesoid X receptor interacts with cAMP response element binding protein to modulate glucagon-like peptide-1 (7-36) amide secretion by intestinal L cell. Journal of Cellular Physiology, 2019, 234, 12839-12846.	4.1	14
1628	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 202-208.	3.6	5
1629	Breakfast replacement with a liquid formula improves glycaemic variability in patients with type 2 diabetes: a randomised clinical trial. British Journal of Nutrition, 2019, 121, 560-566.	2.3	10
1630	Therapeutic medications against diabetes: What we have and what we expect. Advanced Drug Delivery Reviews, 2019, 139, 3-15.	13.7	45
1631	The Regulation of Peripheral Metabolism by Gut-Derived Hormones. Frontiers in Endocrinology, 2018, 9, 754.	3.5	42
1632	Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases. CNS Drugs, 2019, 33, 209-223.	5.9	49
1633	Relationship between glucagon like peptide-1 and non-alcoholic fatty liver disease in diabetic and non-diabetic patients. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 526-529.	3.6	1

#	ARTICLE	IF	CITATIONS
1634	Fasting glucagon-like peptide 1 concentration is associated with lower carbohydrate intake and increases with overeating. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 557-566.	3.3	11
1635	Design strategies for chemical-stimuli-responsive programmable nanotherapeutics. <i>Drug Discovery Today</i> , 2019, 24, 129-147.	6.4	32
1636	Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans. <i>International Journal of Cardiology</i> , 2019, 274, 40-44.	1.7	14
1637	Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 193-201.	3.6	27
1638	Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 586-601.	1.9	54
1639	Metabolic effects of the natural sweeteners xylitol and erythritol: A comprehensive review. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 1986-1998.	10.3	49
1640	Co-ingestion of whey protein hydrolysate with milk minerals rich in calcium potently stimulates glucagon-like peptide-1 secretion: an RCT in healthy adults. <i>European Journal of Nutrition</i> , 2020, 59, 2449-2462.	3.9	14
1641	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 905-927.	6.4	34
1642	Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. <i>Neuropsychopharmacology</i> , 2020, 45, 451-461.	5.4	37
1643	What Is GLP-1 Really Doing in Obesity?. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 71-80.	7.1	37
1644	Acute effects of an isocaloric macronutrient-matched breakfast meal containing almonds on glycemic, hormonal, and appetite responses in men with type 2 diabetes: a randomized crossover study. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 520-529.	1.9	8
1645	Chrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 266-275.	3.6	8
1646	Incretins in obesity and diabetes. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 104-126.	3.8	57
1647	Regulation of insulin and adipokinetic hormone/glucagon production in flies. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2020, 9, e360.	5.9	43
1648	Chicken Intestinal L Cells and Glucagon-like Peptide-1 Secretion. <i>Journal of Poultry Science</i> , 2020, 57, 1-6.	1.6	15
1649	The effect of <i>in vitro</i> gastrointestinal simulation on bioactivities of kefir. <i>International Journal of Food Science and Technology</i> , 2020, 55, 283-292.	2.7	11
1650	A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 127-134.	2.6	11
1651	Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 1211-1221.	1.9	5

#	ARTICLE	IF	CITATIONS
1652	Identification of a subset of trace amine-associated receptors and ligands as potential modulators of insulin secretion. <i>Biochemical Pharmacology</i> , 2020, 171, 113685.	4.4	12
1653	Consumption of a meal containing refined barley flour bread is associated with a lower postprandial blood glucose concentration after a second meal compared with one containing refined wheat flour bread in healthy Japanese: A randomized control trial. <i>Nutrition</i> , 2020, 72, 110637.	2.4	14
1654	Postprandial regulation of prouroguanylin in humans of a healthy weight and those who are overweight or with obesity. <i>Peptides</i> , 2020, 123, 170179.	2.4	4
1655	Developmental Origins and Roles of Intestinal Enteroendocrine Hormones. , 2020, , 599-610.		0
1656	The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats. <i>Obesity Surgery</i> , 2020, 30, 697-706.	2.1	10
1657	Immunohistochemical distribution of glucagon-like peptide 1 in the digestive system of different aquatic vertebrates. <i>Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia</i> , 2020, 49, 31-37.	0.7	0
1658	Gut Hormones in Pregnancy and Lactation. , 2020, , 91-99.		1
1659	Metformin: A review of its therapeutic efficacy and adverse effects. <i>Obesity Medicine</i> , 2020, 17, 100186.	0.9	44
1660	Physiologic Mechanisms of Type II Diabetes Mellitus Remission Following Bariatric Surgery: a Meta-analysis and Clinical Implications. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 728-741.	1.7	19
1661	Neurotransmitters, neuropeptides and their receptors interact with immune response in healthy and psoriatic skin. <i>Neuropeptides</i> , 2020, 79, 102004.	2.2	25
1662	Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F443-F454.	2.7	24
1663	Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E189-E197.	3.5	10
1664	Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders. <i>Obesity</i> , 2020, 28, 225-234.	3.0	63
1665	Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. <i>Cardiovascular Research</i> , 2020, 116, 916-930.	3.8	51
1666	The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 21-28.	4.9	19
1667	Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. <i>Life Sciences</i> , 2020, 241, 117152.	4.3	35
1668	Cardiovascular biology of the GIP receptor. <i>Peptides</i> , 2020, 125, 170228.	2.4	10
1669	Incretin therapy for diabetes mellitus type 2. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 2-10.	2.3	21

#	ARTICLE	IF	CITATIONS
1670	DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects. <i>Neuroscience Bulletin</i> , 2020, 36, 407-418.	2.9	15
1671	Effect of resveratrol on dipeptidyl peptidase-4 inhibitors pharmacokinetics: An in vitro and in vivo approach. <i>Chemico-Biological Interactions</i> , 2020, 315, 108909.	4.0	7
1672	Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. <i>Brain Research</i> , 2020, 1727, 146562.	2.2	23
1673	Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats. <i>European Journal of Pharmacology</i> , 2020, 866, 172835.	3.5	8
1674	Effects and Mechanisms of Vagal Nerve Stimulation on Body Weight in Diet-Induced Obese Rats. <i>Obesity Surgery</i> , 2020, 30, 948-956.	2.1	11
1675	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
1676	Glucagon-like peptide-1 receptor is expressed in human and rodent testis. <i>Andrology</i> , 2020, 8, 1935-1945.	3.5	15
1677	GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E1101-E1111.	3.5	12
1678	A comprehensive insight into the effect of glutamine supplementation on metabolic variables in diabetes mellitus: a systematic review. <i>Nutrition and Metabolism</i> , 2020, 17, 80.	3.0	23
1679	Cyclic tailor-made amino acids in the design of modern pharmaceuticals. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112736.	5.5	39
1680	Protein synthesis with conformationally constrained cyclic dipeptides. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115780.	3.0	6
1681	Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study. <i>International Journal of Biological Macromolecules</i> , 2020, 165, 665-674.	7.5	23
1682	Dipeptidyl peptidase-4 and GLP-1 interplay in STC-1 and GLUTag cell lines. <i>Peptides</i> , 2020, 134, 170419.	2.4	10
1683	An alternative pathway for sweet sensation: possible mechanisms and physiological relevance. <i>Pflügers Archiv European Journal of Physiology</i> , 2020, 472, 1667-1691.	2.8	6
1684	Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. <i>Archives of Physiology and Biochemistry</i> , 2023, 129, 373-378.	2.1	4
1685	Estrogen and gut satiety hormones in vagus-hindbrain axis. <i>Peptides</i> , 2020, 133, 170389.	2.4	7
1686	Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. <i>Translational Psychiatry</i> , 2020, 10, 238.	4.8	23
1687	Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 969-977.	4.4	5

#	ARTICLE	IF	CITATIONS
1688	The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-11.	2.3	5
1689	Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. <i>Nutrients</i> , 2020, 12, 1991.	4.1	9
1690	Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112619.	5.5	4
1691	Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. <i>Cell Reports</i> , 2020, 31, 107768.	6.4	18
1692	Increasing levels of insulin secretion in bioartificial pancreas technology: co-encapsulation of beta cells and nanoparticles containing GLP-1 in alginate hydrogels. <i>Health and Technology</i> , 2020, 10, 885-890.	3.6	5
1693	Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats. <i>Pharmaceuticals</i> , 2020, 13, 407.	3.8	4
1694	First-Phase Insulin and Amylin after Bariatric Surgery: A Prospective Randomized Trial on Patients with Insulin Resistance or Diabetes after Gastric Bypass or Sleeve Gastrectomy. <i>Obesity Facts</i> , 2020, 13, 584-595.	3.4	6
1695	Glucagon-Like Peptide-1 Regulates the Proopiomelanocortin Neurons of the Arcuate Nucleus both Directly and Indirectly via Presynaptic Action. <i>Neuroendocrinology</i> , 2021, 111, 986-997.	2.5	16
1696	Comparison of the Effects of Liraglutide on Islet Graft Survival Between Local and Systemic Delivery. <i>Cell Transplantation</i> , 2020, 29, 096368972097124.	2.5	3
1697	PPAR α and PPAR δ are negatively correlated with proinflammatory markers in leukocytes of an obese pediatric population. <i>Journal of Inflammation</i> , 2020, 17, 35.	3.4	12
1698	The risk of cardiovascular complications with current obesity drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1095-1104.	2.4	14
1699	Insulin Sensitivity and Pancreatic β -Cell Function in Ecuadorian Women With Turner Syndrome. <i>Frontiers in Endocrinology</i> , 2020, 11, 482.	3.5	5
1700	Insights into the potential benefits of black soybean (<i>Glycine max</i>L.) polyphenols in lifestyle diseases. <i>Food and Function</i> , 2020, 11, 7321-7339.	4.6	15
1701	Effects of Ramadan Intermittent Fasting on Gut Hormones and Body Composition in Males with Obesity. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5600.	2.6	33
1702	Effects of active farnesoid X receptor on GLUTag enteroendocrine L cells. <i>Molecular and Cellular Endocrinology</i> , 2020, 517, 110923.	3.2	5
1703	Long-term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020, 2, 459-470.	2.1	12
1704	Mediterranean Diet Effects on Type 2 Diabetes Prevention, Disease Progression, and Related Mechanisms. A Review. <i>Nutrients</i> , 2020, 12, 2236.	4.1	133
1705	The insulinotropic and incretin response to feeding a milk based protein matrix in healthy young women. <i>Journal of Functional Foods</i> , 2020, 72, 104056.	3.4	4

#	ARTICLE	IF	CITATIONS
1706	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3226-3233.	3.6	10
1707	Euglena Gracilis and β -Glucan Paramylon Induce Ca^{2+} Signaling in Intestinal Tract Epithelial, Immune, and Neural Cells. <i>Nutrients</i> , 2020, 12, 2293.	4.1	13
1708	Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. <i>Nutrients</i> , 2020, 12, 3304.	4.1	21
1709	β -Adrenergic Disruption of β Cell BDNF-TrkB Receptor Tyrosine Kinase Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 576396.	3.7	4
1710	Small-molecule GLP-1 secretagogues: challenges and recent advances. <i>Drug Discovery Today</i> , 2020, 25, 2023-2029.	6.4	5
1711	Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system. <i>Scientific Reports</i> , 2020, 10, 18415.	3.3	14
1712	Gut-Brain Axis in the Early Postnatal Years of Life: A Developmental Perspective. <i>Frontiers in Integrative Neuroscience</i> , 2020, 14, 44.	2.1	48
1713	A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1863-1872.	1.9	5
1714	Gut microbiota: a perspective of precision medicine in endocrine disorders. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1827-1834.	1.9	11
1715	A Combination of Apple Vinegar Drink with <i>Bacillus coagulans</i> Ameliorates High Fat Diet-Induced Body Weight Gain, Insulin Resistance and Hepatic Steatosis. <i>Nutrients</i> , 2020, 12, 2504.	4.1	15
1716	Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. <i>Frontiers in Pharmacology</i> , 2020, 11, 1270.	3.5	43
1717	Prenatal over- and undernutrition differentially program small intestinal growth, angiogenesis, absorptive capacity, and endocrine function in sheep. <i>Physiological Reports</i> , 2020, 8, e14498.	1.7	1
1718	GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. <i>Postgraduate Medicine</i> , 2020, 132, 3-14.	2.0	36
1719	The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability. <i>Cells</i> , 2020, 9, 1909.	4.1	217
1720	Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. <i>Pharmaceutics</i> , 2020, 12, 790.	4.5	23
1721	GLP-1 receptors are involved in the GLP-1 (7-36) amide-induced modulation of glucose homeostasis, emesis and feeding in <i>Suncus murinus</i> (house musk shrew). <i>European Journal of Pharmacology</i> , 2020, 888, 173528.	3.5	3
1722	Chicory root flour – A functional food with potential multiple health benefits evaluated in a mice model. <i>Journal of Functional Foods</i> , 2020, 74, 104174.	3.4	9
1723	Capsaicin improves glucose homeostasis by enhancing glucagon-like peptide-1 secretion through the regulation of bile acid metabolism via the remodeling of the gut microbiota in male mice. <i>FASEB Journal</i> , 2020, 34, 8558-8573.	0.5	25

#	ARTICLE	IF	CITATIONS
1724	Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 152-169.	1.5	55
1725	Pectin-Alginate Does Not Further Enhance Exogenous Carbohydrate Oxidation in Running. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 1376-1384.	0.4	14
1726	Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome. <i>Current Diabetes Reports</i> , 2020, 20, 26.	4.2	17
1727	GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation. <i>Cardiovascular Diabetology</i> , 2020, 19, 57.	6.8	18
1728	GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1409-F1417.	2.7	16
1729	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 34-53.	13.7	21
1730	The supramammillary nucleus controls anxiety-like behavior; key role of GLP-1R. <i>Psychoneuroendocrinology</i> , 2020, 119, 104720.	2.7	12
1731	Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics. <i>Psychoneuroendocrinology</i> , 2020, 119, 104744.	2.7	19
1732	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154295.	3.4	18
1733	Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. <i>Pharmacological Research</i> , 2020, 159, 104996.	7.1	15
1734	A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 353-362.	2.5	5
1735	The treatment of hyperglycemia in acute ischemic stroke with incretin-based drugs. <i>Pharmacological Research</i> , 2020, 160, 105018.	7.1	5
1736	GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis. <i>Obesity Surgery</i> , 2020, 30, 3561-3569.	2.1	7
1737	Dried yeast cell walls high in beta-glucan and mannan-oligosaccharides positively affect microbial composition and activity in the canine gastrointestinal tract in vitro. <i>Journal of Animal Science</i> , 2020, 98, .	0.5	23
1738	Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms. <i>Peptides</i> , 2020, 131, 170342.	2.4	45
1739	Health Benefits of Lactic Acid Bacteria (LAB) Fermentates. <i>Nutrients</i> , 2020, 12, 1679.	4.1	157
1740	In vivo studies of glucagon secretion by human islets transplanted in mice. <i>Nature Metabolism</i> , 2020, 2, 547-557.	11.9	18
1741	A Role for GLP-1 in Treating Hyperphagia and Obesity. <i>Endocrinology</i> , 2020, 161, .	2.8	52

#	ARTICLE	IF	CITATIONS
1742	Intense Sweeteners, Taste Receptors and the Gut Microbiome: A Metabolic Health Perspective. International Journal of Environmental Research and Public Health, 2020, 17, 4094.	2.6	23
1743	Extraoral Taste Receptors. , 2020, , 353-381.		1
1744	Human Sperm Express the Receptor for Glucagon-like Peptide-1 (GLP-1), Which Affects Sperm Function and Metabolism. Endocrinology, 2020, 161, .	2.8	15
1745	The AppetiteâSuppressant and GLP-1-Stimulating Effects of Whey Proteins in Obese Subjects are Associated with Increased Circulating Levels of Specific Amino Acids. Nutrients, 2020, 12, 775.	4.1	18
1746	Enteroendocrine K Cells Exert Complementary Effects to Control Bone Quality and Mass in Mice. Journal of Bone and Mineral Research, 2020, 35, 1363-1374.	2.8	12
1747	Apigenin modulates hippocampal CREB-BDNF signaling in high fat, high fructose diet-fed rats. Journal of Functional Foods, 2020, 68, 103898.	3.4	7
1748	Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies. Molecules, 2020, 25, 1093.	3.8	8
1749	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 313-324.	11.4	39
1750	Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes. Epidemiology, 2020, 31, 559-566.	2.7	3
1751	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacological Research, 2020, 160, 105052.	7.1	34
1752	Potential roles of Glucagon-like peptide-1 and its analogues in cognitive impairment associated with type 2 diabetes mellitus. Mechanisms of Ageing and Development, 2020, 190, 111294.	4.6	5
1753	Molecular link between dietary fibre, gut microbiota and health. Molecular Biology Reports, 2020, 47, 6229-6237.	2.3	115
1754	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. International Journal of Obesity, 2020, 44, 1859-1871.	3.4	25
1755	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1064-e1074.	3.6	42
1756	Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a populationâbased study. Diabetic Medicine, 2020, 37, 1157-1166.	2.3	11
1757	Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius. Physiology and Behavior, 2020, 219, 112830.	2.1	4
1758	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2020, 318, G661-G672.	3.4	27
1759	Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease. Journal of the Endocrine Society, 2020, 4, bvz034.	0.2	11

#	ARTICLE	IF	CITATIONS
1760	Towards a comprehensive theory of obesity and a healthy diet: The causal role of oxidative stress in food addiction and obesity. <i>Behavioural Brain Research</i> , 2020, 384, 112560.	2.2	53
1761	A higher level of total bile acid in early mid-pregnancy is associated with an increased risk of gestational diabetes mellitus: a prospective cohort study in Wuhan, China. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1097-1103.	3.3	10
1762	From role of gut microbiota to microbial-based therapies in type 2-diabetes. <i>Infection, Genetics and Evolution</i> , 2020, 81, 104268.	2.3	53
1763	Incretin accelerates platelet-derived growth factor-BB-induced osteoblast migration via protein kinase A: The upregulation of p38 MAP kinase. <i>Scientific Reports</i> , 2020, 10, 2341.	3.3	5
1764	Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1948-1966.e1.	1.3	84
1765	Genetically Engineered Escherichia coli Nissle 1917 Secreting GLP-1 Analog Exhibits Potential Antiobesity Effect in High-Fat Diet-Induced Obesity Mice. <i>Obesity</i> , 2020, 28, 315-322.	3.0	18
1766	Metabolic and Genetic Determinants of Glucose Shape After Oral Challenge in Obese Youths: A Longitudinal Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 534-542.	3.6	8
1767	Rapid changes in neuroendocrine regulation may contribute to reversal of type 2 diabetes after gastric bypass surgery. <i>Endocrine</i> , 2020, 67, 344-353.	2.3	20
1768	Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 938-946.	4.4	126
1769	Selective stimulation of colonic L cells improves metabolic outcomes in mice. <i>Diabetologia</i> , 2020, 63, 1396-1407.	6.3	45
1770	A glycosylated <sc>Fc</sc>-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1455-1468.	4.4	2
1771	Inhibition of Hepatic Bile Acid Uptake by Myrccludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 451-466.	4.5	15
1772	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1234-1241.	8.6	30
1773	Bile acid composition regulates GPR119-dependent intestinal lipid sensing and food intake regulation in mice. <i>Gut</i> , 2020, 69, 1620-1628.	12.1	41
1774	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 178.	3.5	137
1775	Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders?. <i>Nutrients</i> , 2020, 12, 1082.	4.1	154
1776	Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide. <i>Pharmaceutics</i> , 2020, 12, 364.	4.5	14
1777	Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. <i>Nutrients</i> , 2020, 12, 1066.	4.1	128

#	ARTICLE	IF	CITATIONS
1778	Fructo-oligosaccharides alleviate inflammation-associated apoptosis of GLP-1 secreting L cells via inhibition of iNOS and cleaved caspase-3 expression. <i>Journal of Pharmacological Sciences</i> , 2020, 143, 65-73.	2.5	10
1779	<p>Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 943-962.	2.4	38
1780	Novel Strategies to Prevent Total Parenteral Nutrition-Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901270.	3.3	14
1781	Evidence of the Physiologic Functions of the Gastrointestinal Tract as a Complex System. <i>Foundations of Science</i> , 2021, 26, 257-274.	0.7	0
1782	The altered enteroendocrine repertoire following roux-en-Y-gastric bypass as an effector of weight loss and improved glycaemic control. <i>Appetite</i> , 2021, 156, 104807.	3.7	20
1783	Guidelines for gastrostomy tube placement and enteral nutrition in patients with severe, refractory hypoglycemia after gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 456-465.	1.2	7
1784	Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 39-57.	3.6	15
1785	Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. <i>Clinical Nutrition</i> , 2021, 40, 2169-2179.	5.0	5
1786	Endocannabinoids and related lipids in serum from patients with amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2021, 63, 120-126.	2.2	3
1787	Effects of a glucagon-like peptide-1 analog on appetitive and consummatory behavior for rewarding and aversive gustatory stimuli in rats. <i>Physiology and Behavior</i> , 2021, 229, 113279.	2.1	8
1788	Expected values for gastrointestinal and pancreatic hormone concentrations in healthy volunteers in the fasting and postprandial state. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 108-116.	1.6	7
1789	Rationale for the use of metformin and exercise to counteract statin-associated side effects. <i>International Journal of Clinical Practice</i> , 2021, 75, e13900.	1.7	3
1790	GLP-2 decreases food intake in the dorsomedial hypothalamic nucleus (DMH) through Exendin (9-39) in male Sprague-Dawley (SD) rats. <i>Physiology and Behavior</i> , 2021, 229, 113253.	2.1	2
1791	Review: Glucose-sensitive insulin. <i>Molecular Metabolism</i> , 2021, 46, 101107.	6.5	29
1792	Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 697-705.	3.0	2
1793	Gut Microbiota in Patients with Morbid Obesity Before and After Bariatric Surgery: a Ten-Year Review Study (2009-2019). <i>Obesity Surgery</i> , 2021, 31, 317-326.	2.1	18
1794	GLP-1 mimetics and cognition. <i>Life Sciences</i> , 2021, 264, 118645.	4.3	32
1795	Oral Drug Delivery, Absorption and Bioavailability. , 2022, , 406-437.		3

#	ARTICLE	IF	CITATIONS
1796	Glucagon-like peptide-1 regulation by food proteins and protein hydrolysates. Nutrition Research Reviews, 2021, 34, 259-275.	4.1	12
1797	Glucagon-like peptide-1. , 2021, , 239-241.		0
1798	Liraglutide-Induced Hepatotoxicity. Biomedicines, 2021, 9, 106.	3.2	8
1799	Metabolic Messengers: glucagon-like peptide 1. Nature Metabolism, 2021, 3, 142-148.	11.9	73
1800	The infundibular peptidergic neurons and glia cells in overeating, obesity, and diabetes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 180, 315-325.	1.8	0
1801	Obesity: Medical and Surgical Treatment. , 2021, , 131-175.		0
1802	Establishment of a long-term stable Î²-cell line and its application to analyze the effect of Gcg expression on insulin secretion. Scientific Reports, 2021, 11, 477.	3.3	13
1803	The gutâ€“brain axis in vertebrates: implications for food intake regulation. Journal of Experimental Biology, 2021, 224, .	1.7	19
1804	The Emerging Role of Polyphenols in the Management of Type 2 Diabetes. Molecules, 2021, 26, 703.	3.8	37
1805	Pharmacologic gut hormone modulation and eating behavior after esophagogastric cancer surgery: a narrative review. Annals of Esophagus, 0, 4, 42-42.	0.4	0
1806	The Medullary Targets of Neurally Conveyed Sensory Information from the Rat Hepatic Portal and Superior Mesenteric Veins. ENeuro, 2021, 8, ENEURO.0419-20.2021.	1.9	12
1807	A Review of Coumarins and Coumarin-Related Compounds for Their Potential Antidiabetic Effect. Clinical Medicine Insights: Endocrinology and Diabetes, 2021, 14, 117955142110420.	1.9	13
1808	Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-based gene delivery platform. Molecular Psychiatry, 2021, 26, 5266-5276.	7.9	5
1809	Voluntary physical activity protects against olanzapine-induced hyperglycemia. Journal of Applied Physiology, 2021, 130, 466-478.	2.5	4
1810	Association of Gut Hormones and Microbiota with Vascular Dysfunction in Obesity. Nutrients, 2021, 13, 613.	4.1	16
1811	Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot doseâ€“ranging study. Diabetes, Obesity and Metabolism, 2021, 23, 1311-1321.	4.4	19
1812	The effect of acute consumption of resistant starch on appetite in healthy adults; a systematic review and meta-analysis of the controlled clinical trials. Clinical Nutrition ESPEN, 2021, 41, 42-48.	1.2	12
1813	Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids. Pharmaceuticals, 2021, 14, 144.	3.8	22

#	ARTICLE	IF	CITATIONS
1814	Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?. <i>Nutrients</i> , 2021, 13, 762.	4.1	33
1815	Monitoring In Vivo Neural Activity to Understand Gut-Brain Signaling. <i>Endocrinology</i> , 2021, 162, .	2.8	11
1816	Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1. <i>Pharmaceutics</i> , 2021, 13, 263.	4.5	2
1817	FXR-mediated epigenetic regulation of GLP-1R expression contributes to enhanced incretin effect in diabetes after RYGB. <i>Journal of Cellular and Molecular Medicine</i> , 2021, , .	3.6	7
1818	Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 565-573.	2.4	14
1819	Acute hyperglycaemia enhances both vascular endothelial function and cardiac and skeletal muscle microvascular function in healthy humans. <i>Journal of Physiology</i> , 2022, 600, 949-962.	2.9	9
1820	Electronic Bypass for Diabetes: Optimization of Stimulation Parameters and Mechanisms of Glucagon-Like Peptide-1. <i>Neuromodulation</i> , 2022, 25, 1097-1105.	0.8	5
1821	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. <i>Diabetes</i> , 2021, 70, 1347-1356.	0.6	9
1822	Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120317.	5.2	7
1823	Glucagon-like peptide-1 control of GnRH secretion in female sheep. <i>Journal of Endocrinology</i> , 2021, 248, 325-335.	2.6	8
1824	Nutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications. <i>Frontiers in Endocrinology</i> , 2021, 12, 622901.	3.5	16
1825	The Role of Incretins on Insulin Function and Glucose Homeostasis. <i>Endocrinology</i> , 2021, 162, .	2.8	43
1826	Comparative Effects of Intragastric and Intraduodenal Administration of Quinine on the Plasma Glucose Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory Hormones and Gastric Emptying. <i>Journal of Nutrition</i> , 2021, 151, 1453-1461.	2.9	11
1827	Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3479-3492.	6.4	2
1828	Glucagon Shows Higher Sensitivity than Insulin to Grapeseed Proanthocyanidin Extract (GSPE) Treatment in Cafeteria-Fed Rats. <i>Nutrients</i> , 2021, 13, 1084.	4.1	4
1829	Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial. <i>Obesity Science and Practice</i> , 2021, 7, 281-290.	1.9	9
1830	Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00234.	2.4	3
1831	Clinical Impact of Liraglutide as a Treatment of Obesity. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 53-60.	1.2	21

#	ARTICLE	IF	CITATIONS
1832	The effects of Glucagon Like Peptide-1 (GLP-1) on cardiac remodelling: exploring the role of medication and physiological modulation after metabolic surgery: a narrative review. <i>Minerva Endocrinology</i> , 2021, , .	1.1	2
1833	Gut Microbiota and Obesity in Adults and Children: The State of the Art. <i>Frontiers in Pediatrics</i> , 2021, 9, 657020.	1.9	31
1834	Discovery of small molecule positive allosteric modulators of the secretin receptor. <i>Biochemical Pharmacology</i> , 2021, 185, 114451.	4.4	7
1835	POTENTIAL ROLE OF GLP-1 RECEPTOR AGONIST IN A RAT MODEL OF CARDIO-RENAL SYNDROME TYPE-3: EFFECTS ON OXIDATIVE, INFLAMMATORY AND INOS EXPRESSION AXIS. <i>Ain Shams Medical Journal</i> , 2021, 72, 1-28.	0.1	1
1836	Decreased expression of the GLP-1 receptor after segmental artery injury in mice. <i>Journal of Endocrinology</i> , 2021, 248, 289-301.	2.6	5
1837	Gut Feeding the Brain: <i>Drosophila</i> Gut an Animal Model for Medicine to Understand Mechanisms Mediating Food Preferences. , 0, , .		3
1838	PROBIOTICS AND PREBIOTICS IN THE PREVENTION OF GASTROINTESTINAL ADVERSE REACTIONS RELATED TO DIABETES MELLITUS. <i>Farmacia</i> , 2021, 69, 215-218.	0.4	3
1839	Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 632335.	3.5	63
1840	Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions. <i>Current Protein and Peptide Science</i> , 2021, 22, 4-18.	1.4	9
1841	The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. <i>Molecular Metabolism</i> , 2021, 46, 101175.	6.5	29
1842	Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108614.	3.2	16
1843	Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. <i>Journal of Translational Medicine</i> , 2021, 19, 137.	4.4	41
1844	CD36 Senses Dietary Lipids and Regulates Lipids Homeostasis in the Intestine. <i>Frontiers in Physiology</i> , 2021, 12, 669279.	2.8	19
1845	GLP-1 and Intestinal Diseases. <i>Biomedicines</i> , 2021, 9, 383.	3.2	20
1847	Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002083.	2.8	2
1848	Diabetes and Its Complications: Therapies Available, Anticipated and Aspired. <i>Current Diabetes Reviews</i> , 2021, 17, 397-420.	1.3	6
1849	Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy. <i>Current Medicinal Chemistry</i> , 2021, 28, 1003-1024.	2.4	4
1850	Effects of Bitter Substances on GI Function, Energy Intake and Glycaemia-Do Preclinical Findings Translate to Outcomes in Humans?. <i>Nutrients</i> , 2021, 13, 1317.	4.1	8

#	ARTICLE	IF	CITATIONS
1851	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 78.	5.2	82
1852	Effect of Obesity on the Expression of Nutrient Receptors and Satiety Hormones in the Human Colon. <i>Nutrients</i> , 2021, 13, 1271.	4.1	8
1853	Central serotonin participates in the anorexigenic effect of GLP-1 in rainbow trout (<i>Oncorhynchus</i>) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.8	6
1854	The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 803-815.	2.4	1
1855	The Influence of Anti-Diabetic Drugs on Prostate Cancer. <i>Cancers</i> , 2021, 13, 1827.	3.7	12
1856	Combination of Î±-Glycosyl-Isoquercitrin and Soybean Fiber Promotes Quercetin Bioavailability and Glucagon-like Peptide-1 Secretion and Improves Glucose Homeostasis in Rats Fed a High-Fat High-Sucrose Diet. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 5907-5916.	5.2	6
1857	GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase/c-Jun N-terminal kinase pathway. <i>Archives of Biochemistry and Biophysics</i> , 2021, 703, 108851.	3.0	3
1858	The physiological basis of insulin therapy in people with diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108839.	2.8	8
1859	The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. <i>Frontiers in Endocrinology</i> , 2021, 12, 678055.	3.5	32
1860	Role of enteroendocrine hormones in appetite and glycemia. <i>Obesity Medicine</i> , 2021, 23, 100332.	0.9	7
1861	Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. <i>Pediatric Obesity</i> , 2021, 16, e12799.	2.8	6
1862	Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. <i>Basic Research in Cardiology</i> , 2021, 116, 32.	5.9	32
1863	Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab084.	0.2	18
1864	Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154728.	3.4	6
1865	Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. <i>Pharmacological Reports</i> , 2021, 73, 1020-1032.	3.3	23
1866	Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus. <i>Obesity Medicine</i> , 2021, 23, 100329.	0.9	7
1867	MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. <i>European Journal of Endocrinology</i> , 2021, 184, R193-R205.	3.7	14
1868	Melanocortin receptor-4 mediates the anorectic effect induced by the nucleus tractus solitarius injection of glucagon-like Peptide-2 in fasted rats. <i>European Journal of Pharmacology</i> , 2021, 901, 174072.	3.5	3

#	ARTICLE	IF	CITATIONS
1869	Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review. <i>Advances in Nutrition</i> , 2021, 12, 2540-2552.	6.4	10
1870	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. <i>Transplant International</i> , 2021, 34, 1341-1359.	1.6	9
1871	A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers. <i>Hormone and Metabolic Research</i> , 2021, 53, 402-407.	1.5	5
1872	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.8	4
1873	Peptidomics of enteroendocrine cells and characterisation of potential effects of a novel preprogastrin derived-peptide on glucose tolerance in lean mice. <i>Peptides</i> , 2021, 140, 170532.	2.4	7
1874	A 2021 Update on the Use of Liraglutide in the Modern Treatment of "Diabetes": A Narrative Review. <i>Medicina (Lithuania)</i> , 2021, 57, 669.	2.0	14
1875	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. <i>Frontiers in Endocrinology</i> , 2021, 12, 694284.	3.5	22
1876	Mutational Landscape of the Proglucagon-Derived Peptides. <i>Frontiers in Endocrinology</i> , 2021, 12, 698511.	3.5	7
1877	Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?. <i>Frontiers in Endocrinology</i> , 2021, 12, 639856.	3.5	29
1878	Obesity-related gut hormones and cancer: novel insight into the pathophysiology. <i>International Journal of Obesity</i> , 2021, 45, 1886-1898.	3.4	8
1879	An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2955-2972.	2.4	8
1880	Latest developments in tryptophan metabolism: Understanding its role in B cell immunity. <i>Cytokine and Growth Factor Reviews</i> , 2021, 59, 111-117.	7.2	12
1881	Alliances of the gut and bone axis. <i>Seminars in Cell and Developmental Biology</i> , 2022, 123, 74-81.	5.0	16
1882	The Role of Gasotransmitters in Gut Peptide Actions. <i>Frontiers in Pharmacology</i> , 2021, 12, 720703.	3.5	18
1883	Anti-Obesity Effect of Fermented Panax notoginseng Is Mediated Via Modulation of Appetite and Gut Microbial Population. <i>Frontiers in Pharmacology</i> , 2021, 12, 665881.	3.5	9
1884	GLP-1 Receptor: A New Target for Sepsis. <i>Frontiers in Pharmacology</i> , 2021, 12, 706908.	3.5	11
1885	Altered islet prohormone processing: a cause or consequence of diabetes?. <i>Physiological Reviews</i> , 2022, 102, 155-208.	28.8	15
1886	Are the Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A Critical Review of the Literature. <i>Obesity Surgery</i> , 2021, 31, 4575-4584.	2.1	9

#	ARTICLE	IF	CITATIONS
1887	Intestinal MYC modulates obesity-related metabolic dysfunction. <i>Nature Metabolism</i> , 2021, 3, 923-939.	11.9	27
1888	Thermo-Responsive self-assembly of a dual glucagon-like peptide and glucagon receptor agonist. <i>International Journal of Pharmaceutics</i> , 2021, 604, 120719.	5.2	1
1889	Increased of fasting active glucagon-like peptide-1 is associated with insulin resistance in patients with hypertriglyceridemia. <i>International Journal of Diabetes in Developing Countries</i> , 0, , 1.	0.8	1
1890	Effect of L-tryptophan on intestinal glucagon like peptide-1 (GLP-1) in streptozotocin (stz) induced diabetic rat model. <i>Biomedicine (India)</i> , 2021, 41, 194-198.	0.2	1
1891	A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats. <i>Neuropharmacology</i> , 2021, 192, 108599.	4.1	15
1892	How glucagon-like peptide 1 receptor agonists work. <i>Endocrine Connections</i> , 2021, 10, R200-R212.	1.9	17
1893	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021, 12, 645563.	3.5	66
1894	Fluid intake, what's dopamine got to do with it?. <i>Physiology and Behavior</i> , 2021, 236, 113418.	2.1	2
1895	Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice. <i>Frontiers in Pharmacology</i> , 2021, 12, 694476.	3.5	5
1896	Regulation of β -cell glucagon secretion: The role of second messengers. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 7-18.	1.2	5
1897	Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. <i>Journal of Headache and Pain</i> , 2021, 22, 86.	6.0	22
1898	Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy. <i>Pharmaceutics</i> , 2021, 13, 1320.	4.5	30
1899	A Holistic Assessment of Polyethylene Fiber Ingestion in Larval and Juvenile Japanese Medaka Fish. <i>Frontiers in Physiology</i> , 2021, 12, 668645.	2.8	6
1900	Genistein and <i>Momordica charantia</i> L. prevent oxidative stress and upregulate proglucagon and insulin receptor mRNA in diabetic rats. <i>Applied Physiology, Nutrition and Metabolism</i> , 2022, 47, 41-50.	1.9	2
1901	Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium. <i>British Journal of Nutrition</i> , 2022, 128, 55-63.	2.3	1
1902	A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3567-3602.	2.4	146
1903	The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes. <i>Obesity Surgery</i> , 2021, 31, 4376-4385.	2.1	4
1904	Relationships Between Telomere Length, Plasma Glucagon-like Peptide 1, and Insulin in Early-Life Stress-Exposed Nonhuman Primates. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 54-60.	2.2	9

#	ARTICLE	IF	CITATIONS
1905	Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. <i>British Journal of Pharmacology</i> , 2022, 179, 557-570.	5.4	46
1906	Levels of glucagon-like peptide 1 in hyperemesis gravidarum. <i>Interventional Medicine & Applied Science</i> , 2021, 11, 213-215.	0.2	0
1907	Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 621-636.	12.0	11
1908	L-Cell Expression of Melanocortin-4-Receptor Is Marginal in Most of the Small Intestine in Mice and Humans and Direct Stimulation of Small Intestinal Melanocortin-4-Receptors in Mice and Rats Does Not Affect GLP-1 Secretion. <i>Frontiers in Endocrinology</i> , 2021, 12, 690387.	3.5	2
1909	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. <i>Journal of Clinical Medicine</i> , 2021, 10, 3783.	2.4	21
1910	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single-Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1329-1336.	4.7	11
1911	Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Drug Research</i> , 2021, 71, 477-488.	1.7	7
1912	Actions of glucagon-like peptide-1 receptor ligands in the gut. <i>British Journal of Pharmacology</i> , 2022, 179, 727-742.	5.4	22
1913	The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review. <i>Vascular Medicine</i> , 2021, , 1358863X2110345.	1.5	4
1914	Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. <i>Nutrients</i> , 2021, 13, 2826.	4.1	9
1915	Effective oral delivery of Exenatide-Zn ²⁺ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy. <i>Biomaterials</i> , 2021, 275, 120944.	11.4	16
1916	GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies. <i>PLoS ONE</i> , 2021, 16, e0255726.	2.5	8
1917	Enzymatically-Synthesized Glycogen Induces Cecal Glucagon-Like Peptide-1 Production and Suppresses Food Intake in Mice. <i>Journal of Nutritional Science and Vitaminology</i> , 2021, 67, 217-224.	0.6	0
1918	Coffee consumption and cardiovascular diseases and mortality in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2526-2538.	2.6	22
1919	A primer on obesity-related cardiomyopathy. <i>Physiological Reviews</i> , 2022, 102, 1-6.	28.8	9
1920	Treatment of type 2 diabetes in children: what are the specific considerations?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-15.	1.8	5
1921	Future perspectives in diabetes treatment: Semaglutide, a glucagon-like peptide-1 receptor agonist (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1167.	1.8	7
1922	Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis. <i>Current Drug Targets</i> , 2022, 23, 311-327.	2.1	1

#	ARTICLE	IF	CITATIONS
1923	Toward Precise Nutrient Value of Feed in Growing Pigs: Effect of Meal Size, Frequency and Dietary Fibre on Nutrient Utilisation. <i>Animals</i> , 2021, 11, 2598.	2.3	12
1924	Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. <i>British Journal of Pharmacology</i> , 2022, 179, 542-556.	5.4	19
1925	The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. <i>British Journal of Pharmacology</i> , 2022, 179, 625-641.	5.4	37
1926	<i>Escherichia coli</i> small molecule metabolism at the host-microorganism interface. <i>Nature Chemical Biology</i> , 2021, 17, 1016-1026.	8.0	11
1927	Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021, 30, 233-247.	3.6	3
1928	Signaling Pathways Associated with Metabolites of Dietary Fibers Link to Host Health. , 0, , .		0
1929	Pre- and Post-Conditioning of the Heart: An Overview of Cardioprotective Signaling Pathways. <i>Current Vascular Pharmacology</i> , 2021, 19, 499-524.	1.7	14
1930	Unveiling the Metabolic Effects of Glycomacropeptide. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9731.	4.1	1
1931	Understanding the place for <scp>GLP-1 RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 40-52.	4.4	17
1933	Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. <i>Psychiatry Research</i> , 2021, 306, 114227.	3.3	2
1934	The physiological control of eating: signals, neurons, and networks. <i>Physiological Reviews</i> , 2022, 102, 689-813.	28.8	60
1935	Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 461-477.	2.6	36
1936	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 212-220.	4.4	4
1937	Signaling pathways and proteins targeted by antidiabetic chalcones. <i>Life Sciences</i> , 2021, 284, 118982.	4.3	11
1938	Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats. <i>Frontiers in Endocrinology</i> , 2020, 11, 598843.	3.5	10
1939	Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells. <i>Nature Communications</i> , 2021, 12, 110.	12.8	27
1941	Co-ingestion of NUTRALYSÂ® pea protein and a high-carbohydrate beverage influences the glycaemic, insulinaemic, glucose-dependent insulintropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses: preliminary results of a randomised controlled trial. <i>European Journal of Nutrition</i> , 2021, 60, 3085-3093.	3.9	5
1942	The Vagus Nerve and Ghrelin Function. <i>Receptors</i> , 2014, , 53-61.	0.2	3

#	ARTICLE	IF	CITATIONS
1943	Porcine Ex Vivo Intestinal Segment Model. , 2015, , 255-262.		10
1944	The Conventional Gastric Bypass. , 2012, , 217-226.		1
1945	Repurposing GLP1 agonists for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 91-112.	2.0	7
1946	Dairy-derived peptides for satiety. Journal of Functional Foods, 2020, 66, 103801.	3.4	30
1947	PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice. Molecular Metabolism, 2020, 39, 101024.	6.5	20
1948	SGLT inhibitors as antidiabetic agents: a comprehensive review. RSC Advances, 2020, 10, 1733-1756.	3.6	20
1949	AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Bioscience Reports, 2019, 39, .	2.4	43
1950	Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure. Clinical Science, 2020, 134, 1081-1094.	4.3	7
1951	Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by μ -opioid receptor stimulation of the nucleus accumbens in the rat. NeuroReport, 2020, 31, 1283-1288.	1.2	9
1957	Pancreatic \hat{I}^2 -Cell Electrical Activity and Insulin Secretion: Of Mice and Men. Physiological Reviews, 2018, 98, 117-214.	28.8	497
1958	Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia. JCI Insight, 2020, 5, .	5.0	39
1959	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight, 2018, 3, .	5.0	86
1960	Dynamics of insulin secretion and the clinical implications for obesity and diabetes. Journal of Clinical Investigation, 2011, 121, 2118-2125.	8.2	290
1961	Lipotoxicity disrupts incretin-regulated human \hat{I}^2 cell connectivity. Journal of Clinical Investigation, 2013, 123, 4182-4194.	8.2	203
1962	GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. Journal of Clinical Investigation, 2015, 125, 4714-4728.	8.2	145
1963	Nonclassical Islet Peptides: Pancreatic and Extrapankreatic Actions. Clinical Medicine Insights: Endocrinology and Diabetes, 2019, 12, 117955141988887.	1.9	12
1964	Using a Reporter Mouse to Map Known and Novel Sites of GLP-1 Receptor Expression in Peripheral Tissues of Male Mice. Endocrinology, 2021, 162, .	2.8	33
1965	Recent advances in understanding the role of glucagon-like peptide 1. F1000Research, 2020, 9, 239.	1.6	33

#	ARTICLE	IF	CITATIONS
1966	Mathematical Modeling of Interacting Glucose-Sensing Mechanisms and Electrical Activity Underlying Glucagon-Like Peptide 1 Secretion. PLoS Computational Biology, 2015, 11, e1004600.	3.2	9
1967	Effects of Pre-Meal Drinks with Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal. PLoS ONE, 2012, 7, e44731.	2.5	61
1968	Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9â€³36 Amide at the GLP-1 Receptor. PLoS ONE, 2012, 7, e47936.	2.5	30
1969	Hypertrophy Dependent Doubling of L-Cells in Roux-en-Y Gastric Bypass Operated Rats. PLoS ONE, 2013, 8, e65696.	2.5	98
1970	The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice. PLoS ONE, 2013, 8, e77284.	2.5	94
1971	Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress. PLoS ONE, 2014, 9, e101005.	2.5	74
1972	Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury. PLoS ONE, 2015, 10, e0120074.	2.5	41
1973	The GLP-1 Receptor Agonist Exendin-4 and Diazepam Differentially Regulate GABAA Receptor-Mediated Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons. PLoS ONE, 2015, 10, e0124765.	2.5	21
1974	Soluble Fermentable Dietary Fibre (Pectin) Decreases Caloric Intake, Adiposity and Lipidaemia in High-Fat Diet-Induced Obese Rats. PLoS ONE, 2015, 10, e0140392.	2.5	45
1975	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. PLoS ONE, 2016, 11, e0154727.	2.5	7
1976	Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats. PLoS ONE, 2016, 11, e0162733.	2.5	22
1977	Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. PLoS ONE, 2017, 12, e0169469.	2.5	35
1978	Effect of Helicobacter pylori infection on the link between GLP-1 expression and motility of the gastrointestinal tract. PLoS ONE, 2017, 12, e0177232.	2.5	11
1979	Essential roles of aspartate aminotransferase 1 and vesicular glutamate transporters in Î²-cell glutamate signaling for incretin-induced insulin secretion. PLoS ONE, 2017, 12, e0187213.	2.5	15
1980	The incretin system in type 2 diabetes mellitus: cardiovascular effects. Problemy Endokrinologii, 2012, 58, 33-42.	0.8	2
1981	Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus. Journal of Clinical Medicine Research, 2017, 9, 745-753.	1.2	30
1982	Postprandial Reactive Hypoglycemia. Sisli Etfal Hastanesi Tip Bulteni, 2019, 53, 215-220.	0.3	18
1983	Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men. Endocrine Connections, 2019, 8, 1607-1617.	1.9	5

#	ARTICLE	IF	CITATIONS
1984	Stat3-mTOR signaling mediates the stimulation of GLP-1 production induced by IL-27. <i>Journal of Molecular Endocrinology</i> , 2019, 63, 215-226.	2.5	2
1985	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. <i>Journal of Endocrinology</i> , 2020, 246, R65-R74.	2.6	18
1986	The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2018, 33, 114-123.	0.2	2
1987	Hypothyroidism decreases proinsulin gene expression and the attachment of its mRNA and eEF1A protein to the actin cytoskeleton of INS-1E cells. <i>Brazilian Journal of Medical and Biological Research</i> , 2011, 44, 1060-1067.	1.5	4
1988	Nutrient-mediated modulation of incretin gene expression: a systematic review. <i>Nutricion Hospitalaria</i> , 2012, 27, 46-53.	0.3	10
1989	Do glucagonomas always produce glucagon?. <i>Bosnian Journal of Basic Medical Sciences</i> , 2016, 16, 1-7.	1.0	14
1990	Gliptin Therapies for Inhibiting Dipeptidyl Peptidase-4 in Type 2 Diabetes. <i>European Endocrinology</i> , 2010, 6, 19.	1.5	16
1991	Sitagliptin attenuates high glucose-induced alterations in migration, proliferation, calcification and apoptosis of vascular smooth muscle cells through ERK1/2 signal pathway. <i>Oncotarget</i> , 2017, 8, 77168-77180.	1.8	15
1992	Liraglutide activates autophagy via GLP-1R to improve functional recovery after spinal cord injury. <i>Oncotarget</i> , 2017, 8, 85949-85968.	1.8	24
1993	Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection. <i>Oncotarget</i> , 2019, 10, 216-244.	1.8	37
1994	Physiology of Incretins in Health and Disease. <i>Review of Diabetic Studies</i> , 2011, 8, 293-306.	1.3	103
1995	Therapy for Obesity Based on Gastrointestinal Hormones. <i>Review of Diabetic Studies</i> , 2011, 8, 339-347.	1.3	9
1996	The Alpha-Cell as Target for Type 2 Diabetes Therapy. <i>Review of Diabetic Studies</i> , 2011, 8, 369-381.	1.3	49
1997	Long-acting glucagon-like peptide-1 receptor agonist status December 2018. <i>Annals of Translational Medicine</i> , 2019, 7, 83-83.	1.7	11
1998	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 263.	2.4	10
1999	Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. <i>Clinical Pharmacokinetics</i> , 2012, 51, 501-514.	3.5	14
2000	Synthesis of Drugs and Biorelevant N-heterocycles Employing Recent Advances in C-N Bond Formation. <i>Current Organic Chemistry</i> , 2020, 24, 2293-2340.	1.6	1
2001	The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome. <i>Current Drug Metabolism</i> , 2019, 20, 15-22.	1.2	10

#	ARTICLE	IF	CITATIONS
2002	Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.. Current Molecular Medicine, 2015, 15, 905-931.	1.3	3
2003	Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm â€œ What Does the Evidence Show?. Current Vascular Pharmacology, 2019, 17, 432-439.	1.7	5
2004	GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. Current Diabetes Reviews, 2020, 16, 279-292.	1.3	7
2005	A Proficient Approach to the Production of Therapeutic Glucagon-Like Peptide-1 (GLP-1) in Transgenic Plants. Open Biotechnology Journal, 2009, 3, 57-66.	1.2	11
2006	Gastric Emptying Time after Laparoscopic Sleeve Gastrectomy. International Journal of Current Research in Medical Sciences, 2018, 4, 8-13.	0.2	3
2007	Effects of Exercise on Appetite and Food Intake Regulation. Medicina Sportiva, 2009, 13, 82-94.	0.3	39
2009	No Change in Serum Incretins Levels but Rise of Leptin Levels After Smoking Cessation: a Pilot Study. Physiological Research, 2016, 65, 651-659.	0.9	9
2010	The Effect of Glucose When Added to a Fat Load on the Response of Glucagon-Like Peptide-1 (GLP-1) and Apolipoprotein B-48 in the Postprandial Phase. Physiological Research, 2015, 64, S363-S369.	0.9	1
2011	Glucagon-Like Peptide-1 Analogues Exenatide and Liraglutide Exert Inhibitory Effect on the Early Phase of Liver Regeneration After Partial Hepatectomy in Rats. Physiological Research, 2017, 66, 833-844.	0.9	3
2012	Increased Intestinal Permeability in Patients With Short Bowel Syndrome is not Affected by Parenteral Nutrition. Physiological Research, 2019, 68, 817-825.	0.9	2
2013	Dietary Mannoheptulose Increases Fasting Serum Glucagon Like Peptide-1 and Post-Prandial Serum Ghrelin Concentrations in Adult Beagle Dogs. Animals, 2015, 5, 442-454.	2.3	9
2014	Uncoupling protein 2 regulates glucagon-like peptide-1 secretion in L-cells. World Journal of Gastroenterology, 2012, 18, 3451.	3.3	9
2015	Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World Journal of Gastroenterology, 2014, 20, 2653.	3.3	25
2016	In vitro and in vivo Antidiabetic and Antiglycation Properties of Apium graveolens in Type 1 and 2 Diabetic Rat. International Journal of Pharmacology, 2014, 10, 368-379.	0.3	10
2017	Proximate and Chemical Analysis of Gluten-free Enriched, Resistant Starch Type 3 from Maranta arundinacea Flour and its Potential as a Functional Food. Pakistan Journal of Nutrition, 2017, 16, 322-330.	0.2	8
2018	Effect of International and Indonesian Fast Foods on Plasma Ghrelin and Glucagon Like Peptide-1 (GLP-1) Levels, Hunger and Satiety Scores is Similar in Obese Adults. Pakistan Journal of Nutrition, 2016, 16, 38-44.	0.2	1
2021	Effects of alogliptin benzoate in hemodialysis patients with diabetes. Nihon Toseki Igakkai Zasshi, 2011, 45, 49-57.	0.1	1
2022	Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia. Journal of Family Medicine and Primary Care, 2019, 8, 1919.	0.9	6

#	ARTICLE	IF	CITATIONS
2023	Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection. Journal of Steroids & Hormonal Science, 2015, 06, .	0.1	3
2024	Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clinical & Experimental Pharmacology, 2013, 03, .	0.3	11
2025	Population Pharmacokinetics of Lixisenatide, a Once- Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes. Journal of Pharmaceutics & Drug Delivery Research, 2013, 02, .	0.0	5
2026	Grape Pomace Aqueous Extract (GPE) Prevents High Fat Diet-Induced Diabetes and Attenuates Systemic Inflammation. Food and Nutrition Sciences (Print), 2016, 07, 647-660.	0.4	5
2027	Liraglutide as Add-on to Oral Antidiabetic Agents or Insulin in Routine Practice of Patients with Type 2 Diabetes. Journal of Diabetes Mellitus, 2014, 04, 148-154.	0.3	1
2028	Incretin manipulation in diabetes management. World Journal of Diabetes, 2015, 6, 774.	3.5	8
2029	Postprandial Hypoglycemia: An Unusual Presentation for Insulinoma. Turkish Journal of Endocrinology and Metabolism, 2016, 20, 22-25.	0.5	2
2030	Sustained Effect of Isomaltulose on Satiety in Rats. Nihon EiyÅ•ShokuryÅ•Gakkai Shi = Nippon EiyÅ•ShokuryÅ•Gakkaishi = Journal of Japanese Society of Nutrition and Food Science, 2013, 66, 301-307.	0.2	3
2031	Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes. BMB Reports, 2013, 46, 606-610.	2.4	14
2032	Remission of Type 2 Diabetes Mellitus by Ileal Interposition with Sleeve gastrectomy. International Journal of Endocrinology and Metabolism, 2012, 9, 374-381.	1.0	9
2033	Equine glucagon-like peptide-1 receptor physiology. PeerJ, 2018, 6, e4316.	2.0	12
2034	Association of rs7903146, rs12255372, and rs290487 Polymorphisms in TCF7L2 Gene with Type 2 Diabetes in an Iranian Kurdish Ethnic Group. Clinical Laboratory, 2014, 60, 1269-76.	0.5	28
2035	Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clinical Medicine Insights: Endocrinology and Diabetes, 2021, 14, 117955142110516.	1.9	6
2036	The positive effects and underlying mechanisms of <i>Undaria pinnatifida</i> polysaccharides on type 2 diabetes mellitus in rats. Food and Function, 2021, 12, 11898-11912.	4.6	23
2037	Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Seminars in Nephrology, 2021, 41, 331-348.	1.6	3
2039	Modulation of Adipocyte Metabolism by Microbial Short-Chain Fatty Acids. Nutrients, 2021, 13, 3666.	4.1	23
2040	A pilot study about the development and characterization of a Roux en Y gastric bypass model in obese Yucatan minipigs. Scientific Reports, 2021, 11, 20190.	3.3	1
2041	A comprehensive review of the neuroscience of ingestion: the physiological control of eating: signals, neurons, and networks. Physiological Reviews, 2022, 102, 319-322.	28.8	0

#	ARTICLE	IF	CITATIONS
2042	Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus. <i>Inflammopharmacology</i> , 2021, 29, 1625-1639.	3.9	5
2043	Gut-microbiota derived bioactive metabolites and their functions in host physiology. <i>Biotechnology and Genetic Engineering Reviews</i> , 2021, 37, 105-153.	6.2	18
2044	Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1. <i>European Journal of Neuroscience</i> , 2021, 54, 7749-7769.	2.6	7
2045	FTO and PLAG1 Genes Expression and FTO Methylation Predict Changes in Circulating Levels of Adipokines and Gastrointestinal Peptides in Children. <i>Nutrients</i> , 2021, 13, 3585.	4.1	6
2046	GLP-1: 10-year follow-up after Roux-en-Y gastric bypass. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	1.9	3
2047	A phase 1 multiple-ascending dose study of tirzepatide in <scp>Japanese</scp> participants with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 239-246.	4.4	29
2048	Characteristics of the Gut Microbiota and Potential Effects of Probiotic Supplements in Individuals with Type 2 Diabetes mellitus. <i>Foods</i> , 2021, 10, 2528.	4.3	9
2049	Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway. <i>Biochemistry and Cell Biology</i> , 2022, 100, 9-16.	2.0	11
2050	The Modulation of Gut Microbiota Composition in the Pathophysiology of Gestational Diabetes Mellitus: A Systematic Review. <i>Biology</i> , 2021, 10, 1027.	2.8	12
2051	Dipeptidyl Peptidase-4 Inhibition â€“ Advances in our Understanding of Diabetes Management. <i>European Endocrinology</i> , 2008, 4, 47.	1.5	0
2052	Extension of the group of incretin-targeted preparations: Saxagliptin â€“ a new dipeptidyl peptidase-4 inhibitor. <i>Problemy Endokrinologii</i> , 2010, 56, 52-60.	0.8	0
2053	Endocrine graft function after pancreas transplantation. <i>Suizo</i> , 2011, 26, 161-168.	0.1	0
2054	Glucagon-like peptide-1 alleviating peripheral neuropathy in diabetic patients: advance in mechanism. <i>Academic Journal of Second Military Medical University</i> , 2011, 31, 329-333.	0.0	0
2056	Hormones and Gastrointestinal Function. , 2012, , 281-289.		0
2057	Bariatric Surgery on Obese Type 2 Diabetes Patients. , 0, , .		0
2058	L'Intestin mÃ©tabolique : dualitÃ© fonctionnelle des incrÃ©tines et de la flore intestinale. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2013, 197, 79-92.	0.0	0
2059	Anti-obesity drugs currently used and new compounds in clinical development. <i>World Journal of Meta-analysis</i> , 2014, 2, 135.	0.1	1
2061	Pancreatic Glucagon-Like Peptide 1: What is known?. <i>Journal of Diabetes & Metabolism</i> , 2014, 05, .	0.2	0

#	ARTICLE	IF	CITATIONS
2062	The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients. Journal of Diabetes Mellitus, 2014, 04, 334-340.	0.3	0
2063	Molecular Basis of cAMP Signaling in Pancreatic Beta Cells. , 2014, , 1-36.		0
2064	Molecular Basis of cAMP Signaling in Pancreatic Beta Cells. , 2014, , 1-35.		0
2065	Glucagon-like Peptide-1 Suppresses the Proliferation and Migration of Vascular Smooth Muscle Cells: Implications for Preventive Effects on Atherosclerosis. The Showa University Journal of Medical Sciences, 2014, 26, 191-199.	0.1	0
2066	Gut Peptides. , 2014, , 37-55.		0
2067	Molecular Basis of cAMP Signaling in Pancreatic Î² Cells. , 2015, , 565-603.		2
2069	Neural regulation of hindlimb muscle contraction-induced glucagon-like peptide-1 and peptide YY secretion in rats. The Journal of Physical Fitness and Sports Medicine, 2015, 4, 125-131.	0.3	1
2070	Hunger and Satiation. , 2015, , .		0
2071	The Endocrine Regulation of Energy and Body Weight. Endocrinology, 2016, , 1-22.	0.1	0
2072	GLP-1. , 2016, , 1-9.		0
2073	GLP-1R. , 2016, , 1-12.		0
2074	Forkhead Box Protein O. , 2016, , 1-16.		0
2075	Incretin hormones as a target for therapy. , 2016, , 11-30.		0
2076	Hormones and Gastrointestinal Function of Newborns. , 2016, , 1-20.		1
2077	Metabolic and Psychological Restricts of Nutrition Correction in Overweight Children. ZdorovĚie Rebenka, 2016, .	0.2	0
2078	Does Bariatric Surgery Improve Obesity Associated Comorbid Conditions. Advances in Experimental Medicine and Biology, 2017, 960, 545-570.	1.6	3
2079	Prevention Effects of Cacao Polyphenols on Metabolic Syndrome. Oleoscience, 2017, 17, 467-474.	0.0	0
2080	Bile Acids and Metabolic Syndrome. , 2017, , 193-209.		0

#	ARTICLE	IF	CITATIONS
2081	Surgical management of diabetes mellitus: future outlook. Endoscopic Surgery, 2017, 23, 46.	0.2	0
2082	Surgical management of diabetes mellitus: future outlook (part 3). Endoscopic Surgery, 2017, 23, 54.	0.2	0
2083	Use of a Nebulizer to Deliver High Frequency High Flow with a Nasal Cannula. Academic Journal of Pediatrics & Neonatology, 2017, 3, .	0.1	0
2084	PANCREATIC ALPHA CELL DYSFUNCTION IN DIABETES MELLITUS AND ITS MANAGEMENT STRATEGIES. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 2775-2782.	0.0	0
2086	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes Mellitus, 2017, 20, 286-298.	1.9	4
2087	Neuroendocrinology of Energy Homeostasis. Endocrinology, 2018, , 1-24.	0.1	0
2088	Beginning With Very Low Dose (0.2mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice. Journal of Diabetes, Metabolic Disorders & Control, 2017, 4, .	0.1	1
2089	GLP-1. , 2018, , 1-9.		0
2090	The Endocrine Regulation of Energy and Body Weight. Endocrinology, 2018, , 589-610.	0.1	0
2093	GLP-1R. , 2018, , 2106-2117.		0
2094	GLP-1. , 2018, , 2098-2106.		0
2095	Forkhead Box Protein O. , 2018, , 1821-1836.		0
2096	Enfoque terapéutico de la diabetes mellitus tipo 2 en adultos. Más allá de una meta glucémica. Medicina UPB, 2018, 37, 36-46.	0.1	1
2097	GLP-1R. , 2018, , 1-12.		0
2099	A gut feeling about glucagon. Endocrine Abstracts, 0, , .	0.0	2
2101	Pediatric Diabetes: Review Article. Indian Journal of Public Health Research and Development, 2019, 10, 2641.	0.0	0
2102	Egg Consumption for Appetite Control and Body Weight Regulation. Food Chemistry, Function and Analysis, 2019, , 40-59.	0.2	1
2103	Glucagon Processing. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
2104	The Pattern of Fasting and Post 75 G Glucose Loading of Glucagon-Like Peptide 1 Levels in Obese and Non-Obese Subjects. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 358-362.	0.2	3
2105	Peptides come to the rescue of pancreatic β^2 cells. Journal of Biological Chemistry, 2019, 294, 12622-12623.	3.4	0
2106	Co-encapsulation of Beta Cells and Nanoparticles Containing GLP-1 Greatly Improves Insulin Secretion in Alginate-Based Bioartificial Pancreas. IFMBE Proceedings, 2020, , 1215-1222.	0.3	1
2108	Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs in Context, 2019, 8, 1-11.	2.2	4
2110	Principles of anesthetic management of surgeries in diabetes patients. Messenger of Anesthesiology and Resuscitation, 2020, 17, 59-63.	0.6	0
2112	Inflammationâ€modulating nanoparticles for pneumonia therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1763.	6.1	17
2113	Dapigliptide, a novel dual GLPâ€1 and GLPâ€2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1107-1118.	2.6	17
2114	Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture. Diabetes, 2021, 70, 2468-2475.	0.6	14
2115	Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms. Biomolecules, 2021, 11, 1582.	4.0	22
2116	A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors. Neuroscience and Biobehavioral Reviews, 2021, 131, 1169-1179.	6.1	10
2117	Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia. CNS Spectrums, 2022, 27, 347-354.	1.2	3
2118	Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases. Current Topics in Medicinal Chemistry, 2020, 20, 2904-2921.	2.1	5
2119	Postprandial Glucose, Insulin, and Glucagon-Like Peptide-1 Responses in Healthy Adults after Consumption of Chocolate-Products. Preventive Nutrition and Food Science, 2020, 25, 338-345.	1.6	1
2120	Amyloidogenicity of peptides targeting diabetes and obesity. Colloids and Surfaces B: Biointerfaces, 2022, 209, 112157.	5.0	5
2121	Current and future prospective of biosensing molecules for point-of-care sensors for diabetes biomarker. Sensors and Actuators B: Chemical, 2022, 351, 130914.	7.8	10
2122	Etiopathogenesis of NAFLD: Diet, Gut, and NASH. , 2020, , 73-95.		0
2123	Probiotics as an Alternative Food Therapy. Advances in Environmental Engineering and Green Technologies Book Series, 2020, , 97-127.	0.4	0
2124	Anti-incretin Effect: A Missing Link between Obesity, Diabetes, and Metabolic Surgery. , 2020, , 199-204.		0

#	ARTICLE	IF	CITATIONS
2125	Gravicentric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept. Pharmacy Formulas, 2020, 2, 48-60.	0.2	0
2126	Gut Peptides. , 2014, , 37-55.		0
2127	Advances in the treatment of nonalcoholic steatohepatitis. World Journal of Pharmacology, 2020, 9, 1-12.	2.3	1
2128	Role of food fiber in glycemic control of patients affected by type 2 diabetes mellitus. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2020, 179, .	0.1	0
2129	FFA1 (GPR40) Receptor Agonists Based on Phenylpropanoic Acid as Hypoglycemic Agents: Structure–Activity Relationship. Russian Journal of Bioorganic Chemistry, 2020, 46, 972-988.	1.0	3
2131	Outcomes of Roux-en-Y gastric bypass surgery for severely obese patients with type 1 diabetes: a case series report. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 281-3.	2.4	17
2132	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 155-63.	2.4	12
2133	Early impaired β -cell function in chinese women with polycystic ovary syndrome. International Journal of Clinical and Experimental Pathology, 2012, 5, 777-86.	0.5	9
2134	Novel insight into the distribution of L-cells in the rat intestinal tract. American Journal of Translational Research (discontinued), 2013, 5, 347-58.	0.0	30
2135	Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering. Hippokratia, 2012, 16, 100-5.	0.3	3
2136	Memory and eating: A bidirectional relationship implicated in obesity. Neuroscience and Biobehavioral Reviews, 2022, 132, 110-129.	6.1	19
2137	The impact of adolescent nicotine exposure on alcohol use during adulthood: The role of neuropeptides. International Review of Neurobiology, 2022, 161, 53-93.	2.0	0
2138	Is Colectomy Associated with the Risk of Type 2 Diabetes in Patients without Colorectal Cancer? A Population-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 5313.	2.4	3
2139	Dietary Carbohydrate Influences the Colocalization Pattern of Glucagon-like Peptide-1 with Neurotensin in the Chicken Ileum. Domestic Animal Endocrinology, 2021, 79, 106693.	1.6	1
2140	Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents. International Journal of Molecular Sciences, 2021, 22, 12409.	4.1	13
2141	Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference. Frontiers in Systems Neuroscience, 2021, 15, 711750.	2.5	1
2142	Neuroprotective effects of liraglutide against inflammation through the AMPK/NF- κ B pathway in a mouse model of Parkinson's disease. Metabolic Brain Disease, 2022, 37, 451-462.	2.9	19
2143	Prediabetes in Adolescents: Prevalence, Management and Diabetes Prevention Strategies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 4609-4619.	2.4	16

#	ARTICLE	IF	CITATIONS
2144	Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 781668.	2.6	17
2145	Incretins in the Therapy of Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12312.	4.1	4
2146	Jabuticaba juice improves postprandial glucagon-like peptide-1 and antioxidant status in healthy adults: a randomised crossover trial. <i>British Journal of Nutrition</i> , 2022, 128, 1545-1554.	2.3	2
2148	Raman Microscopy Investigation of GLP-1 Peptide Association with Supported Phospholipid Bilayers. <i>Langmuir</i> , 2021, , .	3.5	1
2149	Novel Insight into the Mechanism of Metabolic Surgery Causing the Diversity in Glycemic Status in Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, , .	1.2	1
2150	High Hydrostatic Pressure Processing of Human Milk Increases Apelin and GLP-1 Contents to Modulate Gut Contraction and Glucose Metabolism in Mice Compared to Holder Pasteurization. <i>Nutrients</i> , 2022, 14, 219.	4.1	2
2151	Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion. <i>Cell Reports</i> , 2022, 38, 110179.	6.4	5
2152	Arterial responses to infusion of Glucagon-like Peptide-1 in humans: A randomized trial study. <i>Peptides</i> , 2022, 150, 170736.	2.4	0
2153	<sc>Glucagon-like peptide</sc>-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 769-787.	4.4	12
2154	Dipeptidyl Peptidase-4 (DPP4) Inhibitors. , 2022, , 583-599.		0
2155	Postprandial glycine as a biomarker of satiety: A dose-rising randomised control trial of whey protein in overweight women. <i>Appetite</i> , 2022, 169, 105871.	3.7	7
2156	TGR5 potentiates GLP-1 secretion and cause pancreatic islet regeneration in response to <i>Tithonia diversifolia</i> saponin-rich extract in diabetic model mice. <i>Phytomedicine Plus</i> , 2022, 2, 100203.	2.0	0
2157	SupressÃ£o do apetite induzida pelo exercÃcio fÃsico. , 0, 18, e020034.		1
2158	Drugs for Treating Obesity. <i>Handbook of Experimental Pharmacology</i> , 2021, , 387-414.	1.8	12
2159	The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1600.	4.1	11
2160	Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?. <i>Journal of Internal Medicine</i> , 2022, 291, 557-573.	6.0	7
2161	Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. <i>International Journal of Obesity</i> , 2022, 46, 623-629.	3.4	15
2162	Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022, 38, 114-121.	1.4	1

#	ARTICLE	IF	CITATIONS
2163	Probiotics as an Alternative Food Therapy. , 2022, , 543-565.		0
2164	Cholecystectomy Concomitant with Bariatric Surgery: Safety and Metabolic Effects. Obesity Surgery, 2022, 32, 1093-1102.	2.1	3
2165	Incretins Enhance PGF2Î±-Induced Synthesis of IL-6 and Osteoprotegerin in Osteoblasts. Hormone and Metabolic Research, 2022, 54, 42-49.	1.5	1
2166	Long-term effect of the eradication of Helicobacter pylori on the hemoglobin A1c in type 2 diabetes or prediabetes patients. Korean Journal of Internal Medicine, 2022, 37, 579-590.	1.7	6
2167	New Concepts in the Pathogenesis of Cystic Fibrosisâ€“Related Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1503-1509.	3.6	14
2168	Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism: Clinical and Experimental, 2022, 129, 155157.	3.4	8
2169	Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy. Phytomedicine Plus, 2022, 2, 100225.	2.0	0
2170	Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2581-e2589.	3.6	2
2171	Neurogenin-3 Enteric Endocrinopathy: A Rare Case of Pediatric Congenital Diarrhea and Diabetes Mellitus. JPGN Reports, 2022, 3, e173.	0.4	0
2172	Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients. Metabolites, 2022, 12, 147.	2.9	3
2173	Cardiovascular effects of GLP-1 receptor agonism. Advances in Pharmacology, 2022, , 213-254.	2.0	5
2174	Efecto de liraglutide sobre los niveles de andrÃ³genos sÃ©ricos y la funciÃ³n sexual en mujeres con obesidad. Revista Colombiana De EndocrinologÃa, Diabetes & Metabolismo, 2021, 8, .	0.0	0
2175	Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports, 2022, 9, 27-46.	1.3	1
2176	Current Status of Metabolic/Bariatric Surgery in Type 1 Diabetes Mellitus: an Updated Systematic Review and Meta-analysis. Obesity Surgery, 2022, 32, 1726-1733.	2.1	2
2177	Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2022, Volume 17, 405-414.	2.3	10
2178	Personal dietâ€“microbiota interactions and weight loss. Proceedings of the Nutrition Society, 2022, 81, 243-254.	1.0	8
2179	Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. Frontiers in Pharmacology, 2022, 13, 819470.	3.5	4
2180	Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells. Neuroscience Bulletin, 2022, 38, 622-636.	2.9	3

#	ARTICLE	IF	CITATIONS
2181	GLP-1 (Glucagon-Like Peptide-1) Plays a Role in Carotid Chemoreceptorâ€‘Mediated Sympathoexcitation and Hypertension. <i>Circulation Research</i> , 2022, 130, 708-710.	4.5	2
2182	In silico identification of potential inhibitors from <i>rumex vesicarius</i> against DPP4 of diabetes mellitus. <i>International Journal of Health Sciences</i> , 2022, 6, 1002-1017.	0.1	1
2183	Enteroendocrine System and Gut Barrier in Metabolic Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3732.	4.1	8
2184	The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022, 31, 28-36.	3.6	15
2185	Palatinose™ (Isomaltulose) and Prebiotic Inulin-Type Fructans Have Beneficial Effects on Glycemic Response and Gut Microbiota Composition in Healthy Volunteersâ€‘A Real-Life, Retrospective Study of a Cohort That Participated in a Digital Nutrition Program. <i>Frontiers in Nutrition</i> , 2022, 9, 829933.	3.7	2
2186	Messages from the Small Intestine Carried by Extracellular Vesicles in Prediabetes: A Proteomic Portrait. <i>Journal of Proteome Research</i> , 2022, 21, 910-920.	3.7	4
2187	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 838410.	3.5	42
2188	Diverse and Complementary Effects of Ghrelin and Obestatin. <i>Biomolecules</i> , 2022, 12, 517.	4.0	13
2189	RELATIONSHIP OF LEAKY GUT SYNDROME AND METABOLIC SYNDROME. <i>Health and Society</i> , 2022, 2, .	0.0	0
2190	Dietary Medium-Chain Triglyceride Decanoate Affects Glucose Homeostasis Through GPR84-Mediated GLP-1 Secretion in Mice. <i>Frontiers in Nutrition</i> , 2022, 9, 848450.	3.7	10
2191	The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 665-684.	4.3	24
2192	Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. <i>PLoS ONE</i> , 2022, 17, e0264974.	2.5	15
2193	Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging. <i>Brain Sciences</i> , 2022, 12, 431.	2.3	17
2194	Effect of <i>Prosopis ruscifolia</i> on incretin and insulin secretion in alloxan-induced hyperglycemic rats. <i>Vitae</i> , 2022, 29, .	0.8	0
2195	GLP-1 responds to postprandial hyperglycemia by reducing transcription level in grass carp (<i>Ctenopharyngodon idella</i>). <i>Aquaculture Reports</i> , 2022, 23, 101045.	1.7	2
2196	Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population. <i>Human Genomics</i> , 2022, 16, 11.	2.9	5
2197	GLP-1 â€‘ Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. <i>Current Opinion in Pharmacology</i> , 2022, 63, 102189.	3.5	10
2198	Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112839.	5.6	40

#	ARTICLE	IF	CITATIONS
2199	Evening rather than morning increased physical activity alters the microbiota in mice and is associated with increased body temperature and sympathetic nervous system activation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166373.	3.8	7
2200	The Pivotal Role of Microbiota in Modulating the Neuronalâ€“Glialâ€“Epithelial Unit. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5613-5628.	2.7	11
2201	Semaglutide for the treatment of obesity. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 159-166.	4.9	26
2202	Autonomic Nervous System Neuroanatomical Alterations Could Provoke and Maintain Gastrointestinal Dysbiosis in Autism Spectrum Disorder (ASD): A Novel Microbiomeâ€“Host Interaction Mechanistic Hypothesis. <i>Nutrients</i> , 2022, 14, 65.	4.1	13
2203	Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 759262.	3.5	2
2204	Apple Polyphenols Extracts Ameliorate High Carbohydrate Diet-Induced Body Weight Gain by Regulating the Gut Microbiota and Appetite. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 196-210.	5.2	14
2205	Colonic Delivery of ω -3 Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagonâ€“Like Peptideâ€“1 Secretion and Inhibits Food Intake in Mice. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100978.	3.3	4
2206	The current state of diabetes treatment. , 2022, , 1-31.		0
2207	Advances in Biological and Clinical Research of GLP-1 Receptor Agonists. <i>Advances in Clinical Medicine</i> , 2022, 12, 2979-2988.	0.0	0
2208	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1587-1598.	3.3	10
2209	Regulation of feeding and therapeutic application of bioactive peptides. , 2022, 239, 108187.		4
2210	Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists. <i>ACS Chemical Biology</i> , 2022, 17, 1249-1258.	3.4	2
2224	Role of the gutâ€“brain axis in energy and glucose metabolism. <i>Experimental and Molecular Medicine</i> , 2022, 54, 377-392.	7.7	72
2225	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Frontiers in Nutrition</i> , 2022, 9, 889710.	3.7	4
2226	Production of Indole and Indole-Related Compounds by the Intestinal Microbiota and Consequences for the Host: The Good, the Bad, and the Ugly. <i>Microorganisms</i> , 2022, 10, 930.	3.6	29
2227	Ca^{2+} entry through reverse Na^{+}/Ca^{2+} exchanger in NCI-H716, glucagon-like peptide-1 secreting cells. <i>Korean Journal of Physiology and Pharmacology</i> , 2022, 26, 219-225.	1.2	1
2228	Fasting or the shortâ€“term consumption of a ketogenic diet protects against antipsychoticâ€“induced hyperglycaemia in mice. <i>Journal of Physiology</i> , 2022, 600, 2713-2728.	2.9	7
2229	A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic. <i>PLoS ONE</i> , 2022, 17, e0266833.	2.5	6

#	ARTICLE	IF	CITATIONS
2230	Obesity Does Not Influence Delayed Gastric Emptying Following Pancreatoduodenectomy. <i>Biology</i> , 2022, 11, 763.	2.8	2
2231	Sleeve Gastrectomy Improves High-Fat Diet-Associated Hepatic Steatosis Independent of the Glucagon-like-Petpide-1 Receptor in Rats. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1607-1618.	1.7	0
2232	GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the Egyptian population. <i>Gene</i> , 2022, 834, 146597.	2.2	5
2234	Evolution of the diagnostic value of “the sugar of the blood”, hitting the sweet spot to identify alterations in glucose dynamics. <i>Physiological Reviews</i> , 2023, 103, 7-30.	28.8	2
2235	Expression of the relaxin family peptide 4 receptor by enterochromaffin cells of the mouse large intestine. <i>Cell and Tissue Research</i> , 0, , .	2.9	2
2236	Obesity as a neurobiologic disorder: a heavyweight contender. <i>Current Psychiatry Research and Reviews</i> , 2022, 18, .	0.2	0
2237	Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3850-e3856.	3.6	7
2238	Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 965-971.	1.4	2
2239	An inter-organ neural circuit for appetite suppression. <i>Cell</i> , 2022, 185, 2478-2494.e28.	28.9	53
2240	Isolated ileal interposition in enteroendocrine L cells differentiation. <i>Nature Precedings</i> , 0, , .	0.1	0
2241	Structural changes in intestinal enteroendocrine cells after ileal interposition in normal rats. <i>Nature Precedings</i> , 0, , .	0.1	0
2242	Obesity-related vascular dysfunction persists after weight loss and is associated with decreased vascular glucagon-like peptide receptor in female rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H301-H311.	3.2	2
2243	Comparison of Gastric Emptying Time after the Ingestion of Whisky with Isocalorically Adjusted Glucose Solution. <i>Journal of Nutrition and Metabolism</i> , 2022, 2022, 1-6.	1.8	1
2244	Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. <i>World Journal of Cardiology</i> , 2022, 14, 329-342.	1.5	5
2245	Dual Role of Indoles Derived From Intestinal Microbiota on Human Health. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	45
2246	A pilot randomized controlled trial of liraglutide 3.0Âmg for binge eating disorder. <i>Obesity Science and Practice</i> , 2023, 9, 127-136.	1.9	8
2247	GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes. <i>Diabetologia</i> , 0, , .	6.3	4
2248	Uncoupling protein 2 and aldolase B impact insulin release by modulating mitochondrial function and Ca ²⁺ release from the ER. <i>IScience</i> , 2022, 25, 104603.	4.1	8

#	ARTICLE	IF	CITATIONS
2249	Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. <i>Biomedicine and Pharmacotherapy</i> , 2022, 152, 113236.	5.6	4
2250	Gut Microbiota Potential in Type 2 Diabetes. , 0, , .		0
2251	Obesity, Weight Gain, and Fluid Overload in Peritoneal Dialysis. , 0, 2, .		3
2252	Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism. <i>Science Advances</i> , 2022, 8, .	10.3	21
2253	<scp>INnoVative</scp> trial design for testing the Efficacy, Safety, and Tolerability of 6â€month treatment with incretinâ€based therapy to prevent type 1 <scp>DIAbetes</scp> in autoantibody positive participants: a protocol for three parallel doubleâ€blind randomised controlled trials () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 572 Td (<sc	2.3	2
2254	Editorial: Type 2 diabetes therapeutics: weight loss and other strategies. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2022, 25, 256-259.	2.5	2
2255	GLP-1 Receptor Blockade Reduces Stimulated Insulin Secretion in Fasted Subjects With Low Circulating GLP-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2500-2510.	3.6	9
2256	Multivalent Î³â€PGAâ€Exendinâ€4 Conjugates to Target Pancreatic Î²â€Cells. <i>ChemBioChem</i> , 0, , .	2.6	1
2257	Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 7495-7501.	0.8	1
2258	Purification, Biochemical Characterization, and DPPâ€IV and Î±â€amylase inhibitory activity of Berberine from <i>Cardiospermum halicacabum</i>. <i>Journal of Molecular Recognition</i> , 0, , .	2.1	3
2259	Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure. <i>Life Sciences</i> , 2022, 305, 120757.	4.3	5
2260	The glucagonâ€like peptideâ€1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a postâ€mortem brain study. <i>Addiction Biology</i> , 2022, 27, .	2.6	7
2261	Relationship between Fasting and Postprandial Glucose Levels and the Gut Microbiota. <i>Metabolites</i> , 2022, 12, 669.	2.9	3
2262	Gut Microbiota-Derived Tryptophan Metabolites Maintain Gut and Systemic Homeostasis. <i>Cells</i> , 2022, 11, 2296.	4.1	73
2263	Endurance training improves GLP-1 sensitivity and glucose tolerance in overweight women. <i>Journal of the Endocrine Society</i> , 0, , .	0.2	3
2264	Food preferences and thyroid hormones in children and adolescents with obesity. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	3
2265	Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses. <i>BMC Veterinary Research</i> , 2022, 18, .	1.9	5
2266	Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9477.	2.6	4

#	ARTICLE	IF	CITATIONS
2267	Identification of key genes and pathways revealing the central regulatory mechanism of brain-derived glucagon-like peptide-1 on obesity using bioinformatics analysis. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	2
2268	Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	7
2269	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	90
2270	Short-chain fatty acids: possible regulators of insulin secretion. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 517-530.	3.1	2
2271	Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control. <i>International Journal of Cardiology</i> , 2022, 367, 81-89.	1.7	3
2272	In Silico Ligand Docking Approaches to Characterise the Binding of Known Allosteric Modulators to the Glucagon-Like Peptide 1 Receptor and Prediction of ADME/Tox Properties. , 2022, 1, 143-162.		4
2273	Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. <i>Pharmacological Research</i> , 2022, 184, 106426.	7.1	6
2274	Association between hemoglobin A1C response to glucagon-like peptide-1 receptor agonists and hemoglobin A1C and weight outcomes post-bariatric surgery. <i>Obesity Medicine</i> , 2022, 35, 100450.	0.9	0
2275	Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. , 2022, 239, 108277.		15
2276	GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. <i>Molecular Metabolism</i> , 2022, 65, 101590.	6.5	4
2277	Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. , 2022, 239, 108270.		9
2278	Effect of glucagon-like peptide-1 on differentiation of adipose derived mesenchymal stem cells into cardiomyocytes. <i>Ege Tıp Dergisi</i> , 2022, 61, 507-517.	0.2	0
2279	A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2022, 76, 221.	0.9	1
2280	Glucagon Like Peptide-1: More than Glucose Control and Weight Reduction. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2281	Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. , 2022, , 615-654.		0
2282	Chemical Approaches for Beta-cell Biology. <i>RSC Nanoscience and Nanotechnology</i> , 2022, , 1-52.	0.2	1
2283	Clinical and preclinical data on therapeutic peptides. , 2022, , 657-688.		0
2284	Healthy Sleep Every Day Keeps the Doctor Away. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10740.	2.6	7

#	ARTICLE	IF	CITATIONS
2286	Glucagon-like peptide-1 analogues for overweight or obese adults. The Cochrane Library, 2022, 2022, .	2.8	0
2287	Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 653-665.	9.1	2
2288	A Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cellâ€‘derived Islets. Endocrine Reviews, 2023, 44, 222-253.	20.1	13
2289	Role of Reactive Oxygen Species in Glucose Metabolism Disorder in Diabetic Pancreatic Î²-Cells. Biomolecules, 2022, 12, 1228.	4.0	18
2290	Haploinsufficiency of CYP8B1 associates with increased insulin sensitivity in humans. Journal of Clinical Investigation, 2022, 132, .	8.2	8
2291	Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 2022, 7, .	5.0	23
2292	How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers, 2022, 14, 4651.	3.7	14
2293	Vertical sleeve gastrectomy normalizes circulating glucocorticoid levels and lowers glucocorticoid action tissue-selectively in mice. Frontiers in Endocrinology, 0, 13, .	3.5	0
2294	Gut Bacteria and Neurotransmitters. Microorganisms, 2022, 10, 1838.	3.6	63
2295	Mucosal and hormonal adaptations after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2023, 19, 37-49.	1.2	2
2296	Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neuroscience and Biobehavioral Reviews, 2022, 142, 104896.	6.1	25
2297	Consumption of barley flour increases gut fermentation and improves glucose intolerance <i>via</i> the short-chain fatty acid receptor GPR43 in obese male mice. Food and Function, 2022, 13, 10970-10980.	4.6	5
2299	Safety and effectiveness of newer antidiabetic medications during Ramadan fasting and safety of Ramadan fasting after bariatric surgery. Journal of Diabetes and Metabolic Disorders, 2022, 21, 1991-2004.	1.9	2
2300	Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. International Journal of Molecular Sciences, 2022, 23, 13045.	4.1	5
2301	A single administration of barley Î²-glucan and arabinoxylan extracts reduces blood glucose levels at the second meal via intestinal fermentation. Bioscience, Biotechnology and Biochemistry, 2022, 87, 99-107.	1.3	2
2302	Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism: Clinical and Experimental, 2022, 137, 155332.	3.4	35
2303	Multifaceted role of synbiotics as nutraceuticals, therapeutics and carrier for drug delivery. Chemico-Biological Interactions, 2022, 368, 110223.	4.0	1
2304	Glucagon-like peptide-1 receptor mediates the improvement in glycolipid metabolism disorder via AKT and AMPK signalling pathways in L02 cells with insulin resistance. Journal of Molecular Structure, 2023, 1273, 134328.	3.6	0

#	ARTICLE	IF	CITATIONS
2305	MODERN MEANS AND APPROACHES TO TREATMENT FOR DIABETES MELLITUS TYPE 2. Problemy Zdorov'ya i Ėkologii, 2012, , 23-27.	0.1	0
2306	Macronutrient intake: Hormonal controls, pathological states, and methodological considerations. Appetite, 2023, 180, 106365.	3.7	1
2307	A Cre-driver rat model for anatomical and functional analysis of glucagon (Gcg)-expressing cells in the brain and periphery. Molecular Metabolism, 2022, 66, 101631.	6.5	4
2308	The complex involvement of the digestive tract in human defense behavior â€“ structural and functional arguments. Journal of Medicine and Life, 2022, 15, 1081-1089.	1.3	2
2309	Four sidenotes about glucagon peptides. Peptides, 2023, 159, 170924.	2.4	0
2310	Mesolimbic exendin-4 attenuates reward salience evoked by neuropeptide Y and ghrelin. Behavioural Brain Research, 2023, 440, 114249.	2.2	0
2311	Approach to the Patient With Hypothalamic Obesity. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1236-1242.	3.6	4
2312	Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence. Pulmonary Therapy, 2022, 8, 343-358.	2.2	2
2313	The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis. Journal of Pharmacology and Experimental Therapeutics, 2023, 384, 406-416.	2.5	5
2314	Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. Biomolecules, 2022, 12, 1736.	4.0	6
2315	New therapies for obesity. Cardiovascular Research, 2024, 119, 2825-2842.	3.8	16
2316	Differences in gastrointestinal hormones and appetite ratings between individuals with and without obesityâ€”A systematic review and metaâ€“analysis. Obesity Reviews, 2023, 24, .	6.5	4
2317	Associations of adipokines and metabolic hormones with low-density lipoprotein hypercholesterolemia in men and women under 45 years of age. Kardiologiya, 2022, 62, 63-70.	0.7	0
2319	Glucagon-like peptide-1 stimulates acute secretion of pro-atrial natriuretic peptide from the isolated, perfused pig lung exposed to warm ischemia. , 0, 1, .		0
2320	Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness. British Journal of Diabetes, 2022, 22, 121-124.	0.2	1
2321	Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice.. Experimental and Clinical Psychopharmacology, 2023, 31, 612-620.	1.8	1
2323	Synbiotic as an adjunctive agent can be useful in the management of hyperglycemia in adults: An umbrella review and meta-research of meta-analysis studies. Journal of Functional Foods, 2022, 99, 105355.	3.4	2
2324	Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies. Metabolism: Clinical and Experimental, 2023, 140, 155375.	3.4	2

#	ARTICLE	IF	CITATIONS
2325	Construction of multicopy glucagon-like peptide-1 (GLP-1) open reading frame and its expression in Escherichia coli. AIP Conference Proceedings, 2023, , .	0.4	0
2326	Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery. Journal of Nanobiotechnology, 2023, 21, .	9.1	2
2327	Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches. Frontiers in Endocrinology, 0, 13, .	3.5	4
2328	Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin. Frontiers in Psychiatry, 0, 13, .	2.6	4
2329	Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. The Lancet Gastroenterology and Hepatology, 2023, 8, 179-191.	8.1	28
2330	Glucagon 100 years. Important, but still enigmatic. Peptides, 2023, 161, 170942.	2.4	2
2331	The role of FOXA family transcription factors in glucolipid metabolism and NAFLD. Frontiers in Endocrinology, 0, 14, .	3.5	2
2332	Are gastrointestinal signals the principal guides to human appetite and energy balance?. Medical Research Archives, 2023, 11, .	0.2	1
2333	Gut-brain axis. , 2023, , 445-495.		0
2334	Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open, 2023, 13, e068652.	1.9	3
2335	Plasma concentrations of glucagon and glucagon-like peptide-1 are reduced in dogs with aminoaciduric canine hypoaminoacidemic hepatopathy syndrome versus healthy dogs: a preliminary study. American Journal of Veterinary Research, 2022, , 1-8.	0.6	0
2336	Influence of the Gut Microbiota on Neuroendocrine-Immune Interactions. Masterclass in Neuroendocrinology, 2023, , 279-320.	0.1	0
2337	Clinical potential of glucagon-like peptide-1 analogs in the management of diabetes. Journal of Diabetology, 2023, 14, 1.	0.3	0
2338	Progress in the Study of the Role of Glucagon-Like Peptide 1 (GLP-1) in the Surgical Treatment of Obesity. Advances in Clinical Medicine, 2023, 13, 2811-2816.	0.0	0
2339	Isosinensetin Stimulates Glucagon-like Peptide-1 Secretion via Activation of hTAS2R50 and the GÎ²3-Mediated Signaling Pathway. International Journal of Molecular Sciences, 2023, 24, 3682.	4.1	1
2340	MC4R in Central and Peripheral Systems. Advanced Biology, 2023, 7, .	2.5	2
2341	Supplementation with Akkermansia muciniphila improved glucose metabolism disorder in common carp (Cyprinus carpio L.). Aquaculture, 2023, 572, 739465.	3.5	0
2343	Recent developments in adjunct therapies for type 1 diabetes. Expert Opinion on Investigational Drugs, 2022, 31, 1311-1320.	4.1	3

#	ARTICLE	IF	CITATIONS
2344	FFA-Fetuin-A regulates DPP-IV expression in pancreatic beta cells through TLR4-NFκB pathway. Biochemical and Biophysical Research Communications, 2023, 647, 55-61.	2.1	4
2345	F-actin determines the time-dependent shift in docking dynamics of glucagon-like peptide-1 granules upon stimulation of secretion. FEBS Letters, 2023, 597, 657-671.	2.8	0
2346	Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson's disease by regulating gut microbiota. Frontiers in Aging Neuroscience, 0, 15, .	3.4	10
2347	GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 0, 14, .	3.5	20
2348	Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update. Molecules, 2023, 28, 1369.	3.8	5
2349	Glycogen synthesis kinase-3 β involves in the analgesic effect of liraglutide on diabetic neuropathic pain. Journal of Diabetes and Its Complications, 2023, 37, 108416.	2.3	1
2350	Liraglutide abrogates nephrotoxic effects of chemotherapies. Pharmacological Research, 2023, 189, 106680.	7.1	2
2351	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of Obesity and Metabolic Syndrome, 2023, 32, 25-45.	3.6	14
2352	Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits. European Medical Journal Diabetes, 0, , 57-65.	4.0	3
2353	The Predictive Value of Glucagon-Like Peptide 1 Plasma Levels on Acute Heart Failure. Indonesian Journal of Clinical Pathology, 2022, 28, 127-132.	0.1	0
2354	GABA signalling in human pancreatic islets. Frontiers in Endocrinology, 0, 14, .	3.5	3
2356	Neuroprotective Properties of Peptides. , 0, , .		1
2357	Correlation between glomerular filtration rate, fasting glucagon like peptide 1, and response after 75 gram oral glucose loading in type 2 diabetes mellitus. Jurnal Penyakit Dalam Udayana, 2020, 4, 14-18.	0.1	0
2358	The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 575-595.	2.4	12
2360	Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2023, 198, 110605.	2.8	10
2361	Short-term semaglutide treatment improves <sc>FGF21</sc> responsiveness in primary hepatocytes isolated from high fat diet challenged mice. Physiological Reports, 2023, 11, .	1.7	4
2362	Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review. Lipids in Health and Disease, 2023, 22, .	3.0	3
2363	The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia. Diseases (Basel, Switzerland), 2023, 11, 50.	2.5	1

#	ARTICLE	IF	CITATIONS
2364	Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay. <i>Bioanalysis</i> , 2023, 15, 207-218.	1.5	1
2365	Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice. <i>Endocrinology</i> , 2023, 164, .	2.8	1
2366	<i>Euglena gracilis</i> -derived Î²-glucan paramylon entrains the peripheral circadian clocks in mice. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	1
2367	The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	7
2368	Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment. <i>Open Medicine (Poland)</i> , 2023, 18, .	1.3	3
2369	L-Arginine in diabetes: clinical and preclinical evidence. <i>Cardiovascular Diabetology</i> , 2023, 22, .	6.8	13
2370	Elucidating the central anorexigenic mechanism of glucagon-like peptide 1 in Japanese quail (<i>Coturnix</i>) Tj ETQq0 0 0 µgBT /Overlock 10 T	1.8	0
2371	Pathway specific interventions reveal the multiple roles of ventral hippocampus projections in cognitive functions. <i>Reviews in the Neurosciences</i> , 2023, 34, 825-838.	2.9	3
2372	Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
2373	Liver complications of total parenteral nutrition: the latest therapeutic strategies. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2023, 77, 21-26.	0.1	0
2374	Research Progress on Mechanism of Glucagon-Like Peptide-1 and Aortic Valve Calcification. <i>Advances in Clinical Medicine</i> , 2023, 13, 6439-6449.	0.0	0
2375	Metabolism of Dietary Substrates by Intestinal Bacteria and Consequences for the Host Intestine. , 2023, , 45-144.		0
2376	Glucagon-like peptide 1 aggregates into low-molecular-weight oligomers off-pathway to A-fibrillation. <i>Biophysical Journal</i> , 2023, 122, 2475-2488.	0.5	2
2377	The Neurobiology of Eating Behavior in Obesity: Mechanisms and Therapeutic Targets: A Report from the 23rd Annual Harvard Nutrition Obesity Symposium. <i>American Journal of Clinical Nutrition</i> , 2023, 118, 314-328.	4.7	2
2379	The local GLP-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice. <i>Molecular Metabolism</i> , 2023, 73, 101738.	6.5	2
2380	New approaches to reduce recurrent PCI: to angioplasty and beyond!. <i>European Heart Journal Open</i> , 2023, 3, .	2.3	0
2381	Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	17
2382	In Vitro Screening for Probiotic Properties of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Strains in Assays Relevant for Non-Alcoholic Fatty Liver Disease Prevention. <i>Nutrients</i> , 2023, 15, 2361.	4.1	5

#	ARTICLE	IF	CITATIONS
2383	Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?. <i>Frontiers in Molecular Neuroscience</i> , 0, 16, .	2.9	3
2384	RYGB surgery has modest effects on intestinal morphology and gut hormone populations in the bypassed biliopancreatic limb but causes reciprocal changes in GLP-2 and PYY in the alimentary limb. <i>PLoS ONE</i> , 2023, 18, e0286062.	2.5	1
2385	The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD. <i>Current Issues in Molecular Biology</i> , 2023, 45, 4544-4556.	2.4	4
2386	Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2561-2574.	4.4	3
2387	G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children. <i>Biomedicines</i> , 2023, 11, 1576.	3.2	0
2388	Incretin Therapies: Current Use and Emerging Possibilities. , 2023, , 565-580.		0
2389	Obesity in the Pathophysiology of Diabetes. , 2023, , 217-245.		0
2390	Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors is hemodynamics the key point?. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 325, C243-C256.	4.6	2
2391	Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. <i>Pharmaceuticals</i> , 2023, 16, 836.	3.8	2
2392	Natural products from plants targeting key enzymes for the future development of antidiabetic agents. <i>Natural Product Reports</i> , 2023, 40, 1198-1249.	10.3	4
2393	Roles of bile acids signaling in neuromodulation under physiological and pathological conditions. <i>Cell and Bioscience</i> , 2023, 13, .	4.8	7
2394	Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. <i>Pharmacological Reviews</i> , 2023, 75, 1062-1118.	16.0	1
2395	Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss. <i>European Journal of Pharmacology</i> , 2023, 954, 175837.	3.5	2
2396	Exploring the role of gut microbiota in obesity and PCOS: Current updates and future prospects. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110781.	2.8	1
2397	Effects on Diabetic Mice of Consuming Lipid Extracted from Foxtail Millet (<i>Setaria italica</i>): Gut Microbiota Analysis and Serum Metabolomics. <i>Journal of Agricultural and Food Chemistry</i> , 2023, 71, 10075-10086.	5.2	8
2398	Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2626-2633.	4.4	6
2399	Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a Mechanistic Approach. <i>Molecular Neurobiology</i> , 2023, 60, 4547-4573.	4.0	3
2400	Maternal Weight Management to Prevent the Developmental Programming of MAFLD in Offspring of Obese Mothers. <i>Nutrients</i> , 2023, 15, 2155.	4.1	2

#	ARTICLE	IF	CITATIONS
2401	Chrelin and glucagon-like peptide-1 according to body adiposity and glucose homeostasis. Archives of Endocrinology and Metabolism, 2023, 67, .	0.6	0
2402	No Evidence That Circulating GLP-1 or PYY Are Associated with Increased Satiety during Low Energy Diet-Induced Weight Loss: Modelling Biomarkers of Appetite. Nutrients, 2023, 15, 2399.	4.1	1
2404	100 years of glucagon and 100 more. Diabetologia, 2023, 66, 1378-1394.	6.3	12
2405	Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals. Clinical Nutrition, 2023, 42, 1369-1378.	5.0	1
2406	Global trends and focuses of GLP-1RA in renal disease: a bibliometric analysis and visualization from 2005 to 2022. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	3.0	1
2407	Insulin analogs as an add-on to metformin after failure to oral treatment in type 2 diabetic patients increase diastole duration. The INSulin Regimens and VAScular Functions (INSUVASC) study. Minerva Cardiology and Angiology, 0, , .	0.7	0
2408	GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Frontiers in Endocrinology, 0, 14, .	3.5	2
2409	Neuro-Vulnerability in Energy Metabolism Regulation: A Comprehensive Narrative Review. Nutrients, 2023, 15, 3106.	4.1	4
2411	Regulation of mTOR Signaling: Emerging Role of Cyclic Nucleotide-Dependent Protein Kinases and Implications for Cardiometabolic Disease. International Journal of Molecular Sciences, 2023, 24, 11497.	4.1	4
2412	The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health. Korean Circulation Journal, 0, 53, .	1.9	3
2413	Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?. Diabetes/Metabolism Research and Reviews, 0, , .	4.0	2
2414	The role of the HERG channel in the secretion of glucagon-like peptide-1 (GLP-1) from murine intestinal L-cells. , 2023, 2, .		1
2415	Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST). BJPsych Open, 2023, 9, .	0.7	0
2417	Equine Metabolic Syndrome: A Complex Disease Influenced by Multifactorial Genetic Factors. Genes, 2023, 14, 1544.	2.4	1
2418	No effect of multi-strain probiotic supplementation on metabolic and inflammatory markers and newborn body composition in pregnant women with obesity: Results from a randomized, double-blind placebo-controlled study. Nutrition, Metabolism and Cardiovascular Diseases, 2023, , .	2.6	0
2419	Cordyceps cicadae polysaccharides alleviate hyperglycemia by regulating gut microbiota and its metabolites in high-fat diet/streptozocin-induced diabetic mice. Frontiers in Nutrition, 0, 10, .	3.7	1
2420	Interleukin-6 is not involved in appetite regulation following moderate-intensity exercise in males with normal weight and obesity. Obesity, 2023, 31, 2315-2324.	3.0	1
2421	Glucagon and Its Receptors in the Mammalian Heart. International Journal of Molecular Sciences, 2023, 24, 12829.	4.1	2

#	ARTICLE	IF	CITATIONS
2423	Origins of thirstiness sensation and current food solutions. Comprehensive Reviews in Food Science and Food Safety, 2023, 22, 4433-4450.	11.7	0
2425	Particulate Gastric Contents in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists After Appropriate Perioperative Fasting: A Report of 2 Cases. A&A Practice, 2023, 17, e01712.	0.4	3
2426	Exendin-4 Induces Cytotoxic Autophagy in Two Ovarian Cancer Cell Lines through Inhibition of Mtorc1 Mediated by Activation of AMPK and Suppression of Akt. Folia Biologica, 2020, 66, 186-203.	0.6	1
2427	Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment. International Journal of Molecular Sciences, 2023, 24, 13540.	4.1	0
2428	Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration. Scientific Reports, 2023, 13, .	3.3	0
2429	Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities. Frontiers in Molecular Biosciences, 0, 10, .	3.5	1
2430	Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Molecular Medicine, 2023, 29, .	4.4	1
2431	The role of the indoles in microbiota-gut-brain axis and potential therapeutic targets: A focus on human neurological and neuropsychiatric diseases. Neuropharmacology, 2023, 239, 109690.	4.1	8
2432	Chicken slaughterhouse by-products: A source of protein hydrolysates to manage non-communicable diseases. Trends in Food Science and Technology, 2023, 139, 104125.	15.1	2
2433	Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes. IScience, 2023, 26, 107680.	4.1	1
2434	Post-prandial secretion of glucagon-like peptide-2 (GLP-2) after carbohydrate-, fat- or protein enriched meals in healthy subjects. Peptides, 2023, 169, 171091.	2.4	1
2435	Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/ β -catenin/NeuroD1 pathway. Molecular Medicine, 2023, 29, .	4.4	0
2436	Roles of mitochondrial dynamics and mitophagy in diabetic myocardial microvascular injury. Cell Stress and Chaperones, 2023, 28, 675-688.	2.9	1
2437	Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations. Current Psychiatry Reports, 0, , .	4.5	0
2438	ASSOCIATIONS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL WITH BIOMOLECULES IN METABOLIC DISORDERS IN YOUNG PEOPLE AGED 25â€“44 YEARS. Complex Issues of Cardiovascular Diseases, 2023, 12, 152-160.	0.5	0
2439	Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges. Cureus, 2023, , .	0.5	0
2440	SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS. Trakia Journal of Sciences, 2023, 21, 54-62.	0.1	0
2441	Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice. ACS Synthetic Biology, 2023, 12, 3433-3442.	3.8	2

#	ARTICLE	IF	CITATIONS
2442	Feeding during the resting phase causes gastrointestinal tract dysfunction and desynchronization of metabolic and neuronal rhythms in rats. <i>Neurogastroenterology and Motility</i> , 2023, 35, .	3.0	1
2443	Î²-cell neogenesis: A rising star to rescue diabetes mellitus. <i>Journal of Advanced Research</i> , 2023, , .	9.5	1
2444	Exogenous glucagon-like peptide-1 attenuates glucose absorption and reduces blood glucose concentration after small intestinal glucose delivery in critical illness. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2017, 19, 37-42.	0.1	0
2445	Expression of the <scp><i>GCG</i></scp> gene and secretion of active glucagonâ€like peptideâ€1 varies along the length of intestinal tract in horses. <i>Equine Veterinary Journal</i> , 2024, 56, 352-360.	1.7	0
2446	Promising new pharmacological targets for depression: the search for efficacy. <i>Drug Discovery Today</i> , 2023, , 103804.	6.4	0
2447	Role of cytosolic and endoplasmic reticulum Ca ²⁺ in pancreatic beta-cells: pros and cons. <i>Pflugers Archiv European Journal of Physiology</i> , 2024, 476, 151-161.	2.8	1
2448	Enteroendocrine cell regulation of the gut-brain axis. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	4
2449	Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
2450	Neuroadaptive Biochemical Mechanisms of Remote Ischemic Conditioning. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17032.	4.1	0
2451	Dynamical modeling the effect of glucagon-like peptide on glucoseâ€insulin regulatory system based on mice experimental observation. <i>Mathematical Biosciences</i> , 2023, 366, 109090.	1.9	0
2452	Acute nicotine intake increases feeding behavior through decreasing glucagon signaling in dependent male and female rats. <i>Hormones and Behavior</i> , 2024, 159, 105447.	2.1	0
2453	A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycaemic meal in ponies ¹ . <i>Journal of Animal Science</i> , 0, , .	0.5	0
2454	The benefits of GLP1 receptors in cardiovascular diseases. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 0, 4, .	0.8	1
2455	GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. , 2023, , 103925.		0
2456	High- or low-fibre diet, meal size and frequency: Effect on ileal and total tract digestibility and mean retention time in growing pigs. <i>Animal Feed Science and Technology</i> , 2023, 306, 115827.	2.2	2
2457	Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial. <i>Liver Transplantation</i> , 0, , .	2.4	1
2458	Significance of Hormone Alteration Following Bariatric Surgery. <i>Cureus</i> , 2023, , .	0.5	0
2459	Seeking satiety: From signals to solutions. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0

#	ARTICLE	IF	CITATIONS
2460	Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV. Drug Design, Development and Therapy, 0, Volume 17, 3473-3491.	4.3	0
2461	Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials. Expert Opinion on Investigational Drugs, 2023, 32, 1123-1131.	4.1	0
2462	Optimization of Recombinant Glucagon-like Peptide-1 Production Using Recombinant <i>E. coli</i> . KSBB Journal, 2023, 38, 188-193.	0.2	0
2463	Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	3
2464	GLP-1 Receptor Signaling Has Different Effects on the Perikarya and Axons of the Hypophysiotropic Thyrotropin-Releasing Hormone Synthesizing Neurons in Male Mice. Thyroid, 2024, 34, 252-260.	4.5	1
2466	Graded Replacement of Carbohydrate-Rich Breakfast Products with Dairy Products: Effects on Postprandial Aminoacidemia, Glycemic Control, Bone Metabolism, and Satiety. Journal of Nutrition, 2024, 154, 479-490.	2.9	0
2467	G protein-coupled receptors and obesity. Frontiers in Endocrinology, 0, 14, .	3.5	0
2468	GLP-1 response during pregnancy: variations between trimesters and associations with appetite sensations and usual energy intake. Applied Physiology, Nutrition and Metabolism, 0, , .	1.9	0
2469	Glucagon-like peptide agonists: A prospective review. Endocrinology, Diabetes and Metabolism, 2024, 7, .	2.4	1
2470	New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system. Current Issues in Pharmacy and Medical Sciences, 2023, 36, 232-235.	0.4	0
2471	The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight. American Journal of Physiology - Cell Physiology, 2024, 326, C567-C572.	4.6	0
2472	Nonoperating Room Anesthesia: What Is New? What Is Controversial?. Current Anesthesiology Reports, 2024, 14, 101-109.	2.0	0
2473	GLP-1 metabolite GLP-1(9-36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. Diabetologia, 2024, 67, 528-546.	6.3	1
2474	Bile salt signaling and bile salt-based therapies in cardiometabolic disease. Clinical Science, 2024, 138, 1-21.	4.3	1
2475	Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovascular Diabetology, 2024, 23, .	6.8	1
2476	The gut microbiota modulate locomotion via vagus-dependent glucagon-like peptide-1 signaling. Npj Biofilms and Microbiomes, 2024, 10, .	6.4	0
2477	Nutrient Combinations Sensed by L-Cell Receptors Potentiate GLP-1 Secretion. International Journal of Molecular Sciences, 2024, 25, 1087.	4.1	0
2478	Impaired Physiological Regulation of α Cells: Recent Findings from Type 2 Diabetic Patients. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2479	Advances in the Use of Biologics and Biomaterials toward the Improvement of Pancreatic Islet Graft Survival in Type 1 Diabetes. <i>Advanced NanoBiomed Research</i> , 2024, 4, .	3.6	0
2480	MICROBIOTA INTESTINAL E OBESIDADE: UMA REVISÃO SISTEMÁTICA. <i>Revista Foco</i> , 2023, 16, e3444.	0.0	0
2481	Gastrointestinal hormones: History, biology, and measurement. <i>Advances in Clinical Chemistry</i> , 2024, , 111-154.	3.7	0
2482	Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review. <i>American Journal of Clinical Nutrition</i> , 2024, 119, 599-627.	4.7	0
2483	Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2024, 44, 89-95.	1.4	1
2484	Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 17, 343-362.	2.4	0
2485	Recent advances in the adjunctive management of diabetic foot ulcer: Focus on noninvasive technologies. <i>Medicinal Research Reviews</i> , 0, , .	10.5	0
2486	Effects of physical form of α -lactoglobulin and calcium ingestion on GLP-1 secretion, gastric emptying and energy intake in humans: a randomised crossover trial. <i>British Journal of Nutrition</i> , 0, , 1-10.	2.3	0
2487	A mathematical model of obesity-induced type 2 diabetes and efficacy of anti-diabetic weight reducing drug. <i>Journal of Theoretical Biology</i> , 2024, 581, 111756.	1.7	0
2489	G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?. <i>Biomedicine and Pharmacotherapy</i> , 2024, 172, 116245.	5.6	0
2490	Extraintestinal Manifestations Depending on Sex/Gender and Age: Metabolic Parameters and Glycosylated Hemoglobin A1c. , 2023, , 685-698.		0
2491	Timosaponin A3 Induces Anti-Obesity and Anti-Diabetic Effects In Vitro and In Vivo. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2914.	4.1	0
2492	Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats. <i>International Journal of Molecular Sciences</i> , 2024, 25, 3008.	4.1	0
2493	Effect of inulin on breath hydrogen, postprandial glycemia, gut hormone release, and appetite perception in RYGB patients: a prospective, randomized, cross-over pilot study. <i>Nutrition and Diabetes</i> , 2024, 14, .	3.2	0
2494	Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. <i>International Journal of Obesity</i> , 0, , .	3.4	0
2495	Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives. <i>Acta Pharmaceutica Sinica B</i> , 2024, , .	12.0	0
2496	Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight. <i>British Journal of Pharmacology</i> , 2024, 181, 1829-1842.	5.4	0
2497	Diabetes, Prediabetes, Metabolic Syndrome, and Large Artery Vascular Ageing. , 2024, , 169-185.		0

#	ARTICLE	IF	CITATIONS
2498	New insights into nanomedicines for oral delivery of <scp>glucagon-like</scp> peptide analogs. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2024, 16, .	6.1	0
2499	Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus. Frontiers in Endocrinology, 0, 15, .	3.5	0
2500	Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology. , 2024, 15, 24-37.		0
2501	Deciphering the role of glycosaminoglycans in GPCR signaling. Cellular Signalling, 2024, 118, 111149.	3.6	0
2502	Exploring the significance of microbiota metabolites in rheumatoid arthritis: uncovering their contribution from disease development to biomarker potential. Apmis, 0, , .	2.0	0
2503	Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats. Frontiers in Behavioral Neuroscience, 0, 18, .	2.0	0
2504	A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. Brain Sciences, 2024, 14, 294.	2.3	0